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INVESTIGATING THE SRC KINASE HCK FUNCTIONS IN CHRONIC 
MYELOGENOUS LEUKEMIA USING CHEMICAL GENETICS METHODS 
 
 Teodora Pene Dumitrescu, PhD 
University of Pittsburgh, 2009
 The hallmark of chronic myelogenous leukemia (CML) is a chromosomal translocation between 
the c-abl gene (chromosome 9) and the bcr gene (chromosome 22). This event gives rise to Bcr-
Abl, a chimeric protein with constitutive tyrosine kinase activity that drives the pathogenesis of 
the disease.  Imatinib, a Bcr-Abl kinase inhibitor is the frontline therapy in CML. Although 
imatinib is very effective in the chronic phase of CML, patients in advanced stages develop 
resistance. An increased understanding of the signaling pathways implicated in CML 
pathogenesis and imatinib resistance is critical to the development of improved therapies. 
Previous work in our laboratory found that A-419259, a broad-spectrum Src family 
kinase (SFK) inhibitor induces growth arrest and apoptosis in CML cells, suggesting that SFKs 
are required for Bcr-Abl transformation of myeloid progenitors. Additionally, Hck couples Bcr-
Abl to Stat5 activation in myeloid cells, which may contribute to survival. Furthermore, studies 
on samples from some imatinib-resistant patients found increased expression and activity of Hck 
and Lyn. In this dissertation, using two chemical genetic methods, I addressed the contribution of 
Hck to Bcr-Abl signaling and imatinib resistance. 
To explore the individual contribution of Hck to Bcr-Abl signaling, I developed an A-
419259-resistant mutant of Hck (Hck-T338M). Expression of Hck-T338M fully protected K562 
CML cells from A-419259-induced apoptosis, an effect that correlated with sustained Stat5 
activation. In addition, the Hck-T338M partially protected CML cells against the growth 
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inhibition induced by A-419259. These studies suggest that Hck plays a non-redundant role as a 
key downstream survival partner for Bcr-Abl.  
I also tested whether Hck overexpression was sufficient to induce imatinib resistance in 
CML cells. For this study, I developed a mutant of Hck (Hck-T338A) that is uniquely sensitive 
to NaPP1, an analog of the generic SFK inhibitor pyrrazolo-pyrimidine 1.  Overexpression of 
Hck or Hck-T338A in K562 cells induced resistance to imatinib-dependent apoptosis and growth 
arrest. Furthermore, NaPP1 reversed imatinib resistance in K562-Hck-T338A cells, suggesting 
that Hck-induced imatinib resistance requires Hck kinase activity. Taken together, my work 
validates Hck as a target for the development of apoptosis-inducing drugs and that are likely to 
be effective in imatinib-resistant patients. 
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1.0  INTRODUCTION 
1.1 SRC FAMILY OF KINASES (SFKs) 
1.1.1 Overview 
Almost one century ago, Peyton Rous discovered that injection of cell extracts from chicken 
tumors could cause tumors in healthy chickens (1). This led to the revolutionary idea that cancer 
could be caused by transmissible agents such as viruses, for which Rous received the Nobel Prize 
in Physiology and Medicine in 1966. This pioneering work led to the identification of viral Src 
(v-src), the transforming element of the Rous sarcoma virus in chickens and the first retroviral 
oncogene to be described (2, 3). The realization that v-src was derived from a cellular gene, the 
proto-oncogene c-src, earned J. Michael Bishop and Harold E. Varmus the Nobel Prize in 
Physiology and Medicine in 1989 (4, 5). Since its discovery, c-src and the related family 
members have been the subject of intensive investigation for nearly three decades (6, 7). 
Like its viral counterpart, c-src encodes a non-receptor tyrosine kinase, c-Src - the 
archetype of the Src family kinases (SFKs) (8, 9). In humans, SFK consists of eight 52-62 kDa 
members (Blk, Fgr, Fyn, Hck, Lck, Lyn, c-Src, and c-Yes) (10). In addition, the human genome 
encodes three closely related kinases, frk, srm, and brk, with similar domain organization that 
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were recently classified as SFKs. However, these kinases, together with Src42A have recently 
been re-classified into the Brk family of tyrosine kinases (11). 
Several SFK members (c-Src, Fyn, c-Yes) are ubiquitously expressed (See Table 1 for 
expression pattern of SFKs) (12). The remaining SFKs have a more restricted expression pattern 
and are found mainly in hematopoietic cells (13). In the case of Src, Fyn, Lyn and Hck more than 
one isoform has been identified arising from alternative splicing, separate genetic loci (Lyn), or 
alternative use of translational initiation sites (Hck) (14-17). Taken together, these observations 
indicate that SFKs have a complex and overlapping pattern of expression and that all cells, with 
the exception of erythrocytes, express multiple SFKs and potentially multiple isoforms of an 
individual member. The significance of the SFK isomers or their redundancy in various tissues 
remains elusive. 
Table 1: SFK expression patterns 
SFK Cell type Reference 
Hck Myeloid (18, 19) 
Lyn B cells, myeloid cells, natural killer cells (20) 
Fgr Monocytes, macrophages (21) 
Src Platelets, neural, fibroblasts, mammary (22) 
Fyn T cells (FynT), brain (FynB) (23) 
Lck T cells (24) 
Blk B cells (25) 
Yes Neural, Gastrointestinal (26) 
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1.1.2 Structure and Intramolecular Regulation 
1.1.2.1 Overview of the structure 
All SFK members share a similar domain organization, which includes six distinct regions: a 
Src-homology (SH) 4 domain, a unique region, an SH3 domain, an SH2 domain, an SH1 (kinase 
catalytic domain) and a C-terminal tail containing a regulatory phospho-tyrosine residue (Figure 
1) (27).  
1.1.2.2 The SH4 domain 
The SH4 domain encodes a 9-15 amino acid sequence that contains signals for lipid 
modifications (28). All SFKs contain a consensus myristoylation signal sequence (Met-Gly-X-X-
X-Ser/Thr). Myristoylation directs their localization to the cytoplasmic face of the plasma 
membrane or to other intracellular membranes such as endosomes, perinuclear membranes or 
secretory vesicles (28, 29). In addition, all members of the family except for Src and Blk contain 
cysteine residues within their SH4 domain that are sites of palmitoylation (29, 30). 
Palmitoylation of SFKs is believed to be important for targeting to lipid rafts, which are 
specialized plasma membrane microdomains critical for the clustering of receptor signaling 
complexes (31, 32).  
 3 
  A 
  B 
 
Figure 1: The domain organization of the SFKs 
(A) Crystal structure of Hck is shown as a representative model of SFK in downregulated state (PDB 1QCF). The 
SH4 and unique domains were deleted for crystallization purposes. Domains in the structure are color-coded and 
correspond to the schematic in B. The activating Tyr-416 and inhibitory Tyr-527 residues are indicated in red. 
Phosphorylation at Tyr-416 in the kinase domain is required for activation. The engagement between the SH3 and 
SH2:kinase linker as well as phospho-Tyr-527 in the C-terminal tail interaction with the SH2 domain, contribute to 
the maintenance of the downregulated conformation. By convention, amino-acid residues are numbered as in 
chicken c-Src. (B) Schematic of domain organization of SFKs. 
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While lipid modification is unimportant for the maintenance of kinase activity in vitro, it 
is often essential for the SFK biological activity (28). The importance of SFK targeting to its 
appropriate intracellular location for their proper function and signal transduction, is highlighted 
by the use of myristoylation or palmitoylation inhibitors as effective inhibitors of SFKs (33). For 
example, the most common N-myristoylation inhibitor is 2-hydroxymyristic acid (HMA) (34, 
35). HMA treatment induces relocation of Lck or Fyn to the cytosolic fraction, or the 
displacement of Lyn from lipid rafts. This in turn leads to their inactivation due to their inability 
to associate with their signaling partners (33).  
In addition to lipid attachment, a modification unique to Fyn was recently described. The 
SH4 domain of Fyn was shown to be tri-methylated at Lys residues 7 and/or 9 (36). Mutants of 
Fyn at these residues failed to induce cell adhesion and spreading, suggesting that methylation is 
required for its proper localization and/or function (36). 
1.1.2.3 The Unique Domain 
Following the SH4 domain, the unique domain encompasses 50-70 amino acids. Unlike the rest 
of the molecule, which displays high sequence homology between all the members of the family, 
the unique domain is highly divergent among the family members. Various functions have been 
attributed to the unique domain of various SFKs. For instance, in Lck, the unique domain 
mediates its interaction with the cytoplasmic tails of CD4 and CD8 surface molecules (37), 
indicating that this region has a role in the recruitment of member-specific signaling partners. In 
the case of Hck, it has been shown that autophosphorylation at a residue in the unique domain 
modulates the catalytic activity of this SFK through an unknown mechanism (38). Furthermore, 
Fyn and Lyn are efficiently cleaved in a caspase-dependent manner after an Asp residue at 
position 19 or 18, respectively (39). This process occurs in hematopoietic cells undergoing 
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apoptosis. Cleavage of the N-terminal domain of Fyn and Lyn was linked to increased enzymatic 
activity, suggesting a novel mechanism for the regulation of SFKs with possible functional 
consequences (39). Last but not least, member-specific serine and threonine phosphorylation 
sites were identified in the unique domains of Src or Lck. However, their role in the modulation 
of protein-protein interaction or regulation of catalytic activity remains unclear (40-43).  
1.1.2.4 The SH3 Domain 
In general, SH3 domains contain an average of 40 to 70 amino acids, and bind conserved 
proline-rich sequences initially defined as PXXP motifs, where P is proline and X is a variable, 
usually hydrophobic amino acid (44, 45). 
SH3 domain structure has been extensively studied using both X-ray crystallography and 
NMR spectroscopy (46, 47). A typical SH3 domain has a β-barrel arrangement of five anti-
parallel β-strands that form two β-sheets packed at almost right angles (47-49). In addition, SH3 
domains contain two loops termed RT and n-Src loops (47). The ligand-binding surface of the 
SH3 domains is highly hydrophobic and displays three shallow pockets flanked at either end by 
the RT or n-Src loops (46-48). These loops often contain charged residues that regulate 
specificity and orientation of ligand binding. 
A more in depth characterization of SH3 binding partners led to the description of two 
classes of ligands that bind to SH3 domains in opposite orientations. Class I ligands have a 
RxxPxxP motif while class II ligands have a PxxPxR canonical sequence (50-52). When bound 
to the SH3 domain, both motifs acquire a polyproline type II helical structure (PPII helix). This 
helix has a triangular cross-section with the two prolines at the base of the triangle. The two 
prolines occupy two of the three shallow pockets in the SH3 domain ligand-binding surface. In 
 6 
addition, the third shallow pocket is occupied by a basic Arg residue situated distal from the 
PxxP core (46). 
In SFKs, SH3 domains fulfill two important roles. First, SH3 domains were shown to 
contribute to substrate recruitment (53, 54). In addition, SH3 domains are critical for the 
regulation of the kinase activity. Crystallography studies of several SFKs in a downregulated 
state showed that the SH3 domain binds intramolecularly to a proline-rich sequence in the 
SH2:kinase linker (55, 56). This interaction results in the tethering of the SH3 domain to the 
back of the kinase domain and helps in generating an inactive conformation of the kinase. Figure 
1 shows the molecular model of the SFK Hck in its downregulated conformation, with the SH3: 
linker interaction intact.  
1.1.2.5 The SH2 domain 
SH2 domains contain on average 100 amino acid residues and bind specific phosphotyrosine-
containing peptides (57, 58). Structurally, SH2 domains contain a central β-sheet, with one alpha 
helix packed against each side. These features give rise to two binding pockets, one that 
coordinates the phosphotyrosine by means of a conserved arginine residue, and the second that 
accommodates one or more hydrophobic residues C-terminal to the phosphotyrosine (59). While 
the first pocket is highly conserved, the second recognition pocket is much more divergent, 
serving as a specificity determinant amongst different SH2 domains (57). The SFK SH2 domains 
bind preferentially to a phosphorylated YEEI motif, with phosphotyrosine occupying the first 
pocket and the isoleucine occupying the second (60). 
Similar to the SH3 domain, the SH2 domain in SFKs serves a dual role. First, binding 
interactions mediated by the SH2 domain, contribute to substrate recruitment and facilitate the 
transmission of signals to downstream effectors. Second, within the inactive SFKs, the SH2 
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domain binds a phosphotyrosine residue located in the C-terminal tail of the protein (Tyr-527 in 
chicken c-Src). This interaction was recently shown to be stabilized by an additional interaction 
between the SH2 domain and the SH2:kinase linker (61). This intra-molecular interaction helps 
to lock the kinase in an inactive conformation and represents an additional autoregulatory 
mechanism (56, 62-64). 
1.1.2.6 The SH3/SH2 clamp 
Multiple studies suggest that through their intramolecular interactions, the SH3 and SH2 
domains cooperate to induce a downregulated conformation of the kinase domain. Thus, the SH3 
and SH2 domains are turned inward and bind to the distal face of the kinase domain locking it 
into a rigid conformation (55, 56, 62-64). The effectiveness of the SH3/SH2 clamp was shown to 
depend on a rigid conformational coupling between these domains as well as on the SH2 - C-
terminal tail interaction. Mutation of the SH3-SH2 connector residues to glycines, is sufficient to 
induce a release of the phospho-tyrosine tail of the kinase and to induce activation (65). 
Conversely, the release of the tail from the SH2 domain upon dephosphorylation, induces a 
collapse of the connector that allows individual movement of the SH3 and SH2 domains (65). 
The binding of the SH3/SH2 clamp to the back of the kinase domain may decrease the overall 
flexibility of the kinase domain, a feature important for the enzyme function (66, 67). 
1.1.2.7 Tyrosine kinase domain 
The catalytic domains of Ser/Thr and Tyr kinases contain about 300 residues and, as revealed by 
X-ray crystallography, share a common, bilobed architecture (Figure 2, A)(68, 69). The smaller, 
amino-terminal lobe (N-lobe) is composed of a five-stranded antiparallel beta-sheet and an α 
helix (αC). The larger, carboxy-terminal lobe (C-lobe) consists mainly of α-helices with only a 
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few beta strands. Catalytic activity occurs in a cleft between the two lobes, which are connected 
by a flexible hinge region. This hinge allows the two lobes to move relative to each other during 
activation or inactivation events.  
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Figure 2: The structure of the inactive kinase domain of an SFK 
(A) Cartoon representation of the inactive conformation of Hck kinase domain and C-terminal tail (PDB: 1QCF). 
This cartoon was prepared using Pymol. The elements important for the regulation of activity are color-coded as 
follows: alpha C helix - red; P-loop – blue; catalytic loop – orange; DFG motif – blue; activation loop (which starts 
with the DFG motif) - magenta; Tyr-416 and Tyr-527- red; Lys-295, Glu-310, and Asp-404 - green. (B) Sequence of 
the Hck kinase domain and C-terminal tail, indicating the position of the structural and regulatory elements 
represented in A. All these elements are color-coded consistent with the structure in A.  
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Each of the two lobes contain highly conserved elements that are important for catalysis 
or for the correct conformation of the catalytic site (figure 2, B) (70). In the N-lobe of SFKs, 
these key elements are: Trp-260 at the N-terminus, the phosphate-binding loop (P-loop, amino-
acids 273-281), the αC helix, Lys295 and Glu310 (chicken c-Src numbering). In addition, the C-
lobe elements important for the kinase structure and function are: the catalytic loop (amino-acids 
386-392) with strictly conserved Asp and Asn residues, the activation loop (amino-acids 404-
432) containing the DFG motif (amino-acids 404-406) and Tyr-416, the site of 
autophosphorylation. All of these elements undergo significant modifications in their orientation, 
phosphorylation status or interaction with various partners, and this in turn modulate the 
transition between the inactive to active conformation of the kinase domain, or the catalysis of 
phosphate group transfer. The role of each of these key structural elements is described in more 
detail in the next two sections. 
The inactive conformation 
The structures of downregulated human and chicken Src kinases and human Hck have been 
solved by X-ray crystallography (56, 62, 64). Several elements contribute to the maintenance of 
the inactive conformation of SFKs. For example, Asp-404, which lies at the N-terminus of the 
activation loop within the DFG motif, forms an ionic interaction with Lys-295. This interaction 
induces the side chain of Phe-405 to come into steric clash with the αC helix in N-lobe, and 
pushes it away from the catalytic center (63). In addition, residues 413-418 of the activation loop 
form a short α helix that is located under the αC helix of the N-lobe, and which positions the 
unphosphorylated Tyr-416 into the catalytic site of the kinase domain where it forms hydrogen 
bonds with Arg-385 and Asp-386 (62, 63). Consequently, Tyr-416 is well protected from 
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autophosphorylation and the activation loop occludes the entry to the catalytic domain and 
effectively prevents the binding of peptide substrates. 
Another stabilizing factor for the outward, inactive position of the αC helix is Trp-260, a 
highly conserved residue within SFKs and other non-receptor tyrosine kinases. This residue lies 
at the interface between the SH2:kinase linker and the N-lobe of the kinase and points into a 
hydrophobic region at the C-terminus of the αC helix (64). The role of Trp-260 in the 
stabilization of the αC helix in a non-catalytic conformation is also supported by the fact that this 
residue does not contact the αC helix in the structure of the active Lck kinase domain (71). In 
addition, Leu-255 within the SH2:kinase linker also points into a hydrophobic pocket in the back 
of the N-lobe and may have a role in the stabilization of the inactive αC helix (72). 
The active conformation 
Activation of SFKs occurs upon phosphorylation at Tyr-416 in the activation loop (73, 74). 
Phosphorylation at this residue induces the activation loop to adopt an extended conformation 
away from the catalytic cleft, allowing contacts between Tyr-416 and Arg-385/363 or Arg-
409/387 residues that lie outside of the cleft (71, 75). The change in the orientation of the 
activation loop, in particular of the Arg-404 within the DFG motif induces an inward rotation of 
the αC helix in the N-lobe. This conformational change is stabilized by an ionic interaction 
between Lys-295 and Glu-310, an interaction that is critical for kinase activity (62, 63). 
Another putative mechanism of activation involves the release of the SH3/SH2 clamp. 
The release of the SH3/SH2 clamp may induce a displacement of Trp-260 from the hydrophobic 
pocket in the N-lobe, inducing a destabilization of the non-catalytic αC helix conformation. 
Mutagenesis studies support the notion that Trp-260 acts as a switch to communicate the position 
of the SH3/SH2 clamp to the kinase domain (76). In addition, SH3/SH2 clamp release is likely to 
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disrupt the conformation of the activation loop and to remove the steric clash with the αC helix, 
allowing it to adopt an active conformation (27). 
The transfer of γ-phosphate from the ATP molecule to the tyrosine substrate proceeds by 
direct attack of the hydroxyl oxygen of the tyrosine residue on the γ-phosphate and requires the 
presence of a divalent metal ion (77). This reaction is facilitated by several motifs or individual 
residues located within both the N and C-lobes. The P-loop, which lies between β1 and β2 
strands, coordinates the phosphates in the ATP molecule and contains a highly conserved 
glycine-rich motif (GXGXΦG) where Φ is a Tyr or Phe (78, 79). The Gly residues coordinate 
the phosphates in the ATP molecule via backbone interactions while the Φ residue caps the 
phosphate transfer site. In addition, Asp-386 within the catalytic loop induces a catalytically-
competent orientation of the tyrosyl group. Lastly, Asp-404 within the activation loop binds 
Mg2+, which in turn coordinates the β- and γ-phosphate groups of ATP (80). 
1.1.2.8 C-terminal tail 
The C-terminal tails of SFKs (residues 521 to 535 in c-Src) contain a Tyr residue (Tyr-527) that 
is phosphorylated by either C-terminal Src kinase (Csk) or by the Csk-homologous kinase (Chk) 
(65, 81). Phosphorylation at this residue creates a low-affinity SH2-binding site and induces 
intramolecular binding of the C-terminal tail to the SH2 domain (64, 81, 82). Although this SH2 
binding site is suboptimal, purified SFKs show highly stable association of the SH2 domain and 
the C-terminal tail, with only 2% displaying the SH2 domain released from the tail (83). This 
stable association may also be promoted by an additional interaction between the SH2 domain 
and the SH2:kinase linker (61). Disruption of the SH2:tail interaction is sufficient to activate the 
 13 
kinase. Mutation of Tyr-527 to phenylalanine or deletion of the C-terminal tail (as in v-Src), 
results in a constitutively active tyrosine kinase (84-86). 
1.1.3 Extrinsic regulators of SFK activity 
1.1.3.1 Regulation by phosphorylation 
Phosphorylation at Tyr-416 in the activation loop is required for maximal activation of SFKs 
(87). Phosphorylation at this residue is believed to occur mostly by trans-auto-phosphorylation 
upon clustering of at least two identical molecules in the same area. In addition, it has been 
suggested that different SFKs can transphosphorylate each other on this residue and even that 
other tyrosine kinases can phosphorylate this site (88). While phosphorylation at Tyr-416 
induces tyrosine kinase activation, phosphorylation of the C-terminal Tyr-527 residue induces 
intramolecular interaction with the SH2 domain and promotes an inactive conformation (see 
section 1.1.2.8). 
1.1.3.2 Regulation by dephosphorylation  
Dephosphorylation can either activate or inactivate SFKs, depending on the phospho-Tyr residue 
involved. Dephosphorylation of the C-terminal phospho-Tyr was shown to be mediated by 
several protein tyrosine phosphatases (PTPases) including proline-enriched tyrosine phosphatase 
(PEP), tandem SH2 domain-containing protein tyrosine phosphatase or SHP1, or by the 
transmembrane receptor-like protein phosphatase CD45 (89-91). However, these PTPases were 
also shown to have the ability to dephosphorylate the phospho-Tyr-416 within the activation 
loop (90-93). Interestingly, the same phosphatases have been associated with either activation or 
inhibition of SFKs. Which Tyr residue is dephosphorylated at any given time may depend on the 
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cell type, subcellular compartment, or on the SFK conformation or interaction partners (83). In 
addition, a downregulated conformation of SFKs could be induced by dual action of a kinase and 
a phosphatase. For example, PEP was found to dephosphorylate the Tyr in the activation loop 
while bound to the SH3 domain of Csk that phosphorylates the tail tyrosine (91, 94). 
1.1.3.3 Regulation by interaction with binding partners 
Another mode of SFK activation takes place upon ligand binding to their SH3 domain, which 
induces a disruption of the intramolecular downregulatory interaction with the SH2:kinase linker 
(81). Work in our laboratory and others showed that displacement of the SH3 domain due to 
mutations in the linker PXXP motif or due to binding of HIV-1 Nef to the SH3 domain of Hck is 
sufficient to activate Hck and to induce a transformed phenotype in Rat-2 cells (95-97). Other 
SFK physiological substrates such as p130Cas, Stat3 or Ras act in a similar manner (98).  
Another mode of activation due to interaction with binding partners is through the 
disruption of the SH2:tail interaction. For example, SFKs have been implicated in signal 
transduction by both cytokines and growth factors. The mechanism of SFK activation by growth 
factor receptor tyrosine kinases may involve SH2-dependent recruitment to the activated, 
autophosphorylated form of the receptor. Binding of the SH2 domain to the receptor may induce 
Src activation by displacing the negative regulatory tail leading to phosphorylation of the 
receptor in some cases (81, 99). 
Work in our laboratory suggests that the two modes of activation discussed above may 
occur independently of each other. On one hand, a High Affinity Linker mutant of Hck (HAL) in 
which the SH3 domain is tightly bound to the SH2:kinase linker can be activated through the 
release of the SH2 domain via mutation of the tail Tyr-527 (86). On the other hand, replacement 
of the wild-type tail of Hck with a high-affinity SH2-binding sequence did not affect Hck 
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activation by Nef, suggesting that activation through SH3 recruitment occurs without SH2 
release from the tail (100). 
In addition, several lines of evidence suggest that tandem engagement of both SH3 and 
SH2 domains acts cooperatively to induce the activation of SFKs.  For example, addition of Nef 
to the tail-mutant of Hck further activated the kinase above the level obtained with only the tail 
release (97, 100). Cas, a Src substrate that possesses both SH3 and SH2 –binding motifs was 
shown to require both to induce Src autophosphorylation (101). Furthermore, Focal adhesion 
kinase (Fak) contains closely placed proline and phosphotyrosine motifs shown to bind 
simultaneously to the SH3 and SH2 domains of Fyn (102). 
Collectively, these lines of evidence suggest four possible conformations of SFKs: i) a 
completely downregulated conformation in which both the SH3 and SH2 domains are engaged 
with their intramolecular ligands (linker and tail, respectively); ii) an active conformation in 
which only the SH3 domain is released; iii) an active conformation in which only the SH2 
domain is released and iv) a “fully open” conformation in which both the SH3 and SH2 domains 
are disengaged. Elucidation of these distinct conformations may provide important clues for the 
development of more selective Src inhibitors (103). 
1.1.4 SFK Biological Functions 
1.1.4.1 Overview 
SFKs play critical roles in regulating cellular responses to a variety of stimuli including: growth 
factors, cytokines, G-protein coupled receptors, oxidative stress, signals that trigger mitosis and 
adhesion signals from extracellular matrix (10, 99, 104, 105). As explained in detail in the 
previous section, all members of the family are highly regulated, exhibiting little or no activity in 
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the absence of an activating signal. Constitutively active SFKs are known to be capable of 
inducing malignant transformation of a variety of cell types [reviewed in (106)]. This section 
will focus on the involvement of SFKs in normal hematopoiesis and hematological malignancies 
(a multi-article, comprehensive review of SFK signaling in normal and malignant cells was 
published in 2004, in issue 23 of Oncogene).  
1.1.4.2 Normal hematopoiesis and the role of SFKs in hematopoietic cells 
Hematopoiesis 
Hematopoiesis is a tightly controlled, hierarchical process in which pluripotent stem cells 
develop into various types of mature blood cells [reviewed in (106)]. Mature blood cells develop 
upon stem cell commitment to hematopoietic common lymphoid or myeloid progenitors. These 
progenitor cells maintain some stem cell-like properties but they can only differentiate into a 
particular lineage.  
Hematopoietic cell growth and differentiation are controlled by growth factors and 
cytokines, which include interleukins, colony-stimulating factors, and hematopoietins (107). 
With a few exceptions, the receptors for the majority of these hematopoietic growth factors are 
transmembrane proteins that do not encode a tyrosine kinase catalytic domain (108, 109). Upon 
cytokine stimulation, the cytoplasmic or signal-transducing subunit of the receptor recruits 
cytoplasmic kinases, which results in propagation of the signal to downstream target proteins. 
Some of the kinases recruited and activated by the cytoplasmic subunit of the cytokine receptors 
include the Janus family of kinases (Jak), the SFKs, and the Tec family of kinases (110-115). 
The role of SFKs in hematopoietic cells 
Consistent with the high number of interacting partners, SFKs play multiple roles in the process 
of hematopoiesis. Several lines of evidence suggest a critical role for SFKs in blood cell 
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function. First, many of the eight family members are found predominantly or exclusively in 
various hematopoietic compartments (Table 1). Second, some SFK knock-out mice display 
prominent hematological abnormalities. For example, deletion of the Hck gene induces a defect 
in phagocytosis, although hematopoiesis proceeds normally (116). Fyn-defective mice present 
reduced TcR signaling (117), while Lck knock-out mice have defective T-cell maturation (118). 
Double Hck/Fgr knock-out mice have defective host defense against intracellular macrophage 
pathogens such as Listeria (116). Mice deficient in Lyn have a reduced number of mature B-
cells. Third, a patient with T-cell acute lymphoblastic leukemia has been identified with a fusion 
gene of lck locus and the  β-subunit of T-cell receptor gene, suggesting that SFK defects could 
induce hematological diseases (119). Fourth, several SFKs, including Fyn, Hck and Lyn, have 
been described to co-precipitate with hematopoietin/cytokine receptors (112, 120-122). 
SFKs act downstream of cytokine receptors by activating various pathways involved in 
cell growth and differentiation, migration and adhesion. Within these signaling pathways, SFKs 
either phosphorylate the signal transduction molecule itself (such as FAK) or phosphorylate an 
adaptor protein such as Cbl and Shc that link the SFK to the specific signaling molecule (Ras or 
PI3K) (123-127). 
1.1.4.3 Role of SFKs in hematological malignancies 
Constitutively active SFK variants were shown to induce malignant transformation in a variety 
of cell types [reviewed in (106)]. Activation of one or more members of the family has been 
linked to breast, colorectal, ovarian, gastric, head and neck, pancreatic, lung, brain, or blood 
cancers. In this context, they appear to be involved in multiple aspects of tumor progression, 
including proliferation, migration, invasiveness, angiogenesis, survival and resistance to 
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apoptosis (106). This section will focus on the role of SFKs in hematological malignancies other 
than CML. The roles of SFK in CML will be discussed in detail in section 1.2.4.1.   
Increasing evidence points to a role for SFKs in hematological diseases. Lyn kinase is 
predominantly expressed in B-lymphocytes and monocytes/macrophages and several reports 
suggest a role of Lyn in cancers that arise from these cells. For instance, Lyn kinase activity was 
specifically upregulated in response to IL-3 or IL-6 in myeloid leukemia cell lines or multiple 
myeloma cells, respectively (115, 128). This suggests that Lyn may be involved in IL-3 and IL-
6-dependent signal transduction and proliferation in these malignancies. In addition, Choi et al. 
showed the involvement of Lyn kinase in human malignant lymphomas of B cell origin (129). 
The Lck tyrosine kinase is expressed mainly in T cells. However, Lck may be involved in 
the growth and survival of cancers that arise from multiple blood lineages. For example, Lck 
mRNA was detected in B cell chronic lymphocytic leukemia (130). In addition, it was suggested 
that Lck has a role in B lineage acute lymphoblastic leukemia (ALL) and in B cell chronic 
lymphocyte leukemia (CLL) (131, 132).  
The Fyn tyrosine kinase is expressed as two main isoforms: FynT found in hematopoietic 
T cells and FynB found in brain (16). However, a recent report shows abnormal FynB mRNA 
expression in fresh cells isolated from ALL and CLL (133). Although the FynB protein was 
undetectable by isoform-specific immunoprecipitation, a possible role of minute levels of FynB 
in these blood malignancies could not be ruled out (133). 
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1.2 CHRONIC MYELOGENOUS LEUKEMIA (CML) 
1.2.1 Overview 
Chronic myelogenous leukemia (CML) is a myeloproliferative disease that arises from 
neoplastic transformation of a hematopoietic stem cell (See section 1.2.1.2 for details on the stem 
cell hypothesis of CML). CML accounts for 15-20% of human leukemias and has an incidence 
of approximately 1 to 5 in 100,000 individuals per year, affecting 4,500 Americans per year, or 
about 0.3% of the 1.200.000 new US cancer patients (134, 135). The median age of diagnosis is 
65 to 75 years, with males having a higher incidence (136). 
In 1845, three independent pathologists described patients with massive splenomegaly 
and leukocytosis, which we now know as two clinical hallmarks of CML [reviewed in (137)].  
Today, the clinical features of the disease are well characterized. CML has three distinct clinical 
phases: a chronic phase that may last approximately 2 to 5 years, accelerated phase that lasts 6 to 
18 months, and blast crisis phase that lasts only about 3 to 6 months (136, 138). In the chronic 
phase patients are mostly asymptomatic but develop a tremendously increased number of mature 
granulocytes in peripheral blood, weight loss, and splenomegaly. Both accelerated and blast 
crisis phases are characterized by a severe reduction in hematopoietic differentiation and 
accumulation of immature blasts in the bone marrow and in peripheral blood ( ≥ 30% blasts in 
peripheral blood or bone marrow) (138, 139). The blast crisis phenotype varies, with 
approximative 50% of the patients entering a myeloid blast stage similar to acute myeloblastic 
leukemia (AML); 30% of the patients entering a pre-B blast stage similar to acute lymphoid 
leukemia (B-ALL); and 10% of the patients developing erythroid blasts (137). 
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1.2.1.1 Philadelphia Chromosome 
The first landmark discovery in the pathogenesis of CML came in 1960 when Nowell and 
Hungerford associated CML with the consistent appearance of a chromosomal abnormality, later 
termed the Philadelphia (Ph) chromosome (140). This discovery was the first demonstration that 
a cancer may be associated with a chromosomal rearrangement. In 1973, the Ph chromosome 
was further characterized as a reciprocal translocation between chromosome 9 and chromosome 
22, now described as t(9;22)(q34;q11) (141).  In the 1980s, the Ph chromosome was shown to 
give rise to a unique chimeric gene, Bcr-Abl, due to the fusion between the “break point cluster 
region gene” (Bcr) on chromosome 22 with sequences of the c-abl protooncogene on 
chromosome 9 (142, 143). 
A closer look at Bcr-Abl revealed that there are three breakpoint regions [minor (m); 
major (M); micro (µ)] in the Bcr gene that gives rise to three variants of Bcr-Abl differing in the 
amount of Bcr included in the fusion protein (Figure 3, B) (143). These three Bcr-Abl proteins 
are named p190, in which the junction occurs between the e1 region of Bcr and a2 region of abl; 
p210 in which the junction occurs between b2/a2 or b3/a2 regions of Bcr and Abl, respectively; 
and p230 in which the junction occurs between e3/a2 regions of Bcr and Abl, respectively 
(Figure 3, B) (144). P190 encompasses the oligomerization and SH2 domain of Bcr; p210 has 
the PH and Dbl domains in addition to the oligomerization and SH2 domains; and p230 includes 
an addition of the calcium/phospholipid binding domain of Bcr (145-147). Consistent with the 
differences in the content of Bcr, the three forms of Bcr-Abl display distinct biological properties 
and are associated with different diseases (144). Specifically, p190 Bcr-Abl is associated with 
ALL; p210 with CML, and p230 with chronic neutrophilic leukemia (CNL) and CML with 
thrombocytosis (148, 149).  
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Figure 3: Schematic diagram showing the Bcr and c-Abl genes and the formation of Bcr-Abl variants 
(A) Breakpoints location in Bcr and c-Abl genes; (B) Composition of the chimeric Bcr-Abl mRNA transcripts; (C) 
Domain organization of p210 Bcr-Abl. Regulatory Tyr-412 is illustrated in red. NSL: Nuclear Localization Signal; 
DNA: DNA-binding domain; Actin: Actin-binding domain [Modified from (150)]. 
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The mechanism of Ph chromosome formation is not known. However, people exposed to high 
dose irradiation have a higher risk of developing CML (151). In addition, in vitro high-dose 
irradiation of myeloid cell lines induces the expression of Bcr-Abl transcripts similar to CML 
(152). These observations suggest that high dose irradiation may be one of the risk factors for 
CML.   
Numerous studies in mice confirmed the prediction that Bcr-Abl can induce leukemia in 
vivo. For example, enriched hematopoietic stem cells (HSC) were collected from mice pretreated 
with 5-fluorouracil. These cells were then induced to cycle in vitro using cytokine mixtures, and 
were infected with retroviral vectors carrying p210 Bcr-Abl (153). Subsequently, these HSC 
carrying p210 Bcr-Abl were transplanted in lethally irradiated mice, which later developed 
CML-like disease. More recently, p210 Bcr-Abl was found to induce a CML-like disease upon 
expression under the control of the tec gene promoter, a gene that is preferentially expressed in 
hematopoietic cells (154). In a similar approach, Bcr-Abl expression under the control of PCMV 
promoter of the murine stem cell virus induced a myeloproliferative disease similar to CML 
(150).  
1.2.1.2  Stem Cell Hypothesis 
Stem cells are defined by three distinctive properties: self-renewal, the potential to develop into 
multiple lineages and the ability to proliferate indefinitely. More than 30 years ago, Fialkow et 
al. made the observation that although only myeloid cells are expanded in the chronic phase of 
CML, both granulocytes and erythroid lineage cells contain the Ph chromosome. This suggested 
that the Ph chromosome originally occurs in a HSC and is passed down to both myeloid and 
erythroid lineages (155). In 1977, Fialkow et al. provided evidence supporting the HSC origin of 
the Ph chromosome in an elegant study using X-linked polymorphic glucose-6-phosphate 
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dehydrogenase (G-6-PD) loci in selected female chronic phase patients as markers for the 
monoclonal origin of Ph+ cells (155). Since then, the development of sensitive cytogenetic and 
molecular biology techniques has allowed the detection of Ph chromosome and Bcr-Abl 
transcripts in all hematopoietic lineages except natural killer cells, further supporting the HSC 
origin of Ph chromosome (156). 
Upon the acquisition of the Ph chromosome, the HSC undergoes proliferation and self-
renewal giving rise to a population of cells called leukemic stem cells or leukemia-initiating cells 
that initiate the chronic phase of CML (157). These leukemic stem cells share many properties 
with normal HSCs. For example, leukemic stem cells at steady-state are quiescent, have a long 
life-span and show great proliferative and self-renewal potential that enables them to maintain 
the cancer cell population (158). In addition, they display resistance to drugs and express typical 
HSC markers (159). Similar to the normal HSC, the immunophenotype of CML stem cells is 
CD34+ CD38- (160). However, there is evidence that contrary to HSC, which are negative for 
HLA-DR antigens, in CML stem cells the HLA-DR antigen may be expressed aberrantly (161).  
Using long-term cultures, Coulombel et al. showed that normal HSCs persisted in 
patients during early stages of CML (162). The relative frequency of circulating Ph+ CD34+ cells 
remains under debate and ranges between 60% to 97% (163, 164). Much effort is being made to 
optimize protocols for purging the Ph+ cells and enriching the Ph- stem cells from chronic phase 
CML patients for the purpose of autologous stem cell transplantation (163, 165). 
 More recently, increasing evidence suggests that although the Ph+ CML stem cells 
(leukemia initiating cells) are important for the initial expansion of myeloid progenitors during 
the chronic phase, other cells with stem cell-like properties support the progression to blast crisis. 
Specifically, it was shown that expression of Bcr-Abl in myeloid progenitor cells can induce 
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myeloproliferative disease in transgenic mouse models (166). In addition, Jamieson et al. 
brought evidence that the granulocyte-macrophage progenitor (GMP) pool from patients in blast 
crisis CML have increased levels of ß-catenin, as compared to the levels in normal progenitor 
cells (167). Because the GMP cells display enhanced self-renewal activity, and since in normal 
hematopoietic stem cells the process of self-renewal requires ß-catenin, the authors propose that 
granulocyte-macrophage progenitor cells are the stem-like cells that drive the progression to 
blast crisis. Lastly, a recent mathematical model of CML blast crisis also suggests that CML 
blasts are likely to result from more differentiated leukemic progenitors (168). 
1.2.2 c-Abl 
The Abl family of non-receptor tyrosine kinases consists of c-Abl (Abelson tyrosine kinase) and 
a single homolog, Arg (Abl-related gene) (169). Similar to other proto-oncogenes, c-Abl was 
discovered as the normal cellular form of the v-abl oncogene from the Abelson murine leukemia 
virus (170). c-Abl has two alternative splicing sites that generate two proteins with different 
amino-termini: a myristoylated (1b) splice variant, and a 1a splice variant that is 19 amino acids 
shorter and lacks the myristoylation site (171). c-Abl is localized at multiple intracellular sites, 
including the nucleus, cytoplasm, mitochondria, or endoplasmic reticulum, where it interacts 
with a multitude of cellular proteins, including adaptors, protein kinases and phosphatases, cell-
cycle regulators, transcription factors, and cytoskeletal proteins. c-Abl functions in a range of 
cellular processes such as cell proliferation and survival, oxidative stress, DNA damage 
responses, and actin dynamics [reviewed in (172)].  
c-Abl consists of approximately 1150 residues and is comprised of an N-terminal “cap”, 
followed by an SH3 domain, an SH2 domain, a tyrosine kinase domain, and a long C-terminal 
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region (Figure 4) (173, 174). The structural arrangement of SH3, SH2 and kinase domains of c-
Abl closely resemble the corresponding domains of SFKs (175). The C-terminal region 
encompasses an actin binding domain, DNA and SH3 binding elements, one nuclear export and 
three nuclear localization signals (172, 174, 176). 
1.2.2.1 Structure and Regulation 
Crystallographic analysis of the c-Abl 1b core (N-terminus, SH3, SH2 and kinase domain) 
revealed the structural basis of its regulation (Figure 4) (177). Similar to SFK structure, the c-Abl 
core assumes an autoinhibited conformation stabilized by a complex set of intramolecular 
interactions among its SH3 and SH2 domains and the kinase domain (178, 179). These modular 
domains were shown to dock onto the back of the kinase domain, acting as a clamp and 
restricting its conformational flexibility (177, 178). The SH3 domain interacts with the N-
terminal lobe of the kinase domain through an atypical PXXP motif within the SH2:kinase linker 
that encompasses the residues P242TVY245 (177). Contrary to SFKs, this interaction is maintained 
in the absence of the SH2 domain (180). The tethering of the SH2 domain is mediated through 
the Tyr-245 side chain that points away from the SH3 domain and interacts with the N-lobe of 
the kinase (177). Mutation of Pro-242 or phosphorylation of Tyr-245 can induce an increase in 
Abl kinase activity, suggesting that this “sandwich” interaction is essential for the maintenance 
of the downregulated conformation (181-183). 
In SFKs, the SH2 domain and the C-lobe of the kinase are kept spatially close to each 
other through an interaction between the SH2 and the phospho-Tyr C-terminal tail (184). 
Although c-Abl lacks a phosphorylated ligand, the SH2 domain is docked tightly against the C-
lobe (177). This interaction requires the binding of myristic acid to a hydrophobic pocket in the 
C-lobe, which in turn induces a specific conformational change in helix αI in the C-terminus of 
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the C-lobe. SH2 binding is promoted by the myristate-induced conformational change and is 
stabilized through a series of hydrogen bonds described in detail by Nagar et al. (177). 
Interestingly, although c-Abl 1a is not myristoylated, deletion of the N terminus in both c-Abl 
isoforms induces kinase activation, indicating that 1) the myristoyl moiety is required for the 
stabilization of the downregulated conformation of c-Abl 1b, and 2) in c-Abl 1a, there must be 
other compensatory interactions that stabilize this conformation (173, 185). Engagement of the 
SH2 domain by other proteins induces kinase activation due to the disruption of the 
downregulated conformation (186). 
The short eight-residue connector between the SH3 and SH2 domains forms a rigid 
structure highly similar to that seen in SFKs, a structure stabilized by a network of hydrogen 
bonds (177). This connector dynamically couples the SH3-SH2 into a regulatory “clamp” (177). 
In addition to the SH3-SH2 clamp, the N-terminal “cap” (N-cap) is believed to 
compensate for the lack of the phospho-Tyr tail and to further stabilize the kinase in an inactive 
conformation. For example, when expressed in HEK293, an N-cap deletion mutant of c-Abl 
displayed increased kinase activity as measured by the total cellular phosphotyrosine levels 
(173). The mechanism by which the N-cap provides an extra layer of stabilization is illustrated 
by recent crystallographic and hydrogen exchange mass spectrometry (HXMS) studies (187, 
188). The crystal structure of the c-Abl kinase core shows that residues within the cap region 
interact with both the SH3 and SH2 domains through a network of hydrogen bonds and appear to 
stabilize their docking onto the kinase domain (188). In addition, Ser-69 within the cap region is 
phosphorylated and interacts with the SH3-SH2 rigid linker. Mutations at this residue induce 
kinase activation, presumably due to N-cap destabilization (188). Lastly, studies using HXMS, 
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Chen et al. showed that the N-cap stabilizes the dynamics of the SH3 domain and has 
implications for the SH3 binding and downregulation of Abl kinase activity (187). 
Similar to SFKs, c-Abl kinase activity is also regulated by tyrosine phosphorylation and 
this process has been extensively studied (Figure 4). In the absence of activating stimuli, 
endogenous c-Abl was found to be unphosphorylated at Tyr residues (181, 189). 
Crystallographic studies showed that when unphosphorylated at Tyr-412, the activation loop 
folds into the active site, preventing substrate and ATP binding (190). Tyr-412 
autophosphorylation in trans or by SFKs was shown to induce kinase activation (191, 192). In 
addition to Tyr-412, Tyr-245 in the SH2:kinase domain linker was shown to be required for full 
activation of the kinase (183). However, the exact mechanism by which Tyr-245 participates in 
kinase activation is not well understood, HXMS studies showed that phosphorylation at this 
residue does not induce disruption of SH3-SH2:linker interaction  (183). 
Phosphorylation at several other Tyr residues has been implicated in controlling c-Abl 
activity. These residues include Tyr-134 in the SH3 domain, which is directly involved in 
binding the PXXP motif in the SH2:kinase linker, and Tyr-283 in the amino-terminal lobe of the 
kinase domain, which comes into close contact with Ser-94 of the SH3 domain (193). 
Phosphorylation at any of these residues was predicted to disrupt the SH3-linker-N-lobe of the 
kinase domain interaction and to activate c-Abl (178). In addition, c-Abl is phosphorylated by 
SFKs at various residues such as Tyr-89 in the SH3 domain (194). Phosphorylation at this 
residue results in the disruption of the negative regulatory interaction with the linker and SH2 
domain (195). 
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Figure 4: Crystal structure of the c-Abl kinase core 
The crystal structure begins at Ala-65. c-Abl regions are color-coded: cyan for the Ncap; blue for the SH3 domain;  
yellow for the SH3 domain; purple for the SH3:SH2 linker; green for the SH2 domain; light bleu for the kinase 
domain; orange for myristoyl moiety. Some of the tyrosine residues shown to be important for the regulation of 
kinase function are displayed: red for Tyr-412 and Ser-69; yellow for Tyr-245; purple for Tyr-89; cyan for Tyr-134; 
green for Ser-94; bleu for Tyr-283 (PDB: 2FO0).  
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1.2.3 Bcr-Abl 
As described in section 1.2.1.1., Bcr-Abl is a chimeric protein with constitutive tyrosine kinase 
activity, which arises upon a chromosomal translocation between chromosome 9 and 
chromosome 22 (Figure 3, A). There are three forms of Bcr-Abl: the 190 kDa Bcr-Abl that 
induces ALL, the 210 kDa that induces CML, and the 230 kDa Bcr-Abl that induces CNL 
(Figure 3, B) (196, 197). 
Structurally, Bcr-abl contains multiple domains, as shown in Figure 3, C in section 
1.2.1.1. The Bcr region is comprised of a coiled-coil oligomerization domain, a serine/threonine 
kinase domain, a pleckstrin homology domain, a Dbl/cdc24 guanine exchange factor homology 
domain, serine/threonine and tyrosine phosphorylation sites, and binding sites for the Abl SH2 
domain and Grb2 (198, 199). Because of N-terminal Bcr fusion, Bcr-Abl lacks the regulatory N-
terminal “cap” of c-Abl, but includes the SH3 and SH2 domains, the tyrosine kinase domain, and 
the large C-terminal region.  
The fusion of Bcr sequences upstream of c-Abl constitutively activates the Abl tyrosine 
kinase and is essential for Bcr-Abl oncogenicity (200, 201). The N-terminal oligomerization 
domain of Bcr is required for Bcr-Abl kinase activation (202). Zhao et al. showed that 
structurally, the first 72 amino acids of Bcr form N-shaped monomers that dimerize through the 
formation of an antiparallel coil-coil, and that two dimers associate to form tetramers (203). 
Although Bcr-Abl exhibits constitutive tyrosine kinase activity, the kinase domain may 
retain some of the intra-molecular constrain and inhibitory interactions of c-Abl (178). An 
important clue in Bcr-Abl regulation that supports this idea comes from a non-biased 
mutagenesis screen performed by Azam et al. to identify mutants of Bcr-Abl that induce imatinib 
resistance (204). In this screen, in addition to identifying residues that directly contact imatinib, 
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the authors also identified residues that map at the interface between the kinase domain and the 
SH3-SH2 clamp that had been previously shown to regulate c-Abl kinase activity (173, 181, 186, 
193, 205). The fact that mutations at residues that disrupt c-Abl inhibition also induce imatinib 
resistance in Bcr-Abl strongly suggests that mechanisms that govern c-Abl autoinhibition are 
preserved in Bcr-Abl (178). 
1.2.4 Bcr-Abl Oncogenic Signaling 
Bcr-Abl promotes leukemic transformation through several mechanisms that include: induction 
of constitutive mitogenic signaling; induction of growth-factor independence; impairment of cell 
adhesion properties; promotion of resistance to apoptosis; and disruption of the DNA-repair 
response mechanisms. Bcr-Abl oncogenic potential relies on its constitutive tyrosine-kinase 
activity and its ability to activate many different signal transduction pathways, which are 
discussed in the following sections. 
1.2.4.1 SFK-dependent signaling 
The pathological involvement of SFKs in Bcr-Abl signaling has been studied extensively and 
various groups report seemingly controversial findings (206). This controversy arises most likely 
from the different specific phases of the disease in which their role has been probed or due to 
assay differences (disease onset vs. chronic phase vs. blast crisis). In this section, I will give an 
overview of the arguments that either support or contest a role of SFKs in CML pathogenesis.  
Based on the fact that Bcr-Abl induces cytokine independence of myeloid cells and that 
SFKs are activated by these cytokines, Danhauser-Riedl et al. investigated for the first time 
whether Bcr-abl induces activation of SFKs (207). The authors showed that Bcr-Abl associates 
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with and activates Hck and Lyn kinases in murine 32D cells transformed with Bcr-Abl and in 
CML cell lines such as K562 (207). The interaction between Bcr-Abl and Hck is mediated by the 
SH3, SH2, kinase domain, and the C-terminus of Bcr-Abl, and the SH3 and SH2 domains of Hck 
(208, 209). Interestingly, although the interaction between the isolated SH2 domain of Hck and 
Bcr-Abl requires autophosphorylation of Bcr-Abl (209), the interaction of full-length Hck and 
Bcr-Abl did not require Abl kinase activity (210). These studies suggest that Bcr-Abl may 
activate SFKs through the displacement of one or more intra-molecular inhibitory interactions in 
Hck, and that multiple interaction modes may exist, depending on the activation status of Bcr-
Abl.   
Some SFKs activated by Bcr-Abl act as intermediates between Bcr-Abl and downstream 
pathways involved in leukemic transformation. For example, co-immunoprecipitation 
experiments in Bcr-Abl-transformed murine 32D myeloid cells, show that Bcr-Abl, Hck and 
Stat5 form a stable complex, in which Stat5 is phosphorylated at Tyr-699 and thereby activated. 
Expression of a kinase-dead Hck mutant suppressed Stat5 activation, suggesting that Stat5 is a 
substrate of Hck and not of Bcr-Abl (211). Importantly, work in our laboratory had shown that 
expression of this kinase-dead mutant of Hck blocks Bcr-Abl-induced transformation of myeloid 
cells (209). Together, these data suggest that Hck couples Bcr-Abl to Stat5 signaling and this 
Bcr-Abl?Hck?Stat5 pathway is required for Bcr-Abl-induced transformation.  
Lyn activation by Bcr-Abl is another example of an SFK acting as an intermediate to 
activate downstream signaling pathways (212). Bcr-Abl-induced activation of Lyn triggers G-
protein coupled receptor CXCR4-dependent signaling and results in loss of responsiveness to 
stromal-derived factor 1 (SDF-1) and activation of PI3K. This pathological pathway blocks the 
response to the SDF-1 chemokine and disrupts chemotaxis, thus increasing the ability of 
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hematopoietic progenitor cells to escape the bone marrow and potentially contributing to 
oncogenicity of Bcr-Abl (212). Interestingly, the CXCR4 expression level was shown to be 
highly downregulated in CD34+ cells from patients in blast crisis phase compared to either 
control individuals or chronic phase patients (213). Also, in a recent study, Diaz-Blanco et al. 
compared the molecular signature of CD34+ cells from chronic phase CML patients with normal 
CD34+ using microarrays that covered more than 8700 genes (214). In this study, the authors 
found Lyn and Yes to have a significantly higher mRNA expression than in normal CD34+ cells, 
providing a rationale for using dual Abl/Src inhibitors for the eradication of primitive progenitor 
cells in CML. 
Work in our laboratory performed in the CML cell lines K562 and Meg01 showed that 
A-419259, a SFK selective inhibitor, blocks CML cell proliferation and induces apoptosis 
without affecting the growth and survival of Ph-negative myeloid cells (215). The effects of this 
compound correlate with downregulation of both Stat5 and ERK activation, suggesting once 
again that SFKs couple Bcr-Abl to downstream signaling pathways. Importantly, as a 
continuation of these studies, work presented in this thesis shows that A-419259 induces growth 
arrest and apoptosis in CD34+ cells isolated from CML patients in chronic phase at a level 
comparable to imatinib (Chapter 2) (216). This strongly argues for a role of SFKs in proliferation 
and survival of CML progenitor cells, suggesting that SFKs may be an important therapeutic 
target for the eradication of CML stem cells. Indeed, dasatinib, a dual Bcr-Abl/SFK inhibitor was 
shown to be more effective against an earlier progenitor population than imatinib in primary 
CML samples (217). 
Multiple studies have implicated SFKs in phosphorylation of various sites in c-Abl or 
Bcr-Abl, which may affect their regulation, signaling or oncogenicity. For example, Hck and 
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Lyn can phosphorylate Bcr-Abl on Tyr-177 in the Bcr part of the molecule (194, 210, 218). 
Since Tyr-177 is a known binding site for Grb2, these SFKs link Bcr-Abl to the Ras and 
MEK/ERK oncogenic signaling cascades (194, 210, 218). Furthermore, Tyr-245 and Tyr-412 
were shown to represent sites of SFK-mediated phosphorylation in c-Abl (191, 192). 
Phosphorylation at Tyr-412 is necessary for the catalytic activity of c-Abl (191), while 
phosphorylation at Tyr-245 strongly up-regulates c-Abl activity, possibly due to the disruption of 
the SH3-linker interaction (183). In addition, recent work in our laboratory demonstrated that 
Hck, Lyn, and Fyn phosphorylate multiple Tyr residues in the SH3-SH2 region of Bcr-Abl, 
possibly by inducing dissociation of the autoregulatory interactions that may be retained in Bcr-
Abl (194, 195). Importantly, phosphorylation at these sites is required for full Bcr-Abl 
oncogenicity (194). Finally, Hck was shown to induce desensitization of c-Abl to inhibition by 
imatinib due to induction of an active conformation upon phosphorylation at Tyr-412 (182, 190). 
Several lines of evidence suggest a role of SFKs in CML progression to blast crisis. For 
example, Donato et al. showed that overexpression and/or activation of Hck and Lyn occur 
during CML progression (219). Furthermore, using a mouse model of CML, Hu et al. 
demonstrate that the transition of CML to lymphoid blast crisis requires the presence of Lyn, 
Hck, and Fgr (220). In addition, downregulation of Lyn using RNAi induced apoptosis in cells 
from both myeloid and lymphoid blast crisis patients (221). Lastly, Bcr-Abl was shown to induce 
elevated IGF-1 expression in blast crisis cells through the activation of Hck and Stat5b, 
suggesting a role of these proteins in the transition to blast crisis (222). 
SFKs may play an additional role in CML through a direct effect on ß-catenin, which in 
turn was implicated in CML stem and progenitor cell self-renewal, and in progression to blast 
crisis (167). Briefly, Src was shown to phosphorylate the 72 amino-acid cytoplasmic domain of 
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Muc1 (Muc1-CD), a transmembrane glycoprotein, shown to be overexpressed in various cancers, 
including CML (223, 224). Src-induced phosphorylation promotes binding of Muc1-CD to ß-
catenin and targeting of ß-catenin to the nucleus (224).  
Some of the evidence that disputes a role of SFKs in CML pathogenesis comes from 
genetic studies. For example, Hu et al. addressed the requirement of SFKs in Brc-Abl-dependent 
induction of CML using SFK-knockout mice (225). The authors used a Bcr-Abl retrovirus to 
transduce bone marrow from mice lacking the myeloid-expressed SFKs (Hck, Lyn, and Fgr), and 
determined that these marrow cells were still able to induce a CML-like syndrome in recipient 
animals. Conversely, these cells did not induce a B-cell acute lymphoblastic leukemia (B-ALL)-
like syndrome, which is also dependent on Bcr-Abl. In addition, a SFK selective inhibitor was 
effective in blocking the growth of ALL cells in vitro and in B-ALL mice, but had no effect in 
blocking CML progression (225). Together, these data suggest that Hck, Lyn, and Fgr are 
required for the onset of B-ALL but not of CML. However, it should be pointed out that 
knockout of one or more SFKs may induce functional compensation due to overexpression of 
other SFKs.  Therefore, these studies do not persuasively rule out a requirement of Hck, Lyn, or 
Fgr or of other SFKs in CML induction.  
In summary, the data discussed above represent an overwhelming body of evidence for 
the various roles of SFKs in Bcr-Abl signaling and CML pathogenesis. These include a role in 
linking Bcr-Abl to mitogenic and survival pathways; modulation of Bcr-Abl oncogenicity; 
disruption of chemotaxis that in turn may favor the escape of CML progenitor cells from the 
bone marrow; or a role in disease progression. In addition, an increasing number of studies point 
to a role for SFKs in induction of Bcr-Abl – independent resistance to imatinib. This topic will 
be discussed in detail in section 1.2.5.3. 
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1.2.4.2 SFK-independent signaling 
Ras/Raf/MEK/ERK signaling 
The MAPK pathway (Ras/Raf/MEK/ERK) is activated by many growth factors and cytokines 
and has important mitogenic and antiapoptotic roles in hematopoietic cells via downstream 
transcription factors including NF-kB, CREB, Ets-1, AP-1 and c-Myc (226-228). 
Some of the first reports linking Bcr-Abl to Ras showed that phosphorylation of Tyr-177 
in the Bcr-derived part of Bcr-Abl generates a binding site for Grb2 adapter protein. This in turn 
recruits the Sos guanine nucleotide exchange factor and facilitates Ras activation (229-232). The 
importance of Tyr-177 for Bcr-Abl oncogenicity has been widely debated. For example, 
mutation of Tyr-177 to Phe reduces Ras activation and fibroblast transformation (229) and 
prevents the induction of myeloproliferative disorder in a CML mouse model (233, 234). 
However, this mutant retains the ability to render hematopoietic cell lines growth-factor 
independent (230), suggesting the existence of alternate Bcr-Abl-dependent pathways that allow 
continuous activation of Ras (198, 235). Indeed, it was shown that Bcr-Abl activates Ras through 
another adapter molecule Shc (236, 237). Goga et al. demonstrated that recruitment of Shc by 
Bcr-Abl requires the SH2 domain of Bcr-Abl, while Cortez et al. showed that this interaction 
also required Bcr-Abl kinase activity (230, 238). Lastly, Bcr-Abl can activate Ras by binding and 
phosphorylating CrkL-C3G adapter complex (239, 240). Interestingly, to illustrate the 
importance of this complex in Bcr-Abl-induced activation of the Ras pathway, Oda et al. used a 
cell-permeable CrkL-SH3-domain blocking peptide and showed that this peptide inhibits 
proliferation of blast cells from CML patients (240). 
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STAT signaling 
The signal transducer and activator of transcription proteins (Stats) regulate many aspects of cell 
growth, survival and differentiation [reviewed in (241)]. Stats are monomeric cytoplasmic 
transcription factors that require phosphorylation at a specific, conserved Tyr residue for 
activation (241). Phosphorylation at this Tyr residue induces oligomerization, nuclear transport, 
and DNA binding. Stats were shown to be activated downstream of receptor tyrosine kinases 
(such as EGFR or PDGFR), or receptors without tyrosine kinase activity that recruit various 
cytoplasmic tyrosine kinases (such as Jaks or SFKs) (242, 243). 
The major Stats activated by Bcr-Abl are Stat1, Stat3 and Stat5 (244-246). The role of 
Stat1 in Bcr-abl-induced transformation is less clear since disruption of the stat1 gene in mice 
leads to compromised immune function and unresponsiveness to interferon (247). In addition, 
Bcr-Abl-induced transformation of growth-factor-dependent 32Dcl3 murine myeloid cells 
induced a very robust activation of Stat5, while Stat1 was only weakly activated and Stat3 
activation was not detected (248). 
Stat3 was shown to be constitutively active in Bcr-Abl–expressing embryonic stem (ES) 
cells and to promote self-renewal even in the absence of LIF (244). This constitutive activation 
of Stat3 in ES cells is also dependent on MEK kinase 1 (249). More importantly, Stat3 was 
found to be active in primary CD34+ cells from CML patients, suggesting that it might be 
involved in the maintenance of an undifferentiated phenotype in CML stem cells (244). 
The importance of Stat5 activation in Bcr-Abl leukemogenesis is supported by multiple 
observations. For example, ectopic expression of a dominant-negative Stat5 mutant decreases 
Bcr-Abl-dependent cell proliferation of Ba/F3 cells, and blocks Bcr-Abl-dependent 
transformation of primary mouse bone marrow cells (248, 250). In addition, Stat5 activation is 
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consistently observed in CML (246) and it was proposed to play a role in disease progression to 
blast crisis (251). Activation of Stat5 by Bcr-Abl was shown to require both SH3 and SH2 
domains of Bcr-Abl and to be Jak2-independent (248, 252). The mechanism of Bcr-Abl induced 
activation of Stat5 is mediated by SFKs and was discussed in section 1.2.4.1. 
Jak2 signaling 
Jak2 is a member of the Janus kinase (Jak) family of non-receptor tyrosine kinases, which are 
important regulators of cytokine growth factor receptors (253). Although Jak2 was not linked to 
the activation of Stats in response to Bcr-Abl, increasing evidence points to a role of Jak2 in Bcr-
Abl leukemogenesis. In collaboration with our laboratory, Xie et al. showed that Bcr-Abl binds 
and phosphorylates Jak2 at Tyr-1007, a residue required for its activation (254). The same group 
showed that Bcr-Abl-induced activation of Jak2 induces phosphorylation of Gab2 (found in the 
same multimolecular complex), hence linking Jak2 to other signaling pathways such as 
phosphatidylinositol-3 kinases (PI-3K) and Ras (255). In addition, Jak2 activation in Bcr-Abl 
positive cells was linked to c-Myc protein induction, a transcription factor required for Bcr-Abl 
transformation (256). Lastly, treatment of CML cell lines and 32D/Bcr-Abl cells with Jak2 
inhibitors induced apoptosis, suggesting that Jak2 may be a critical target in CML (255). 
PI-3K signaling 
The PI-3Ks are a family of proteins that catalyze the transfer of γ phosphate from ATP to 
phosphoinositides that act as anchors for pleckstrin homology (PH) domain-containing proteins 
such as Akt or phosphoinositide-dependent protein kinase-1 (PDK1). The class Ia of PI-3Ks are 
homodimers composed of a p85 regulatory and a p110 catalytic subunit.  
Bcr-Abl activates PI-3K through the recruitment of the scaffolding Grb2/Gab2 protein 
complex to phospho-Tyr-177 in the Bcr part of the molecule. This in turn interacts with the p85 
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regulatory subunit and induces PI-3K activation (257, 258). Replacement of Tyr-177 with Phe 
results in a Bcr-Abl mutant that exhibits decreased tyrosine phosphorylation of Gab2 and 
decreased PI-3K activation (259). In addition, bone-marrow myeloid progenitors from Gab2 (-/-) 
mice are resistant to transformation by Bcr-Abl, suggesting that Gab2 is a critical mediator of 
Bcr-Abl-induced activation of PI-3K (260).  
Additional scaffolding proteins implicated in the activation of PI-3K are c-Cbl, CrkL and 
c-Crk. Sattler et al. showed that Bcr-Abl induces the formation of a multimeric complex of 
signaling molecules that leads to the recruitment of p85. CrkL or c-Crk bind to Bcr-Abl through 
their SH3 domains and to c-Cbl through their SH2 domains, while p85 binds directly to c-Cbl 
through its SH3 and SH2 domains (261, 262). 
  PI-3K kinase triggers Akt activation, an upstream regulator of various transcription 
factors and pro-apoptotic molecules that have a critical role in Bcr-Abl transformation (263, 
264). For example, Akt phosphorylates BAD and inhibits its pro-apoptotic activity by inducing 
its cytoplasmic sequestration due to interaction with 14-3-3ß (265, 266). In addition, Akt inhibits 
p53 tumor suppressor function by phosphorylating MDM2, inducing its cytoplasmic export from 
the nucleus and promoting p53 ubiquitination and degradation (267, 268). Furthermore, Akt 
phosphorylates inhibitor of NF-kB kinase (IkB-kinase-α), which in turn induces phosphorylation 
and proteasomal degradation of IkB (269, 270). Degradation of IkB releases NF-kB, allowing its 
translocation into the nucleus where it functions as a transcription factor for an entire spectrum 
of target genes that facilitate tumor progression, inflammation, cell survival, angiogenesis, 
proliferation, and metastasis [reviewed in (271)]. Lastly, the PI-3K/Akt pathway was shown to 
regulate production of high levels of reactive oxygen species, which is associated with Bcr-Abl 
transformation (272, 273).  
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WNT/ß-catenin signaling 
The WNT/ß-catenin pathway promotes hematopoietic stem cell renewal since expression of a 
degradation-resistant ß-catenin mutant induces sustained proliferation in culture and in vivo 
bone-marrow reconstitution (274). In the absence of WNT signals, ß-catenin is found in a 
cytosolic complex with APC, Axin, and the Ser/Thr-kinase GSK3. GSK3 constitutively 
phosphorylates ß-catenin and initiates its degradation by the proteasome (275, 276). WNT 
factors are lipid-modified proteins that bind to Frizzled (FZD) receptors and induce inhibition of 
GSK3. This in turn induces accumulation and nuclear translocation of ß-catenin, where it 
functions as a transctiptional coactivator for genes like c-myc, c-jun and cyclin D1 (277). Several 
hematological malignancies display increased ß-catenin expression and stabilization in 
committed myeloid and lymphoid progenitors (278). 
Several reports link abnormal ß-catenin function with CML stem cells. For example, 
Jamieson et al. showed for the first time that granulocyte-macrophage progenitors from blast-
crisis and imatinib-resistant CML patients have elevated levels of nuclear ß-catenin (167). More 
recently, Bcr-Abl was shown to physically interact with ß-catenin and phosphorylate it on Tyr-86 
and Tyr-654. Phosphorylation at these Tyr residues induces disruption of ß-catenin association 
with Axin/GSK3, increasing stability, and ß-catenin transcriptional activity (279). In addition, ß-
catenin was shown to be essential for the survival and self-renewal of leukemic stem cells in 
CML cells and mouse models (167, 280-282). 
1.2.5 CML therapy 
The effectiveness of CML therapies is measured by the degree of hematological, cytogenetic or 
molecular responses. CHR, or complete hematological response, denotes the return to a normal 
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white blood count. CCyR, or complete cytogenetic remission denotes the absence of Ph 
chromosome within 20 metaphases on karyotype analysis. Lastly, CMR, or complete molecular 
response denotes the elimination of Bcr-Abl mRNA as measured by real-time quantitative RT-
PCR (283). 
1.2.5.1 Treatment before the emergence of Bcr-Abl targeted therapy 
The only curative treatment for CML remains allogeneic transplantation of normal bone marrow 
cells following a conditioning phase for the destruction of normal and leukemic cells by 
chemotherapy or irradiation (284). However, only 20% of patients are candidates for allogeneic 
bone marrow transplantation due to the lack of available compatible donors or age limitations. 
Lastly, the 5-year disease-free survival rate varies largely between 30 % to 80 % (284, 285). 
Introduced about 25 years ago, interferon-α (INF-α) was for a long time the standard 
CML therapy in patients with no matched bone marrow donor. INF-α leads to both 
hematological and cytogenetic responses in chronic phase patients (286). It has been suggested 
that INF-α induces its antileukemic effects by blocking the Jak1-Stat1 pathway and activation of 
INF-α responsive genes (287). Despite the prolonged survival, the majority of patients develop 
resistance and ultimately die of the disease. 
The second-line treatment in patients either resistant or intolerant to INF-α was Busulfan 
or hydroxyurea, which nonspecifically blocks the proliferation of both normal and Ph+ leukemic 
cells. These treatments obtained hematological responses only in the chronic phase of CML 
[reviewed in (135)]. 
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1.2.5.2 Targeted Bcr-Abl kinase inhibitor: Imatinib 
Validation of Bcr-Abl as an ideal therapeutic target in CML comes from the massive number of 
studies showing that Bcr-Abl is required for the onset and maintenance of the disease. Imatinib 
(Signal Transduction Inhibitor – STI571) is a derivative of 2-phenylaminopyrimidine, and was 
originally discovered in a screen for inhibitors of the platelet-derived growth factor receptor 
tyrosine kinase (PDGF-R). Further testing showed that imatinib specifically inhibits the 
proliferation of Bcr-Abl positive cells in vitro and the growth of Bcr-Abl positive tumors in vivo 
(288). In contrast, imatinib does not inhibit immortalized or transformed cell lines that do not 
express Bcr-Abl. Similar selective depletion of Bcr-Abl-positive cells has been observed in long-
term bone marrow cultures (289). More detailed testing revealed that imatinib inhibits c-Abl, v-
Abl, Bcr-Abl, PDGF-R α and ß, c-Kit, Arg, and c-Fms (290-294). This promiscuity was shown 
to be key to the therapeutic effects of Bcr-Abl. Wong et al. engineered an inhibitor analog-
sensitive mutant of Bcr-Abl that allowed selective inhibition of this kinase without the 
concomitant inhibition of the other target kinases, and showed that simultaneous inhibition of 
Bcr-Abl and c-Kit was required for the potent cytotoxic effects of imatinib on CML cells (295). 
In an initial, phase I clinical study, imatinib proved remarkably successful with 53 out of 
54 patients displaying CHR after only 4 weeks of treatment (296). 96% percent of these patients 
maintained CHR for over a year (297). In addition, 55% of the patients in accelerated phase or 
blast crisis achieved hematological responses (21/38) (297). In a phase II clinical study, 55% of 
the patients showed CCyR and 91% of the patients in chronic phase obtained CHR. From these, 
89% showed no disease progression (297). However, the rate of CHR in patients in accelerated 
phase of blast crisis was 69% and 29%, respectively (282, 297). In a phase III clinical study 
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conducted in CML chronic phase patients, only 3.3% showed disease progression after 18 
months (298). 
To elucidate the mechanism of imatinib binding and specificity towards Abl, numerous 
studies described the crystal structure of c-Abl core or c-Abl kinase domain in complex with 
imatinib (179, 190). Schindler et al. showed that imatinib binds to an inactive conformation of 
the kinase domain in which the activation loop is not phosphorylated and points inward (190). A 
close evaluation of these crystal structures shows that the drug is sandwiched between the N- and 
C-terminal lobes of the kinase domain. More specifically, the compound tightly fits between the 
activation loop and helix αC, locking the kinase in an inactive conformation. The binding of 
compound is stabilized through 6 hydrogen bonds with Met-318, Thr-315, Glu-286, His-361, Ile-
360, and Asp-381, and through numerous van der Waals interactions (179). 
 A comparison of active and inactive conformations of different classes of kinases 
suggested that whereas the conformations of protein kinases in active state are very similar 
amongst different kinase families, there are important differences in their downregulated 
conformations (179). Therefore, it has been proposed that the high selectivity towards Abl 
displayed by imatinib stems from its ability to exploit a fairly unique conformation of the 
inactive kinase.  
1.2.5.3 Mechanisms of resistance to Imatinib 
Despite the high rates of hematological and cytogenetic responses to imatinib, emergence of 
resistance upon exposure to the drug is a major problem for the treatment of CML (299). There 
are two main types of resistance to imatinib: Bcr-Abl-dependent and – independent mechanisms.  
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Bcr-Abl-dependent mechanisms of resistance  
One Bcr-Abl-dependent mechanism of resistance is due to gene amplification. For example, 
using dual-color fluorescence in situ hybridization (FISH), Gorre et al. reported the presence of 
multiple copies of Bcr-Abl gene in metaphase spreads from 11 patients. This amplification 
occurred within a unique inverted duplicate Ph chromosome. Interestingly, one patient displayed 
this unique Ph chromosome before imatinib exposure (300). 
A second and very well characterized Bcr-Abl-dependent mechanism of resistance is due 
to the presence of Bcr-Abl point mutations that renders it refractory to imatinib. Gorre et al. 
reported for the first time a substitution of Thr-315 with Ile in 6 patients that relapsed on imatinib 
treatment (300). This substitution not only precludes formation of a critical hydrogen bond with 
imatinib, but also, since Ile has an extra hydrocarbon group in the side chain, induces a steric 
clash with imatinib (300). Consequently, the binding of imatinib is prevented.  
Since this first report, more than 50 additional mutations inducing imatinib resistance 
have been described (301-303). These mutations tend to cluster in certain areas of the kinase 
domain such as the imatinib-binding interface (Thr-315), within the phosphate-binding loop (for 
example Glu-255, Tyr-253), activation loop (for example His-396), or at the SH2-kinase 
interface (Met-351) [reviewed in (304)]. However, many of these mutants are relatively rare in 
clinical specimens. The most common mutations, accounting for 60-70 % of all mutations, occur 
at residues Gly-250, Tyr-253, Glu-255, Thr-315, Met-351, and Phe 359 (305). Interestingly, 
some of these mutations were shown to exist prior to the onset of treatment with imatinib (303, 
306). Furthermore, two of the most clinically frequent imatinib-resistant mutants (Y253F, 
E255K) have a greater transforming potential than the wild type Bcr-Abl in cell-based assays and 
are associated with a poor prognosis (307-309). Lastly, mutation at the c-Abl residue 
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corresponding to T315 in Bcr-Abl was recently reported to induce kinase activation and 
transformation activity (310). This mutation was also associated with a much poorer prognosis 
(311).  
In an elegant study, Azam et al. used random mutagenesis on Bcr-Abl and in vitro 
selection for imatinib resistance to identify additional imatinib-resistant Bcr-Abl mutants (204). 
It is interesting that many of these mutations occur at sites that do not directly contact the drug. 
For example, some of these mutations mapped to the SH2:kinase linker, or others at the SH3-
SH2 domain linker, many of them in positions required to maintain inactive states of the enzyme 
(204, 302). Although many of these mutants were not clinically relevant and conferred only low 
resistance to imatinib, they are important for understanding Abl kinase regulation and 
mechanisms of resistance.  
Bcr-Abl-independent mechanisms 
Bcr-Abl-independent resistance has been attributed to many different mechanisms including 
enhanced drug efflux from target cells through P-glycoprotein-mediated active transport, or 
reduced intracellular drug delivery due to the presence of α1 acid glycoprotein in the membrane 
(312, 313). Other mechanisms such as activation of secondary tyrosine kinases or leukemic stem 
cells refractoriness and residual disease will be discussed below. 
In a series of articles published in the last 5 years, Donato et al. suggested a mechanism 
of resistance to imatinib involving SFKs. First, the authors showed that K562 CML cells cultured 
in increasing concentrations of imatinib displayed upregulated Lyn activity (219). Inhibition of 
Lyn kinase reduced proliferation and survival of these cells, while it did not have any effect in 
imatinib-sensitive K562 cells. In addition, analysis of clinical samples from patients in the 
advanced stages of CML that relapsed upon imatinib treatment showed an association between 
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imatinib-resistance and upregulation of either Hck or Lyn in the absence of Bcr-Abl mutations 
(219, 314).  Reducing Lyn by siRNA in mononuclear cells isolated from a patient with increased 
Lyn levels induced a reduction in cell survival (314).  
Although the vast majority of patients in chronic phase achieve CCyR when treated with 
imatinib, relapses are commonly observed after imatinib cessation (315, 316) due to the 
persistence of a limited, “residual” population of CML stem and progenitor cells that are 
intrinsically resistant to imatinib. Determination of the mutation status of Bcr-Abl in these cases 
showed that usually the relapse is not accompanied by a mutated Bcr-Abl phenotype. This 
refractoriness to imatinib was causatively associated with the stemness character of the leukemia 
initiating cells and their relative quiescence. Refractory CML cells were shown to upregulate 
genes for proteins responsible for drug efflux, elimination and detoxification (317). Numerous 
studies have addressed the cause of imatinib resistance in this population. In a recent report, 
Diaz-Blanco assessed differential gene expression in total CD34+ from CML patients in chronic 
phase compared to normal CD34+ cells, using microarrays covering over 8700 genes (214). 
Apart from some known transcriptional changes previously shown to take place upon Bcr-Abl 
expression in this cellular compartment (activation of MAPK and PI-3K pathways), this analysis 
revealed some novel transcriptional changes. For example, the data showed higher expression 
levels of proliferation-associated genes such as CDKs and various cyclins, as well as 
downregulation of proapoptotic factors such as interferon regulatory factor 8 (214). Interestingly, 
the SFKs Lyn and Yes were found in significantly higher levels (1.56 and 1.38 times, 
respectively), suggesting a potential role for SFKs in CD34+ CML cells (214).  
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1.2.5.4 Strategies to circumvent resistance to current therapies 
The discovery of imatinib resistance has prompted a quest for the development of alternative 
therapies to override this resistance. Within these new therapies, Bcr-Abl kinase activity remains 
a valid target since many cases of resistance occur due to the accumulation of a leukemic clone 
with Bcr-Abl point mutations. However, in the case of residual disease or other types of 
resistance, it is important to direct these new therapies towards novel targets in alternative 
pathways.  
Improved Bcr-Abl inhibitors recently developed include: 1) selective Abl inhibitors such 
as nilotinib (Novartis) that is about 30 times more potent than imatinib and inhibits 32 of 33 Bcr-
Abl imatinib-resistant mutants, with the exception of T315I mutants (318, 319); 2) non-ATP 
competitive inhibitors such as GNF-2 which binds to the myristoyl binding site and inhibits the 
kinase activity allosterically (320); and 3) Aurora kinase inhibitors such as MK-0457 (Merck) 
which inhibits Aurora kinase, Flt3, Abl, and Jak2. Importantly, MK-0457 also inhibits T315I 
mutant of Bcr-Abl (321). Although some of these inhibitors have improved activity towards 
some Bcr-Abl imatinib-resistant mutants, in many cases this improved activity is accompanied 
with a wider spectrum of activity that historically has been associated with increased side effects 
or intolerance.  
 Given the importance of SFKs in Bcr-Abl signaling and resistance to imatinib, dual Abl 
and SFK inhibitors such as dasatinib (Bristol-Myers Squibb) are very promising compounds. The 
dual character of dasatinib lies in its flexibility in binding to different conformations of Bcr-Abl, 
some of which are similar to the SFK active conformations (322). It has been shown that 
dasatinib inhibits 21 out of 22 imatinib-resistant Bcr-Abl mutants, with the sole exception once 
again being the T315I mutant (323, 324). 
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Another unique mechanism of inducing Bcr-Abl inhibition was recently described by 
Bartholomeusz et al. and consists of induction of a Bcr-Abl-destruction pathway by WP1130. 
WP1130 is a second-generation tyrphostin derivative (degrasyn) discovered during screens for 
AG490-like molecules that suppress IL-6 and IL-3 activation of Stats (325). Although WP1130 
was shown to induce rapid downregulation of Jak kinases, the mechanism of Bcr-Abl destruction 
is currently unknown.  
Finally, due to the general resistance and refractoriness of CML stem cells, targeting the 
“residual disease” has proved very challenging. However, recently two approaches show 
significant promise. First, BMS-214662, a farnesyl transferase inhibitor developed by Bristol-
Myers Squibb shows apoptotic activity not only against imatinib-resistant or blast crisis CML 
cells, but also against CML stem and progenitor cells (326). Second, based on proven cell-
surface presentation of Bcr-Abl epitopes encompassing the fusion region, immunotherapy of 
residual disease is also promising (327). Multiple immunotherapy clinical trials are currently 
ongoing.  
1.3 HYPOTHESES AND SPECIFIC AIMS 
1.3.1 Hypotheses 
The Src family of non-receptor tyrosine kinases (SFK) is comprised of eight members in 
humans: c-Src, Hck, Fgr, Blk, Lck, Lyn, c-Yes, and Fyn. Although some Src members are 
ubiquitously expressed, Hck, Lyn, Fgr, Lck, and Blk, are restricted to a few hematopoietic cell 
types. SFKs critically regulate a variety of cellular processes such as proliferation, motility, 
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adhesion, angiogenesis, and survival (7). However, overexpression and/or aberrant activation of 
SFKs have been linked to various cancers (7, 328).  In the context of chronic myelogenous 
leukemia (CML), Bcr-Abl, the oncogenic protein-tyrosine kinase responsible for the onset of 
CML, binds to both Hck and Lyn, and this interaction leads to an increase in Lyn and Hck 
tyrosine kinase activity (207). Work in our laboratory has shown that general Src-kinase 
inhibitors of the pyrrolo- and pyrazolo-pyrimidine (PP) classes block the transforming activity of 
Bcr-Abl in CML-derived cell lines (215). In addition, Hck has been shown to couple Bcr-Abl to 
Stat5 activation in leukemia cells, which may increase survival (211). Given the involvement of 
Hck in the pathogenesis of CML, I propose the hypothesis that Hck cooperates with Bcr-Abl 
in CML pathogenesis. Furthermore, although imatinib, the frontline therapy in CML, proved 
remarkably effective in patients in the initial phase of CML, patients in advanced phases develop 
resistance. In 50 % to 70 % of the cases, resistance to imatinib occurs due to point mutations in 
the abl kinase domain of Bcr-Abl that interfere with imatinib binding (329). Interestingly, in 
other patients with wild type Bcr-abl, resistance has been associated with either overexpression 
or overactivation of the SFKs Hck and Lyn (330, 331).  Based on this association, I also propose 
the hypothesis that Hck overexpression in CML cells induces imatinib resistance. To 
address this hypotheses, I used the power of chemical genetics and pursue the following aims (1) 
to investigate the independent contribution of Hck to Bcr-Abl signaling and cellular 
transformation in K562 cells using a mutant that is genetically engineered to be resistant to the 
general SFK inhibitor, A-419259; and (2) to investigate the effect of Hck overexpression on 
imatinib resistance in the context of a wild-type Bcr-Abl.  
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1.3.2 Specific Aims 
Aim 1. To investigate the independent contribution of Hck to Bcr-Abl signaling and 
cellular transformation in K562 cells using a mutant that is genetically engineered to be 
resistant to the general SFK inhibitor, A-419259. 
In this aim, I adapted a chemical genetics approach to develop an A-419259-resistant mutant of 
Hck by replacing the gatekeeper residue (Thr-338) in the inhibitor-binding site with a bulkier 
methionine residue (Hck-T338M).  This substitution reduced Hck sensitivity to A-419259 by 
more than 30-fold without affecting kinase activity in vitro. Expressing this mutant in CML 
cellular models and pairing it with the global SFK inhibitor, A-419259, I was able to show that 
Hck plays a non-redundant role as a key downstream antiapoptotic signaling partner for Bcr-Abl.  
 
Aim 2. To investigate the effect of Hck overexpression on imatinib resistance in the context 
of a wild-type Bcr-Abl. 
In this aim, I showed that Hck overexpression in CML cells is sufficient to induce resistance to 
imatinib. In addition, to establish the mechanism of Hck-induced resistance to imatinib, I used a 
second chemical genetic strategy, originally developed by Shokat and co-workers (332). This 
strategy introduces a silent mutation into the ATP-binding pocket of Hck (T338A) to produce 
unique sensitivity to NaPP1, a bulky analog of global SFK inhibitors of the pyrazolo-pyrimidine 
class. Using this inhibitor-sensitive mutant of Hck, I determined that Hck-kinase activity is 
required to induce imatinib-resistance in K562 cells.  
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2.0  AN INHIBITOR-RESISTANT MUTANT OF HCK PROTECTS CML CELLS 
AGAINST THE ANTI-PROLIFERATIVE AND APOPTOTIC EFFECTS OF THE 
BROAD-SPECTRUM SRC-FAMILY KINASE INHIBITOR A-419259 
2.1 ABSTRACT 
Chronic myelogenous leukemia (CML) is driven by Bcr-Abl, a constitutively active protein-
tyrosine kinase that stimulates proliferation and survival of myeloid progenitors. Global 
inhibition of myeloid Src-family kinase (SFK) activity with the broad-spectrum pyrrolo-
pyrimidine inhibitor A-419259 blocks proliferation and induces apoptosis in CML cells, 
suggesting that transformation by Bcr-Abl requires SFK activity. However, the contribution of 
Hck and other individual SFKs to Bcr-Abl signaling is less clear. Here we developed an A-
419259-resistant mutant of Hck by replacing the gatekeeper residue (Thr-338) in the inhibitor 
binding site with a bulkier methionine residue (Hck-T338M).  This substitution reduced Hck 
sensitivity to A-419259 by more than 30-fold without affecting kinase activity in vitro.  
Expression of Hck-T338M protected K-562 CML cells and Bcr-Abl-transformed TF-1 myeloid 
cells from the apoptotic and anti-proliferative effects of A-419259.  These effects correlated with 
persistence of Hck-T338M kinase activity in the presence of the compound, and were 
accompanied by sustained Erk and Stat5 activation.  In contrast, control cells expressing 
equivalent levels of wild-type Hck retained sensitivity to the inhibitor.  We also show for the first 
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time that A-419259 induces cell-cycle arrest and apoptosis in primary CD34+ CML cells with 
equal potency to imatinib.  These data suggest that Hck plays a non-redundant role as a key 
downstream signaling partner for Bcr-Abl and may represent a potential drug target in CML.    
2.2 INTRODUCTION 
Chronic myelogenous leukemia is an acquired genetic hematological malignancy that affects 1 in 
100,000 people each year and is characterized by clonal expansion of transformed multipotent 
hematopoietic stem cells (135). The hallmark genetic anomaly of CML is the Philadelphia 
chromosome (Ph+) that results from a reciprocal chromosomal translocation between the c-abl 
locus on chromosome 9 and the bcr locus on chromosome 22 (141, 333). Bcr-Abl, the protein 
product of this translocation, is a 210 kDa chimeric tyrosine kinase with abnormal cytoplasmic 
localization (334). Bcr-Abl transforms fibroblasts, growth factor-dependent hematopoietic cell 
lines and primary bone marrow cells in culture (335-337) and induces a myeloproliferative 
disorder that closely resembles CML in mice (153, 338). 
Constitutive tyrosine kinase activity and cytoplasmic relocalization underlie the ability of 
Bcr-Abl to activate numerous signal transduction pathways and promote cell proliferation and 
survival (261). For example, Bcr-Abl was shown to activate the Stat5 transcription factor, 
inducing its nuclear translocation and transcription of cell growth and survival genes such as 
Cyclin-D1 and Bcl-XL (245, 246, 339, 340). Bcr-Abl also activates the PI3K/Akt pathway upon 
phosphorylation of Tyr-177 in the Bcr region and recruitment of Grb2/Gab2 adapter proteins 
(261). Additionally, PI3K is also activated by Bcr-Abl via other adapter proteins such as Shc 
(341, 342), Crkl and c-Cbl (261) or by direct binding of the p85 subunit of PI3K to Bcr-Abl 
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(263, 343). Activation of PI3K leads to suppression of programmed cell death via Akt and other 
pathways.  Similarly, the Ras/Erk pathway is activated by Bcr-Abl either upon phosphorylation 
of Bcr-derived Tyr-177 and direct Grb2/Sos recruitment or via the Shc adaptor protein (230, 
259). By stimulating the Ras/Erk pathway, Bcr-Abl increases growth-factor independent cell 
proliferation. 
Members of the Src-kinase family have been strongly linked to Bcr-Abl signaling and 
leukemogenesis (209, 211, 225). Several reports have demonstrated that Bcr-Abl binds to 
multiple Src-family members including Hck, Lyn and Fyn leading to their activation (194, 207, 
209, 210).  Activation of SFKs may have a positive feedback effect on Bcr-Abl signaling, as 
SFKs directly phosphorylate Bcr-Abl at key Tyr residues critical for regulation and function. 
These sites include Tyr-177 in the Bcr part of the protein, Tyr-89 and Tyr-134 in Abl-derived 
SH3 domain, Tyr-245 in SH2-kinase linker, and Tyr-412 in the activation loop of the Abl kinase 
domain (194, 210, 229, 233, 234, 344). On the other hand, SFKs may serve as key intermediates 
linking Bcr-Abl with downstream effectors.  For example, Hck has been shown to couple Bcr-
Abl to Stat5 activation in myeloid leukemia cells, which may contribute to survival (211).  
Furthermore, global inhibition of SFK activity with the ATP-competitive pyrrolo-pyrimidine 
compound A-419259 blocks Stat5 and Erk signaling, leading to growth arrest and apoptosis in 
CML cell lines (215).  Here we show for the first time that A-419259 also blocks proliferation 
and induces apoptosis in primary CD34+ CML cells.  Other studies have shown that Hck and 
Lyn are overexpressed and activated in CML blast-crisis patients, and up-regulation correlates 
with disease progression and drug resistance (330, 331). Taken together, these studies emphasize 
the significant role of SFKs in Bcr-Abl signaling. 
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Consistent with the critical role for Bcr-Abl in CML, the Abl kinase inhibitor imatinib 
mesylate produces dramatic hematological and cytogenetic remission in most chronic phase 
CML cases (135, 345).  However, patients with advanced disease often acquire drug resistance 
and continue to progress despite imatinib therapy. In addition, residual Bcr-Abl+ primitive 
progenitor cells (CML stem cells) can persist in patients achieving complete cytogenetic 
remission (346), highlighting the need for additional therapeutic targets.  Given their important 
role in Bcr-Abl signaling and in imatinib resistance, SFKs have recently emerged as novel 
targets for CML treatment. However, the relative contribution of individual SFKs to Bcr-Abl 
signaling is not fully understood. 
In this study we investigated the independent contribution of Hck to Bcr-Abl signaling 
using a mutant (Hck-T338M) with engineered resistance to the broad-spectrum SFK inhibitor, 
A-419259. Expression of this mutant in the CML cell line K562 and in TF-1 myeloid cells 
acutely transformed with Bcr-Abl allowed persistence of Hck kinase activity in the presence of 
A-419259 at concentrations that inhibited all endogenous SFK activity. Remarkably, Hck-
T338M rescued both K562 and TF-1/Bcr-Abl cells from the apoptotic effects of A-419259 
treatment. This result correlated with sustained activation of Stat5 in the presence of the inhibitor 
and provides direct evidence that Hck alone is able to transmit anti-apoptotic signals from Bcr-
Abl.  In addition, Hck-T338M had a partial protective effect on A-412959-induced growth arrest 
that correlated with rescue of Erk signaling in K562 cells.  Taken together, our data demonstrate 
the utility of engineered inhibitor-resistant mutants to dissect the roles of individual members of 
a closely related family of protein kinases in oncogenic signaling, and point to Hck as a clinically 
relevant target for CML therapy. 
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2.3 RESULTS 
2.3.1 Design of an inhibitor-resistant mutant of Hck 
Many ATP-competitive inhibitors of protein kinases access a small hydrophobic pocket adjacent 
to the ATP-binding site in kinase domain.  Accessibility of inhibitors to this hydrophobic pocket 
is controlled by a non-conserved amino acid often referred to as the “gatekeeper” residue (347). 
Numerous studies have shown that natural variation in the gatekeeper residue is one of the main 
structural determinants of kinase sensitivity to small molecule inhibitors (300, 332, 348-350). 
Tyrosine kinases that possess a threonine at this position are sensitive to various classes of 
inhibitors that access the hydrophobic pocket (Table 1). However, replacement of the gatekeeper 
residue with more bulky amino acids such as methionine or isoleucine has been reported to 
induce resistance to these inhibitors (Table 1 and Discussion).  
 
Kinase Gatekeeper Residue Gatekeeper Mutation Inhibitor Class Refs 
c-Abl FYIIT315EFMTYGN T?I Imatinib 2-phenylaminopyrimidine (300) 
Kit TLVIT670EYCCYGD T?I Imatinib 2-phenylaminopyrimidine (351) 
PDGFR 
alpha IYIIT674EYCFYGD T?I Imatinib 2-phenylaminopyrimidine (352) 
EGFR VQLIT766QMPFGD T?M Gefitinib anilino-quinazoline (353) 
Src IYIVT338EYMSKGS T? I PP58/PP1 pyrido/pyrazolo-pyrimidine (349, 354) 
Hck IYIIT338EFMAKGS T?M A-419259 pyrrolo-pyrimidine (this study) 
 
Table 2: Peptide sequences surrounding the gatekeeper threonine at the ATP-binding site of several tyrosine 
kinases 
Mutations of this residue to methionine or isoleucine account for a common mechanism of resistance to inhibitors of 
various classes as described in the text. 
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 To determine whether we could artificially engineer resistance to A-419259 in Hck by 
increasing the size of the gatekeeper residue, we examined the crystal structure of Hck in 
complex with a related pyrazolo-pyrimidine inhibitor, A-420983 (Figure 5).  The crystal 
structure revealed close contact between the Hck gatekeeper residue [Thr-338; human c-Src 
crystal structure numbering (62)] and the inhibitor, suggesting that replacement of Thr-338 with 
a bulkier methionine residue would result in A-419259 resistance due to steric clash without 
affecting kinase activity.  
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Figure 5: Structure-based design of Hck inhibitor-resistant mutant 
(A) Orientation of A-420983, an analog of A-419259, in the Hck nucleotide-binding pocket. The overall structure of 
Hck is shown on the left, with the SH3 domain in red, the SH2 domain in blue, and the kinase domain in grey.  The 
side chain of the gatekeeper residue (T338; c-Src numbering) is highlighted in magenta. The relationship of the 
gatekeeper residue to the pyrazolo-pyrimidine moiety of A-420983 is enlarged on the right.  This model was 
produced using PyMol and the PDB file 2COI.  (B) Chemical structures of A-419259 and A-420983. 
 57 
 To address whether the T338M substitution induced Hck resistance to A-419259, wild-
type and Hck-T338M were expressed in Sf9 insect cells and purified to homogeneity in their 
downregulated conformations. Normally, Hck as well as other SFKs adopt an inactive, 
downregulated conformation in vivo due to phosphorylation of a conserved tyrosine residue in 
the C-terminal (Tyr-527) by the regulatory kinases Csk and Chk (27). To attain this 
conformation while avoiding the co-expression of the regulatory kinases, both forms of Hck 
were altered at the C-terminal tail from Tyr-527-Gln-Gln-Gln-Pro to Tyr-527-Glu-Glu-Ile-Pro 
(referred to hereafter as Hck-YEEI).  This modification promotes autophosphorylation of the tail 
independently of Csk, and was previously shown to have a higher affinity for the SH2 domain, 
stabilizing the downregulated conformation (27, 63, 82). Importantly, Hck-YEEI undergoes 
autophosphorylation and exhibits substrate phosphorylation kinetics similar to wild-type Hck 
(27, 355).  The sensitivity of recombinant Hck-YEEI and Hck-T338M-YEEI to A-419259 were 
compared in an in-vitro kinase assay using a peptide substrate. As shown in Figure 6, the T338M 
mutation induced dramatic resistance to A-419259, increasing the IC50 value by almost 30-fold 
from 11.26 ± 1.23 nM for wild-type Hck to 315.6 ± 80.3 nM for the T338M mutant. Kinetic 
analysis showed a modest difference in the Km for ATP in the T338M mutant compared to wild-
type Hck (10.7 ± 2.5 μM for wild-type vs. 3.9 ± 0.8 μM for T338M). 
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Figure 6: In vitro kinase assay of recombinant wild-type and T338M forms of Hck 
Recombinant wild-type Hck and Hck-T338M were purified from Sf9 insect cells in their downregulated 
conformations and assayed for kinase activity with a peptide substrate in vitro in the presence or absence of the 
indicated concentrations of A-419259. A representative experiment is shown and the extent of inhibition is 
expressed as mean ± S.D. of four assays.  The entire experiment was repeated twice with comparable results. Data 
from two independent experiments were best-fit by non-linear regression analysis and yielded IC50 values of 11.26 ± 
1.23 nM for wild-type Hck and 315.6 ± 80.3 nM for Hck-T338M. 
2.3.2 Hck-T338M retains its activity and A-419259-resistance in fibroblasts 
We next investigated whether the T338M resistance mutation influenced Hck biological 
signaling and if resistance to A-419259 was maintained in intact cells.  To address these 
questions, both wild-type Hck and Hck-T338M were activated by replacing the C-terminal Tyr-
527 with phenylalanine (YF mutation). This mutation was previously shown to up-regulate Hck 
kinase activity and to induce oncogenic transformation of fibroblasts, which do not express 
endogenous Hck (86, 95, 96, 356). Rat-2 fibroblasts expressing Hck-YF, Hck-T338M-YF, as 
well as wild-type Hck or the neo resistance marker as negative controls were plated in soft-agar 
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in the presence or absence of increasing concentrations of A-419259. As shown in Figure 7A, the 
T338M mutation did not impair biological activity, as cells expressing Hck-YF or Hck-T338M-
YF produced similar numbers of transformed colonies in the absence of the inhibitor. To 
determine whether transformation correlated with constitutive activation of the kinase, cell 
lysates were tested for reactivity with the phosphospecific antibody pY418. This antibody 
recognizes the conserved phosphotyrosine residue in the activation loop of active Hck and other 
SFKs (215, 356, 357). Consistent with the transformation results, both Hck-YF and Hck-T338M-
YF reacted strongly with this phosphospecific antibody (Figure 7B).  Furthermore, activation 
loop phosphorylation correlated with phosphorylation of the endogenous Hck substrate protein, 
pp40 (95, 356) as shown by anti-phosphotyrosine immunoblots of the cell lysates (Figure 7B).  
In contrast, wild-type Hck did not exhibit kinase or transforming activity. Taken together, these 
results show that the T338M mutation is functionally silent and does not influence Hck 
biological activity.  
Next, we investigated the sensitivity of Rat-2 cells transformed by each form of Hck to 
A-419259.  As shown in Figure 7A, 0.3 μM A-419259 almost completely blocked colony 
formation by cells expressing the Hck-YF mutant. This was accompanied by complete inhibition 
of Hck-YF autophosphorylation and pp40 substrate phosphorylation (Figure 7B). In contrast, the 
same concentration of A-419259 induced only a 25% decrease in colony formation in cells 
expressing Hck-T338M-YF mutant with no detectable change in kinase activity (Figure 7A). 
Interestingly, the activity of Hck-T338M-YF was also unaffected by 1 μM A-419259, despite a 
further decrease in colony-forming activity.  This finding suggests that endogenous A-419259-
sensitive SFKs may cooperate with Hck to induce the transformed phenotype. 
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Figure 7: Hck-T338M maintains its biological activity and A-419259 resistance in fibroblasts 
Rat-2 fibroblasts were infected with recombinant Hck-YF and Hck-T338M-YF retroviruses. Cells infected with a 
virus carrying only the selection marker (Neo) or wild-type Hck served as negative controls. Upon G418 selection, 
cells were plated in soft agar in the presence or absence of the indicated concentrations of A-419259 for 10 to 14 
days.  Transformed colonies were visualized using MTT staining. (A) Colony numbers for each cell line were 
determined using scanned images of the plates and BioRad QuantityOne colony-counting software. Results from a 
representative experiment are shown as the mean number of colonies ± S.D. The entire experiment was performed 
twice and yielded comparable results. (B) Lysates from each of the cell lines shown in (A) were probed with 
phosphospecific antibodies against the Hck activation loop phosphotyrosine residue (pHck).  Replicate membranes 
were probed with a general anti-phosphotyrosine antibody to determine phosphorylation of the endogenous Hck 
substrate pp40, with an anti-Hck antibody to determine Hck expression levels, and with anti-actin as a loading 
control.  
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2.3.3 Hck-T338M expression in K562 cells confers resistance to A-419259-induced growth 
arrest and apoptosis 
The in vitro and cell-based assays described above support the idea that the T338M mutation 
induces Hck resistance to A-419259 without affecting kinase activity, providing a unique probe 
to test the singular contribution of Hck to Bcr-Abl signaling in CML cells.  To test whether Hck-
T338M is resistant to A-419259-induced inhibition in the context of a CML-derived cell line, we 
used K562 cells, a Ph+ human CML cell line in which endogenous Hck expression is not 
detectable by immunoblot (Figure 8). K562 cells were infected with recombinant retroviruses 
carrying wild-type Hck, the Hck-T338M mutant, or a control virus carrying only the neo 
resistance marker. Following G418 selection, these three cell populations (K562-Hck, K562-
Hck-T338M, and K562-Neo) were treated in parallel with various concentrations of A-419259, 
and the effect of inhibitor treatment on Hck activity was assessed with the phosphospecific 
antibody, pY418, as described above. As shown in Figure 8, A-419259 caused partial inhibition 
of wild-type Hck at 0.1 μM and complete inhibition at 0.3 μM in K562-Hck cells. This 
observation is consistent with previous findings that A-419259 inhibits overall SFK activity in 
K562 and other CML cell lines with an IC50 value of 0.1-0.3 μM (215).  In contrast, little change 
in Hck-T338M pY418 phosphorylation was observed at these A-419259 concentrations, 
although partial inhibition was observed at 1 μM A-419259.  
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Figure 8: Hck-T338M is resistant to inhibition by A-419259 in K562 cells 
Wild-type and Hck-T338M proteins were expressed in K562 cells using recombinant retroviruses. K562-Hck wild-
type and K562-Hck-T338M cells were treated with A-419259 at the indicated concentrations for 5 h. Hck activity 
was assessed by immunoprecipitation of Hck from clarified cell lysates and immunoblotting with phosphospecific 
antibodies against the Hck activation loop phosphotyrosine residue (pHck). Duplicate blots of the 
immunoprecipitates were blotted with the anti-Hck antibody to insure equal loading.  Representative blots are shown 
at the top.  Phosphotyrosine signal intensities from the blots of two independent experiments were normalized to the 
levels of Hck.  Results are presented as percent of control levels ± S.D. in the bar chart. 
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Previous work has shown that A-419259-dependent inhibition of SFK activity in K562 
cells induces growth arrest and apoptosis (215). In addition, this prior study found that A-419259 
is 300 to 1000 times more potent against SFKs compared to c-Abl in vitro. To determine whether 
A-419259 has a direct inhibitory effect on Bcr-Abl in our experimental system, we probed the 
lysates from the inhibitor-treated K562 cell populations with a phosphospecific antibody against 
the phosphotyrosine residue in the activation loop of active Bcr-Abl (pY412). As shown in 
Figure 8B, A-419259 did not significantly inhibit Bcr-Abl phosphorylation at the autoactivation 
site.  In contrast, imatinib caused a dose-dependent inhibition of the pY412 signal (Figure 8C).   
These data support the selectivity of A-419259 for SFKs in K562 cells, in agreement with our 
previous data in this cell line (215). 
To investigate the contribution of Hck alone to Bcr-Abl-induced transformation and 
signaling in CML, K562-Hck, K562-Hck-T338M, and K562-Neo cells were treated with 0.1 to 
1.0 μM A-419259 and cell proliferation was measured over 72 hours.  Figure 9 shows that 0.1 
μM A-419259 induced 75-80% growth arrest of K562-Hck and K562-Neo cells. Conversely, 
K562-Hck-T338M cells exhibited only a 50% reduction in cell proliferation at this inhibitor 
concentration. This result correlates with sustained Hck-T338M kinase activity compared to the 
wild-type Hck in the presence of the inhibitor (Figure 8).  Given that 0.1-0.3 μM A-419259 
completely inhibits endogenous SFK activity in CML cells (215), this result suggests that Hck 
alone is able to partially sustain Bcr-Abl-induced cell proliferation (see Discussion). 
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 Figure 9: Hck-T338M expression in K562 cells confers resistance to A-419259-induced growth arrest 
K562 cells expressing wild-type Hck, the T338M mutant, as well as the vector control cells (Neo) were treated with 
A-419259 at the indicated concentrations. Cell proliferation was monitored 24, 48 and 72 h later using the CellTiter-
Blue cell viability assay as described under “Materials and Methods”. Three replicate wells were monitored for each 
dose in three independent experiments and gave comparable results; a representative example is shown. 
 
We next investigated whether expression of Hck-T338M also confers resistance to A-
419259-induced apoptosis in CML cells. To address this issue, K562-Neo, K562-Hck and K562-
Hck-T338M cells were treated with A-419259 for 72 h and apoptosis was measured using an 
Alexa-Fluor-conjugated anti-phosphatidylserine (PS) antibody and flow cytometry.  As shown in 
Figure 10, A-419259 potently induced dose-dependent apoptosis in K562-neo and K562-Hck 
cells starting at 0.3 μM.  In contrast, Hck-T338M expression completely rescued K562 cells 
from apoptosis induced by 0.3 μM A-419259.  Furthermore, K562-Hck-T338M cells also 
displayed significant resistance to apoptosis induced by 1 μM A-419259. These data correlate 
with Hck-T338M kinase activity, which is not affected by 0.3 μM A-419259 and only partially 
inhibited by this compound at 1 μM (Figure 8). 
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Figure 10: Hck-T338M protects K562 cells against the apoptotic effect of the SFK inhibitor A-419259 
K562 cells expressing wild-type Hck, the T338M mutant, as well as the vector control (Neo) cells were plated in the 
absence or presence of the indicated concentrations of A-419259 for 72 h. Apoptotic cells were detected by anti-
phosphatidylserine-Alexa Fluor 488 conjugated antibody staining and flow cytometry. (A) Representative 
experiment with the percentage of apoptotic cells in each population shown above the bar.  (B) Bar graph showing 
the average of three independent experiments and plotted ± S.D. Statistical analyses were performed at each drug 
concentration between Neo and Wild-type, Neo and T338M, and Wild-type and T338M, using two tailed Student’s 
T test. Only statistically significant differences are displayed. 
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2.3.4 Expression of Hck-T338M in K562 cells rescues the inhibitory effects of A-419259 
on Stat5 and Erk activation 
Previous reports suggest that Hck may couple Bcr-Abl to Stat5 and Erk activation in myeloid 
leukemia cells (210, 211).  In addition, work in our laboratory has shown that inhibition of SFK 
activity in K562 cells using A-419259 induces apoptosis and growth arrest that correlates with 
decreased Ras/Erk and Stat5 activation (215). To assess the individual contribution of Hck to the 
activation of growth and survival pathways downstream of Bcr-Abl, we focused on the ability of 
Hck-T338M to rescue Ras/Erk and Stat5 activation from the inhibitory effects of A-419259.  
K562-Neo, K562-Hck, and K562-Hck-T338M cells were treated with A-419259 and cell lysates 
were probed with phosphospecific antibodies for activated Erk by immunoblotting. As shown in 
Figure 11, A-419259 induced a dose-dependent inhibition of Erk phosphorylation in K562-Hck 
and K562-Neo cells.  In both cases, the phospho-Erk signal was partially reduced at 0.3 μM and 
completely absent at 1.0 μM.  However, expression of Hck-T338M completely rescued Erk 
activation at 0.3 μM A-419259, and showed a partial effect at 1.0 μM.  While these data are 
consistent with the partial reversal of A-419259 growth-arrest observed in K562-Hck-T338M 
cells (Figure 8), they suggest that Hck-independent and Erk-independent pathways also 
contribute to Bcr-Abl-driven proliferation. 
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Figure 11: Expression of Hck-T338M in K562 cells reverses the inhibitory effects of A-419259 on Erk 
activation 
K562 cells expressing wild-type Hck, the T338M mutant, as well as the vector control cells (Neo) were treated with 
the indicated concentrations of A-419259 for 5 h.  (A) Cell lysates were prepared and analyzed for the presence of 
active Erk by immunoblotting with phosphospecific antibodies (pErk). Duplicate blots were probed with antibodies 
to Erk2 as a loading control. Representative blots are shown.  (B) Phospho-Erk signal intensities from the blots of 
two independent experiments were normalized to the levels of Erk, and are presented as percent of control levels ± 
S.D.  
 
Next, we examined the effect of Hck-T338M on Stat5 activation. To address this 
question, Stat5 was immunoprecipitated from lysates of A-419259-treated cells and probed with 
phosphospecific antibodies for active Stat5 by immunoblotting. As shown in Figure 12, A-
419259 induced a dose-dependent inhibition of Stat5 activation in K562-Neo and K562-Hck 
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cells.  In contrast, only a modest change in Stat5 phosphorylation was observed in K562-Hck-
T338M cells, indicating that Hck plays a major role coupling Bcr-Abl to Stat5 activation.  This 
result correlates with the change in Hck-T338M activity (Figure 8A) and with the ability of Hck-
T338M to rescue K562 cells from A-419259-induced apoptosis. 
 
 
Figure 12: Expression of Hck-T338M in K562 cells opposes the inhibitory effects of A-419259 on Stat5 
activation  
K562 cells expressing wild-type Hck, the T338M mutant, as well as the vector control cells (Neo) were treated with 
the indicated concentrations of A-419259 for 5 h.  Stat5 tyrosine phosphorylation was assessed by 
immunoprecipitation of Stat5 from clarified cell lysates and immunoblotting with anti-phosphotyrosine antibodies 
(pStat5). Duplicate membranes were blotted with anti-Stat5 antibody to insure equal loading (Stat5). Representative 
blots are shown. (B) Stat5 phosphotyrosine signal intensities from the blots of two independent experiments were 
normalized to the levels of Stat5 protein, and the results are presented as percent of control levels ± S.D.  
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2.3.5 Effect of Hck-T338M on Bcr-Abl Tyrosine Phosphorylation 
Recent data from our laboratory and others show that Src kinases directly phosphorylate Bcr-Abl 
at sites including Tyr-89 located in the SH3 domain, Tyr-245 in the SH2-kinase linker, and Tyr-
412 in the kinase domain activation loop (215) [(Abl residue numbering as per the human c-Abl 
crystal structure (188).]  Tyr-89 and Tyr-245 lie along the interface between the SH3-SH2 clamp 
and the back of the kinase domain, and phosphorylation of these sites may destabilize these intra-
molecular interactions and promote an active conformation of the kinase (194). Mutation of Tyr-
89 to phenylalanine diminished transformation of TF-1 cells to cytokine independence by Bcr-
Abl, while mutation of Tyr-245 to phenylalanine abolished fibroblast transformation by Bcr-Abl 
(194, 344). Similarly, phosphorylation at Tyr-412 is required for full activation of Bcr-Abl and 
mutation of this site was sufficient to abolish Bcr-Abl-induced fibroblast transformation (344). 
Moreover, previous work showed that Hck phosphorylates the Bcr component of Bcr-Abl at Tyr-
177 (Bcr numbering) in transfected COS cells (210) creating an SH2-binding site for the Grb2-
Sos guanine nucleotide exchange factor for Ras (229, 231). Phosphorylation at this site was 
shown to be required for transformation of fibroblasts and for efficient induction of CML-like 
myeloproliferative disease by Bcr-Abl in mice (229, 233, 234). Given the importance of these 
phosphorylation sites for Bcr-Abl regulation and leukemogenic potential, we decided to 
investigate the contribution of Hck to their phosphorylation in K562 cells using our unique A-
419259-resistant form of Hck. 
To address this question, lysates from A-419259-treated K562-neo, K562-Hck, and 
K562-Hck-T338M cells were first probed with phosphospecific antibodies for Tyr-89 in the SH3 
domain. As shown in Figure 13, A-419259 completely blocked phosphorylation of Tyr-89 in 
K562-neo and K562-Hck cells at concentrations of 0.3 μM or higher. In contrast, K562-Hck-
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T338M showed only a partial inhibition of the pY89 signal at these concentrations.  This result 
suggests that while Hck is partially responsible for phosphorylation of Tyr-89, additional Src-
family members may also trans-phosphorylate Bcr-Abl at this site consistent with previous 
findings (194).  
Similar to phosphorylation at Tyr-89, 0.3-1.0 μM A-419259 treatment induced complete 
inhibition of Tyr-245 phosphorylation in K562-neo and K562-Hck cells but only a partial 
inhibition of the pY245 signal in K562-Hck-T338M cells.  This result suggests that while Hck 
contributes to transphosphorylation at this regulatory site, other SFKs present in K562 cells are 
also involved, consistent with earlier data  (194).  Importantly, incubation with A-419259 did not 
have any effect on total Bcr-Abl protein levels or on Tyr-412 autophosphorylation in the kinase 
domain activation loop. As a positive control for the anti- pY412 antibody, we performed 
immunoblots on cells incubated with increasing concentrations of the Abl-selective inhibitor, 
imatinib. As expected, imatinib induced a dose-dependent inhibition of Bcr-Abl phosphorylation 
at Tyr-412 in all three cell lines (Figure 8C). Taken together, these data are consistent with the 
report that A-419259 is a Src-selective inhibitor and at these concentrations, it does not inhibit 
Bcr-Abl activity in vivo (215).  
We also surveyed the phosphorylation of Bcr-Abl at Bcr-derived Tyr-177. As shown in 
Figure 13, A-419259 induced a partial reduction in pY177 signal intensity in K562-neo and 
K526-Hck cells at the highest concentration tested (1 μM). In contrast, the pY177 signal remains 
unchanged in K562-Hck-T338M cells, suggesting that while Hck may contribute to Tyr-177 
phosphorylation in vivo, this site may be primarily a Bcr-Abl autophosphorylation site or may be 
targeted by other tyrosine kinase families in K562 CML cells. 
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Figure 13: Hck-T338M transphosphorylates Bcr-Abl on multiple tyrosine residues in K562 cells  
(A) K562-neo, K562-Hck and K562-Hck-T338M cells were treated with the indicated concentrations of A-419259 
for 5 h.  Cell lysates were prepared and probed with phosphospecific antibodies against Abl pY89, Bcr pY177, Abl 
pY245, and Abl pY412 as well as Bcr-Abl protein levels by immunoblotting.  (B) K562-neo, K562-Hck and K562-
Hck-T338M cells were treated with the indicated concentrations of imatinib for 5 h. Cell lysates were 
immunoblotted with antibodies for Abl pY412 and Abl protein as indicated. 
 
2.3.6 Expression of Hck-T338M in Bcr-Abl-transformed TF-1 cells confers resistance to 
the apoptotic effects of A-419259 and correlates with sustained Stat5 activity 
All of the data presented thus far are derived from the K562 CML cell line.  To rule out the 
possibility that our observations are unique to this particular system, we turned to the human 
GM-CSF-dependent myeloid cell line, TF-1 (358, 359).  Expression of Bcr-Abl in TF-1 cells 
results in cytokine-independent survival and proliferation (359), providing a CML model system 
that lacks the secondary genetic aberrations present in K562 cells.  TF-1 cells were first infected 
with a Bcr-Abl retrovirus, which resulted in transformation to a cytokine-independent phenotype 
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as expected (Figure 14A).  These TF-1/Bcr-Abl cells were then infected with the wild-type and 
T338M Hck retroviruses as well as the control virus carrying only the drug selection marker.  
Expression of these Hck proteins did not significantly affect the cytokine-independent growth of 
these cells (Figure 14A).  We also expressed the Hck proteins in TF-1 cells alone, and observed 
that they were unable to stimulate GM-CSF-independent proliferation on their own (Figure 
14A).  All of the cell lines grew in the presence of GM-CSF (data not shown). 
Next, we examined the effect of A-419259 treatment on survival of TF-1/Bcr-Abl cells.  
As shown in Figure 14B, incubation of the TF-1/Bcr-Abl vector control cells with A-419259 
induced apoptosis in a dose-dependent manner.  Note that parental TF-1 cells are completely 
unresponsive to A-419259 in this assay (215).  Expression of wild-type Hck partially reversed 
apoptosis in response to 0.3 and 1 μM A-419259 in the TF-1/Bcr-Abl population.  However, TF-
1/Bcr-Abl/Hck-T338M cells displayed much more resistance to A-419259-induced apoptosis, 
with an almost complete reversal of apoptosis at 0.3 μM. This effect closely parallels that 
observed in K-562 cells expressing Hck-T338M (Figure 10). 
We next assessed Hck and Stat5 activity in each TF-1/Bcr-Abl cell population following 
A-419259 treatment.  As shown in Figure 14B, wild-type Hck activity was partially inhibited 
with 0.1 and 0.3 μM A-419259 and completely blocked at 1 μM. Conversely, Hck-T338M 
showed significant resistance to A-419259, with partial inhibition observed only with 1 μM A-
419259.  Similarly, expression of wild-type Hck partially rescued Stat5 activation at 0.1 μM A-
419259 compared to control TF-1/Bcr-Abl cells. More importantly, expression of Hck-T338M 
rescued Stat5 activation at 0.3 and 1 μM A-419259. Taken together, these data are consistent 
with the partial reversal of A-419259-induced apoptosis by wild-type Hck and the more 
pronounced effect observed with Hck-T338M (Figure 14B). 
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Figure 14: Expression of Hck-T338M protects TF-1/Bcr-Abl cells against the apoptotic effects of A-419259 
(A) Transformation of TF-1 cells to cytokine independence with Bcr-Abl.  TF-1 cells were first transduced with 
Bcr-Abl retroviruses or the corresponding vector control and selected with G-418.  The resulting populations were 
then transduced with wild-type Hck, Hck-T338M, or vector control retroviruses and selected with puromycin.  The 
six resulting cell populations were then tested for growth in the absence of GM-CSF using the CellTiter Blue assay 
(see Materials and Methods).  The average fold increase in the relative number of cells from three replicate wells is 
shown ± S.D. Two separate experiments from independently derived cell populations gave comparable results; a 
representative example is shown.  (B) TF-1/Bcr-Abl cells expressing the wild-type and T338M Hck proteins along 
with vector control cells were plated in the absence or presence of the indicated concentrations of A-419259 for 72 
h. Apoptotic cells were detected by anti-phosphatidylserine-Alexa Fluor 488 conjugated antibody staining and flow 
cytometry as described in “Materials and Methods”. The bargraph shows the average of two independent 
experiments plotted ± S.D.  (C) TF-1/Bcr-Abl cells expressing wild-type and T338M Hck along with the vector 
control were treated with the indicated concentrations of A-419259 for 5 h.  Hck and Stat5 were immunoprecipitated 
from clarified cell lysates and immunoblotted with an anti-Hck phosphospecific pY418 antibody (pHck) or an anti-
phosphotyrosine antibody (pStat5). Duplicate membranes were blotted with anti-Hck or anti-Stat5 antibody to insure 
equal loading. Representative blots are shown.  
 
2.3.7 A-419259 inhibits proliferation and induces apoptosis in CML CD34+ progenitor 
cells 
In a final series of experiments, we determined whether selective inhibition of SFK activity 
affects the growth and survival of primary CD34+ CML cells. Because purified CD34+ 
progenitor cells undergo rapid differentiation when cultured in the presence of cytokines, we first 
determined the time course of differentiation as indicated by the loss of CD34+ from the cell 
surface. As shown in Figure 16, 48 h post isolation, 95 % of the cells still retained CD34 at the 
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cell surface, while at 72 h and 96 h, CD34 dramatically dropped to 81 % or 41 %, respectively. 
In order to determine the effects of SFK inhibition on CD34+ cells and to avoid interference from 
differentiated cells, we conducted the apoptosis experiments at 16 and 48 h time points. Thus, 
purified CD34+ progenitors from three chronic-phase CML patients were incubated with A-
419259 in the presence of cytokines (see Materials and Methods). A-419259 treatment induced a 
dose-dependent inhibition of cell proliferation in all three patient samples, with caspase 
activation evident as early as 16 h (Figure 16). The extent of growth inhibition and caspase 
activation is comparable to that observed with 1 μM imatinib treatment. These results provide 
the first evidence that inhibition of SFK activity is sufficient to induce cell-cycle arrest and 
apoptosis in primary CD34+ CML cells.  
 
 
Figure 15: Time course of the loss of CD34+ signal in CML primary cells in culture 
Purified CD34+ cells from chronic phase CML patients cultured in the presence of cytokines as described in 
“Materials and Methods”. At each of the indicated time points an aliquot has been removed and processed for 
CD34+ signal detection by flow cytometry. The experiment was repeated twice with similar results, using samples 
from two different patients. One representative experiment is shown.  
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Figure 16: A-419259 induces growth arrest and apoptosis in CD34+ progenitor cells from CML patients 
Purified CD34+ cells from three chronic phase CML patients were plated in triplicate in 96-well plates at 105 
cells/ml and incubated for 16 or 48 h in the presence of A-419259 or imatinib at the concentrations indicated. (A) 
Cell proliferation was monitored using the CellTiter-Blue viability assay as described in “Materials and Methods”. 
The average fold increase in the relative number of cells from three replicate wells is shown ± S.D.  (B) Apoptosis 
was measured in each well using the Apo-One Caspase-3/-7 assay as described in “Materials and Methods”. The 
average fold increase in caspase-3/-7 signal intensity from three replicate wells is shown ± S.D. 
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2.4 DISCUSSION 
Given the important role of SFKs in Bcr-Abl signaling and imatinib resistance, these kinases 
have recently emerged as novel therapeutic targets for the treatment of CML (360). This idea has 
been validated by the success of dual Abl/Src inhibitors such as dasatinib in CML therapy (361, 
362). However, these inhibitors have a broad range of molecular targets. For example, dasatinib 
inhibits not only the SFKs Fgr, Fyn, Hck, Lck, Lyn, Yes (363) and Bcr-Abl, but also c-Kit, 
PDGFR, and the Ephrin receptor tyrosine kinase (364). Although there is emerging evidence that 
compound promiscuity is critical to the efficacy of a significant number of approved drugs, this 
property has traditionally been regarded as undesirable due to possible adverse effects.  This 
concept points to a need for drugs that have “controlled promiscuity” – drugs that specifically 
target only disease-relevant targets. In the case of CML, one key to effective progress in 
designing such drugs is a more in-depth understanding of the relative contribution of individual 
SFK members to Bcr-Abl signaling. Work presented here provides a novel approach to dissect 
the individual roles of myeloid SFKs to Bcr-Abl signaling and provides new evidence supporting 
a unique role for Hck in Bcr-Abl-induced proliferation and survival.  
In this study, we exploited engineered inhibitor resistance to help elucidate the role of the 
SFK member Hck in Bcr-Abl signaling. Inhibition of protein kinases by target-selective, ATP-
competitive compounds often depends on the presence of a relatively small threonine residue at 
the gatekeeper position adjacent to the hydrophobic pocket in the catalytic site. Substitution of 
the gatekeeper residue with amino acids bearing bulkier side-chains can dramatically reduce 
inhibitor potency without affecting kinase activity (Table 1).  Some of the first drugs developed 
against protein-tyrosine kinases include imatinib, which inhibits Abl, c-Kit, and the PDGFR, as 
well as and gefitinib and erlotinib, which target the EGFR.  In each case, these compounds target 
 78 
the hydrophobic pocket and in some cases make direct hydrogen bonds to the gatekeeper residue 
(e.g. imatinib and Thr-315 in the Abl kinase domain).  Interestingly, one of the most common 
mechanisms of clinical resistance to these inhibitors arises from mutations that replace the 
gatekeeper residue with bulkier amino acids (349).  For example, replacement of Thr-315 in Bcr-
Abl with isoleucine, Thr-671 in Kit with isoleucine, or Thr-766 in EGFR with methionine leads 
to clinically relevant insensitivity to imatinib or gefitinib, respectively (353, 365). Furthermore, a 
change in v-Src versus c-Src at the gatekeeper position induces resistance to the pyrazolo-
pyrimidine inhibitor, PP1 (347).  Resistance mutants similar to those described above, were first 
used as research tools for the purpose of identifying off-target effects of various inhibitors (350). 
Based on these observations, we engineered an A-419259-resistant Hck allele by replacing the 
gatekeeper residue, Thr-338, with methionine. This mutant allowed us to test the hypothesis that 
expression of inhibitor-resistant Hck alone is sufficient to rescue CML cells from the anti-
proliferative and apoptotic effects of this broad-spectrum SFK inhibitor (215). 
Using both in vitro and cellular model systems, we first provide proof-of-principle 
evidence that the T338M mutation renders Hck resistant to A-419259.  Thus, Hck-T338M was 
30-fold less sensitive to A-419259 than wild-type Hck in an in-vitro kinase assay (Figure 6). In 
addition, expression of active forms of wild-type Hck or the Hck-T338M mutant in Rat-2 
fibroblasts induced similar levels of transformation, suggesting that T338M mutation does not 
significantly affect the biological function of Hck in a cell-based system (Figure 7A). The Hck-
T338M-YF mutant was at least 10-fold less sensitive to A-419259 than Hck-YF in the fibroblast 
transformation assay (Figure 7). Interestingly, while Hck-T338M-YF activity was not affected 
by 1 μM A-419259 in fibroblasts, transformed colony numbers were partially reduced (Figure 
7B). This observation suggests that Hck-YF may require endogenous A-419259-sensitive SFKs 
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to generate a full transforming effect.  More importantly, we show that Hck-T338M also 
maintains resistance to A-419259 upon expression in K562 cells, allowing us to test the 
individual contribution of Hck to Bcr-Abl transformation in this CML cell line (Figure 8).  As 
described in the results section, the Hck T338M mutation induces a subtle decrease in the Km for 
ATP relative to the wild-type kinase.  Whether the T338M mutation induces changes in substrate 
recognition or impacts other biological functions of Hck is not known. This possibility represents 
a caveat of the inhibitor-resistant mutant approach. 
Experiments with A-419259 and other inhibitors as well as a Hck dominant-negative 
mutant suggest that SFKs contribute to Bcr-Abl-induced cell proliferation (10, 209, 210, 215).  
A-419259 treatment also led to suppression of Erk activity, a critical component of proliferation 
signaling downstream of Bcr-Abl (215, 366).  In the present study, we show that Hck-T338M 
expression has a moderate protective effect on the A-419259-induced inhibition of cell 
proliferation (Figure 9), and this effect correlated with a rescue of Erk activity (Figure 11). The 
observation that Hck-T338M does not fully reverse A-419259-induced growth arrest and Erk 
inhibition suggests that other SFKs contribute to Bcr-Abl-mediated cell proliferation.  
Previous work in our laboratory has shown that collective SFK inhibition in K562 cells 
using A-419259 induces apoptosis and that this effect correlates with a decrease in Stat5 
activation (215).  Here we show that Hck-T338M but not wild-type Hck expression fully protects 
K562 cells against the apoptotic effects of 0.3 μM A-419259 (Figure 10). This new finding 
suggests a compelling non-redundant role for Hck in Bcr-Abl survival signaling in CML cells.  
In addition, the Hck-T338M protective effect correlates with rescue of Stat5 activation, which is 
completely blocked by A-419259 in control cells as well as cells over-expressing wild-type Hck 
(Figure 12). These results identify Hck as an important target for the development of apoptosis-
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inducing drugs for the treatment of CML. However, our data do not exclude the possibility that 
additional SFKs may participate in Bcr-Abl anti-apoptotic signaling in other experimental 
systems. For example, siRNA against Lyn induces apoptosis of CML blast crisis cells, especially 
of lymphoid origin (221). Furthermore, Lyn overexpression has been identified as an alternative 
mechanism of imatinib resistance in the absence of Bcr-Abl mutations (314, 330). Taken 
together, these findings suggest that differences may exist in the role of various SFKs within 
different hematopoietic lineages transformed by Bcr-Abl and emphasize the need to further 
investigate the role of other individual SFKs in CML.  
Several studies have shown that SFK-dependent trans-phosphorylation modulates the 
function of both c-Abl and Bcr-Abl, drug sensitivity and signaling.  Fursatoss et al. showed that 
c-Src phosphorylates c-Abl at both Tyr-412 and Tyr-245 (367), while Brasher and Van Etten 
proposed that phosphorylation at Tyr-245 enhances c-Abl activity by disrupting the negative 
regulatory interaction between the SH3 domain and the SH2-kinase linker (183). Recently, our 
laboratory has shown that Hck and other SFKs phosphorylate Bcr-Abl at SH3 domain sites Tyr-
89 and Tyr-134 as well as other sites that lie at the interface between the SH3-SH2 domains and 
the SH2-kinase linker (194).  Based on the crystal structure of the downregulated c-Abl core 
(188) phosphorylation of these sites is predicted to promote displacement of negative regulatory 
interactions of the SH3-SH2 clamp and sustain an active conformation of the Abl core within 
Bcr-Abl. Other experiments performed in COS cells have shown that Hck phosphorylates Bcr-
Abl in the Bcr-derived portion of the protein at Tyr-177, an event required in leukemogenesis 
(229, 233, 234).  Experiments presented here with Hck-T338M suggest that in CML cells, Hck 
contributes to Bcr-Abl phosphorylation at Tyr-89, Tyr-177 and Tyr-245. However, Hck-T338M 
does not completely reverse phosphorylation at these sites in A-419259-treated cells, suggesting 
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a role for other SFKs in Bcr-Abl trans-phosphorylation. Alternatively, Bcr-Abl may undergo 
autophosphorylation at these sites, as suggested by previous studies of c-Abl (183). 
In contrast to the regulatory sites in the SH3-SH2-linker region, A-419259 treatment did 
not affect phosphorylation of the Bcr-Abl activation loop (Tyr-412; Figure 13).  This observation 
suggests that SFKs do not contribute to activation loop phosphorylation in K562 cells, and also 
provides evidence of the selectivity of this compound for SFKs vs. Bcr-Abl directly (368, 369).  
In other work, high concentrations of A-419259 did suppress Bcr-Abl Tyr-412 phosphorylation, 
a result that is likely reflective of the different CML cell line used (194).   Note that Tyr-412 
phosphorylation was completely blocked by imatinib in all three K562 cell lines used here, 
suggesting that autophosphorylation may be the primary mechanism of activation loop 
phosphorylation in K562 cells (Figure 13). 
There is increasing evidence that some patients that achieve complete cytogenetic 
remission on imatinib have persistent residual CML stem cells (non-proliferating CD34+ cells) 
which might be responsible for relapse upon imatinib cessation (370-372). These quiescent 
CD34+ cells represent less than 1% of total CD34+ cells (217).  Here we show for the first time 
that selective inhibition of SFK activity by A-419259 blocks proliferation and induces apoptosis 
in primary CML CD34+ progenitor cell populations as effectively as imatinib (Figure 15).  This 
observation suggests that SFKs play a critical role in Bcr-Abl signaling in primary CML 
progenitors as well as the cell lines examined here.  Future work will address the effect of 
selective SFK inhibition on the non-proliferating CD34+ cell population.  
By pairing an inhibitor-resistant SFK mutant with a broad-spectrum SFK inhibitor, we 
have established new pharmacological evidence for Hck in Bcr-Abl survival signaling in K562 
CML cells and in TF-1 cells acutely transformed by Bcr-Abl. This work validates Hck as a 
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specific target for the development of apoptosis-inducing drugs for the treatment of CML.  In 
addition, these studies demonstrate the utility of mutants with engineered resistance to general 
inhibitors as an approach to address the contributions of individual members of a highly 
homologous kinase family to specific signaling pathways. 
2.5 MATERIALS AND METHODS 
2.5.1 Cell culture 
K562 cells, derived from a CML patient in blast crisis (373), were obtained from the American 
Type Culture Collection (ATCC) and maintained in RPMI 1640 supplemented with 10% fetal 
bovine serum (FBS) (Atlanta Biologicals), 100 U/ml penicillin G, 100 μg/ml streptomycin 
sulfate, and 0.25 μg/ml amphotericin (Antibiotic-Antimycotic, Invitrogen). The human GM-
CSF-dependent myeloid leukemia cell line TF-1 (358) was obtained from ATCC and grown in 
RPMI 1640 supplemented with 10% FBS, Antibiotic-Antimycotic (Invitrogen) and 1 ng/ml 
human recombinant GM-CSF.  Rat-2 fibroblasts were obtained from the ATCC and cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 5% FBS and Antibiotic-Antimycotic 
(Invitrogen).  Sf9 insect cells were maintained in Grace’s medium (Gibco) supplemented with 
10% FBS and 50 μg/ml gentamicin (Gibco). 
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2.5.2 Selection of CD34+ progenitors 
Leukapheresis samples from three CML patients were thawed and cultured overnight in RPMI 
1640 supplemented with 10% FBS, and Antibiotic-Antimycotic (Invitrogen). CD34+ cells were 
isolated using an immunomagnetic column separation method (Miltenyi Biotech, Auburn, Ca, 
USA) following the manufacturer’s instructions.  Upon isolation, CD34+ cells were cultured in 
SFEM medium (StemCell Technologies) supplemented with 40 μg/ml LDL (Sigma), and a five 
cytokine cocktail comprised of SCF, Flt3-L (100 ng/ml each), IL-3 and IL-6 (20 ng/ml each; 
StemCell Technologies) and 20 ng/ml G-CSF (Peprotech). The enrichment of CD34+ cells was 
determined by flow cytometry using anti-CD34-FITC (Miltenyi Biotech) and ranged between 
95% and 99% (data not shown). 
2.5.3 Hck protein purification and kinase assay 
The Thr-338 to methionine (T338M) mutation was introduced into human p59 Hck-YEEI (86) 
via site-directed mutagenesis (QuikChange XL Site-directed Mutagenesis Kit, Stratagene).  
Human Hck-YEEI and Hck-T338M-YEEI were expressed in Sf9 insect cells as N-terminal 
hexahistidine fusion proteins and purified as described (63, 374). Kinase assays were performed 
using the FRET-based Z’-Lyte Src kinase assay kit and Tyr-2 peptide substrate according to the 
manufacturer’s instructions (Invitrogen). The assay was first optimized to determine the amount 
of each kinase and the incubation time necessary to phosphorylate 50-60% of the Tyr-2 peptide 
in the absence of inhibitor.  Final ATP and Tyr-2 substrate concentrations were held constant at 
50 μM and 2 μM, respectively.  For inhibition experiments, each kinase was pre-incubated with 
A-419259 in kinase assay buffer for 30 min, followed by incubation with ATP and Tyr-2 peptide 
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for 1 h. Fluorescence was assessed on a Gemini XS microplate spectrofluorometer (Molecular 
Devices).  
2.5.4 Retrovirus-mediated expression of Hck constructs in Rat-2 fibroblasts 
Active forms of Hck and Hck-T338M were obtained by replacing the negative regulatory 
tyrosine residue in the C-terminal tail with phenylalanine using a PCR-based strategy (95, 96, 
357). The constructs were then subcloned into the retroviral vector pSRαMSVtkneo (375), and 
used to generate high-titer retroviral stocks as described elsewhere (96, 376). For transformation 
experiments, Rat-2 fibroblasts (2.5 x 104) were plated in 6-well tissue culture plates and 
incubated overnight.  The following day, the medium was replaced with 5 ml undiluted viral 
stock containing 4 μg/ml polybrene, and cultures were centrifuged at 1000 x g for 4 h at 18° C. 
Following infection, the virus was replaced with fresh medium. Forty-eight h later, cells were 
trypsinized and equally divided into four 60 mm culture dishes and 5 ml of medium containing 
G418 (800 μg/ml) was added. After 14 days of selection, cells were used in either soft-agar 
assays or for SDS-PAGE analysis of protein expression and tyrosine kinase activity.    
2.5.5 Rat-2 fibroblast transformation assay (soft-agar assay) 
Soft-agar assays were performed in 35 mm Petri dishes (Falcon) using Seaplaque Agarose (FMC 
Bioproducts). Briefly, a 0.5% bottom agarose layer in complete culture medium was poured in 
the presence of either vehicle alone (0.5% DMSO) or A-419259 at twice the final desired 
concentration. After the bottom layered had hardened, the top layer was poured containing 1 x 
104 Rat-2 cells in culture medium containing 0.3% agarose. Ten to 14 days later the colonies 
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were stained with MTT and quantitated using densitometry and colony counting software 
(BioRad QuantityOne).  
2.5.6 Immunoprecipitation and Immunoblotting  
The antibodies used in this study include anti-Hck polyclonal (N-30; Santa Cruz Biotechnology), 
anti-Hck monoclonal (Transduction Laboratories), anti-Src phosphospecific (Src pY-418; 
BioSource International), anti-phosphotyrosine (PY-99; Santa Cruz), anti-Actin (MAB1501; 
Chemicon), and anti-Stat5 (BD Transduction Laboratories). 
To analyze Hck expression and phosphorylation in Rat-2 cells, 5 x 105 cells were plated 
in 100 mm dishes and treated with either A-419259 or vehicle control (0.5% DMSO). After 
incubation at 37 °C overnight, cells were lysed in ice-cold radioimmunoprecipitation assay 
(RIPA) buffer (96).  Cell lysates were clarified by centrifugation at 16000g for 10 min at 4 °C, 
and protein concentrations were determined using either the Bradford or BCA assay (Pierce). 
Aliquots of total protein were heated directly in SDS sample buffer and separated by SDS-
PAGE. To analyze expression and phosphorylation of Hck in K562 cells, 107 cells were collected 
by centrifugation, washed twice with PBS and lysed in ice-cold RIPA buffer and processed as 
above.  For Hck or Stat5 immunoprecipitation, protein concentrations were first normalized in 
lysis buffer, followed by addition of 1 μg of anti-Hck or anti-Stat5 antibody and 25 μl of protein 
G-Sepharose (50% slurry; Amersham Pharmacia Biotech). Following incubation for 2 h at 4°C, 
immunoprecipitates were washed three times with 1.0 ml of RIPA buffer and heated in SDS 
sample buffer. Following SDS-PAGE, proteins were transferred to PVDF membranes for 
immunoblot analysis. Immunoreactive proteins were visualized with appropriate secondary 
antibody-alkaline phosphatase conjugates and NBT/BCIP colorimetric substrate (Sigma).  
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2.5.7 Retroviral transduction of leukemia cell lines  
Wild-type and T338M mutant forms of Hck were subcloned into the retroviral expression vector 
pMSCV-IRES-neo (Clontech) between the MSCV promoter and IRES sequence. Retroviral 
stocks were produced from the resulting constructs by co-transfection of 293T cells with an 
amphotropic packaging vector as described above.  K562 cells (2 x 105) were incubated with 5 
ml of viral stock in the presence of 4 μg/ml polybrene, and centrifuged at 3000 rpm for 3 h at 
room temperature. After infection, cells were washed, returned to regular medium for 48 h and 
then put under G418 selection (800 μg/ml) for 14 days. At the end of the selection period, cells 
were maintained in medium with 400 μg/ml G418. Transformation of TF-1 cells with a Bcr-Abl 
retrovirus carrying a G418 resistance marker is described elsewhere (194).  These cells were then 
infected with pMSCV-IRES-puro-based retroviruses carrying wild-type and T338M forms of 
Hck or the empty vector control as described above and selected with 2 μg/ml puromycin. 
2.5.8 Proliferation assays 
Proliferation was assessed using the CellTiter-Blue Cell Viability assay (Promega) according to 
the manufacturer‘s protocol. Fluorescence intensity was then measured using a Gemini XS 
microplate spectrofluorimeter (Molecular Devices), with the excitation wavelength set at 544 nm 
and emission at 590 nm. Data were analyzed with SoftMax Pro software (Molecular Devices).  
Each condition was assayed in triplicate and the results are presented as the mean fluorescence  ± 
S.D. 
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2.5.9 Apoptosis assays 
Apoptosis was measured using an anti-phosphatidylserine (PS) antibody conjugated to Alexa 
Fluor 488 (Upstate Biotechnology) and flow cytometry.  Cells (105/ml) were treated with A-
419259 or vehicle alone (0.5% DMSO) for 72 h at 37°C, centrifuged at 1000 rpm for 10 min, 
washed three times with ice-cold PBS and resuspended to 4 x 106 cells/ml in staining buffer (1% 
FBS in PBS).  Aliquots (50 μl) were transferred to 96-well round bottom tissue culture plates and 
the anti-PS antibody was added to a final concentration of 0.21 μg/well.  After 1 h incubation on 
ice, cells were washed three times in ice-cold PBS and analyzed using a FACSCalibur flow 
cytometer (Becton-Dickinson) and data were analyzed using CellQuest software. 
Caspase activation was measured in CD34+ cells, using the Apo-One Caspase-3/-7 assay 
(Promega) and the manufacturer’s instructions. Fluorescence intensity was measured using a 
Gemini XS microplate spectrofluorometer (Molecular Devices), with the excitation wavelength 
set at 485 nm and emission at 520 nm. Data were analyzed with SoftMax Pro software 
(Molecular Devices).  Each condition was assayed in triplicate and the results are presented as 
the mean fluorescence  ± S.D. 
2.5.10 Statistical analysis 
Data obtained from multiple independent experiments are given as mean ± S.D. values. 
Statistical comparisons between two cell lines at individual drug concentrations were performed 
using two-tailed unpaired Student’s t test (normal distribution, and unequal variance). For all 
analyses a P< 0.02 was considered statistically significant. Statistical analyses were performed in 
Excel.  
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3.0  EXPRESSION OF HCK IN CML CELLS INDUCES RESISTANCE TO 
IMATINIB IN A KINASE-DEPENDENT MANNER 
3.1 ABSTRACT 
Imatinib is the frontline therapy used to treat chronic myelogenous leukemia (CML). Although 
imatinib is remarkably efficient in CML patients in chronic phase, patients with accelerated or 
blast crisis CML, often develop resistance. Several recent studies performed on clinical 
specimens from imatinib-resistant patients with wild-type Bcr-Abl, found that the Src family 
kinase members Hck and Lyn are overexpressed or highly active, suggesting that Src kinases 
may play a role in imatinib resistance. To test whether Hck overexpression in CML cells induces 
resistance to imatinib in an Hck-kinase-dependent manner, we employed a chemical genetic 
method to generate an Hck mutant (Hck-T338A) that is sensitive to inhibition by a mutant –
specific inhibitor, NaPP1. In vitro, Hck-T338A was 48 times more sensitive to NaPP1 than the 
wild-type kinase. In addition, the mutation was functionally silent and did not induce a loss or 
gain of function in a fibroblast transformation assay. Expression of wild-type Hck or the T338A 
mutant in K562 CML cells resulted in resistance to imatinib-induced apoptosis and inhibition of 
soft-agar colony formation. Treatment with the Hck-T338A-selective inhibitor NaPP1 restored 
sensitivity to imatinib in a NaPP1 concentration-dependent manner only in cells expressing the 
Hck-T338A mutant. In contrast, cells expressing wild-type Hck were not affected by NaPP1 
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addition, showing the selectivity of NaPP1 for the Hck-T338A mutant. This result demonstrates 
that Hck-induced imatinib resistance requires Hck kinase activity. Together, these data establish 
a direct cause and effect relationship between Hck overexpression and imatinib resistance in 
CML cells, and show that imatinib resistance requires Hck kinase function.  Selective drug 
targeting of Hck may be of therapeutic benefit in imatinib-resistant CML patients with increased 
Hck expression or activity.  
3.2 INTRODUCTION 
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell disease with an incidence of 
approximately 5 cases per 100,000 people per year, and which progresses through three clinical 
phases. The initial chronic phase is characterized by a massive expansion of myeloid cells that 
retain their ability to undergo terminal differentiation. As the disease progresses, patients enter 
an accelerated phase followed by blast crisis characterized by differentiation arrest and 
accumulation of immature blast cells in bone marrow and blood. Accelerated and blast crisis 
phases frequently exhibit additional genetic abnormalities (377).  
The cytogenic hallmark of chronic myelogenous leukemia (CML) is the Philadelphia 
chromosome, which arises upon a “head-to-tail” fusion of the BCR (breakpoint cluster region) 
locus on chromosome 22 with c-ABL proto-oncogene on chromosome 9. This translocation is 
present in 90% of CML patients and leads to the expression of Bcr-Abl, a chimerical protein of 
210 kDa (142, 143) with abnormal cytoplasm localization and constitutive tyrosine kinase 
activity (378). This deregulated protein tyrosine kinase drives the pathogenesis of CML through 
the phosphorylation and activation of a broad range of downstream signaling pathways that 
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increase cell survival and promote unregulated cell cycle progression (379). These pathways 
include but are not limited to the mitogen-activated protein kinase/extracellular signal-regulating 
kinase cascade (MAPK/ERK), the nuclear factor kB (NF-kB) signaling pathway, the 
phosphtidylinositol 3’-kinase/Akt survival pathway, and activation of the signal transducers and 
activators of transcription (Stat) family (380-382).  
In addition, Bcr-Abl has been shown to activate other non-receptor protein-tyrosine 
kinases, particularly members of the Src kinase family including Hck or Lyn (207). The 
importance of this interaction in CML pathogenesis is illustrated by numerous studies. Briefly, 
expression of a kinase-defective mutant of Hck blocked Bcr-Abl-induced transformation of 
DAGM myeloid leukemia cells to cytokine independence (209). In addition, Hck was shown to 
couple Bcr-Abl to Stat5 signaling and to be required for Bcr-Abl-induced transformation of 
32Dcl3 murine myeloid cells (211).  Furthermore, SFK-selective inhibitors block leukemia cell 
proliferation and induce apoptosis without affecting Philadelphia chromosome-negative myeloid 
cells (215). Moreover, work presented in Chapter 2 of this dissertation shows that Hck plays a 
non-redundant role in Bcr-Abl survival signaling in CML cells (216). Taken together, these 
reports indicate that SFKs act as essential mediators of Bcr-Abl-induced leukemogenesis. 
Because Bcr-Abl plays a critical role in the initiation and maintenance of the CML 
phenotype, targeting its tyrosine kinase activity is the therapeutic strategy of choice. Imatinib 
mesylate (formerly known as STI-571) is a potent small molecule tyrosine kinase inhibitor 
relatively specific to Bcr-Abl that has become the frontline therapy for patients with CML (379, 
383).  Most CML patients in chronic phase achieve and maintain major cytogenetic responses 
and significant molecular responses (384, 385). However, despite its remarkable therapeutic 
effects, approximately 4% of chronic phase patients treated with imatinib develop drug 
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resistance per year.  In addition, accelerated or blast crisis patients display higher rates of 
imatinib resistance (300, 302). Clinical resistance to imatinib can be grouped into several 
categories including Bcr-Abl mutation-dependent or Bcr-Abl mutation independent. The former 
category includes mutations in the Abl kinase domain of Bcr-Abl at residues that directly contact 
imatinib or at positions that can allosterically influence imatinib binding (204). The focus of this 
chapter is the mechanism of resistance in the latter category. 
Overexpression of the myeloid SFKs Hck and Lyn has been associated with resistance to 
imatinib in the context of a wild-type Bcr-Abl. Selection of K562 CML cells for resistance to 
high-levels of imatinib resulted in cells with increased Lyn protein and activity levels (219). 
Exposure of these cells to imatinib resulted in an incomplete suppression of Bcr-Abl activity and 
was accompanied by persistent tyrosine phosphorylation of Bcr-Abl at Tyr-177, a known binding 
site for Grb2 that links Bcr-Abl to the Ras signaling cascade (210, 218). Examination of samples 
from patients upon imatinib failure found increased Hck and/or Lyn activity levels that were not 
affected by Bcr-Abl inhibition (219). In addition, no Bcr-Abl kinase domain mutations 
associated with imatinib resistance were present in these patients (219). Decreased Lyn 
expression using siRNA technology, or inhibition with dasatinib, a dual Abl/SFK inhibitor, 
induced apoptosis in cells from these imatinib-resistant patients (314). Collectively, these reports 
point to a role for both Hck and Lyn in imatinib resistance in the absence of Bcr-Abl mutations. 
While the role of Lyn has been addressed in some detail the contribution of Hck to this type of 
imatinib resistance is less well understood.  
To address this question, we developed a system in which Hck activity could be 
suppressed in a highly specific manner. Typically, small molecule inhibitors are limited with 
regard to their specificity and selectivity for a particular kinase family. To circumvent this 
 93 
specificity problem, we employed a chemical genetic method originally described by Shokat et 
al. [reviewed in (386)]. In this method, pyrazolo-pyrimidine 1 (PP1), a global SFK small 
molecule inhibitor was modified to obtain the more bulky, naphthyl-pyrazolo-pyrimidine 1 
(NaPP1) that is far less potent towards SFKs. In addition, using site-directed mutagenesis, the 
ATP-binding site of a tyrosine kinase was engineered to become exclusively susceptible to 
inhibition by the bulkier NaPP1 molecule (300, 332, 348-350, 386). This “lock and key” 
approach allows rapid, reversible and unique inhibition of the activity of the desired kinase. For 
this approach to be useful, the mutation within the ATP-binding site has to be functionally silent 
and the modified kinase has to be used in a system that doesn’t endogenously express the wild-
type allele.  
In this study, we used the chemical genetic principles described above to successfully 
engineer an Hck mutant (Hck-T338A) that is uniquely sensitive to NaPP1 inhibition. The 
validity of the mutant was confirmed in an in vitro assay using purified recombinant Hck and 
Hck-T338A and in a Rat-2 fibroblast transformation assay. To address the role of Hck over-
expression in Bcr-Abl-mutation independent resistance to imatinib, we expressed wild-type Hck 
and the Hck-T338A mutant in the CML cell line K562, which does not express endogenous Hck. 
Expression of both Hck and Hck-T338A rendered K562 CML cells resistant to imatinib-induced 
inhibition of colony formation and apoptosis. This effect correlated with sustained 
phoshporylation of Bcr-Abl at several Tyr residues including Tyr-177, a residue that links Bcr-
Abl to the Ras signaling pathway (210, 218).  Furthermore, NaPP1 treatment restored imatinib 
sensitivity to cells expressing the Hck-T338A mutant but not the wild type kinase. This effect 
correlated with inhibition of Hck-T338A activity and loss of Bcr-Abl phosphorylation at Tyr-
177.  In contrast, NaPP1 did not have any effect on cells expressing the wild-type kinase or on 
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control cells. Taken together, these results establish a cause and effect relationship between Hck 
over-expression and imatinib resistance and identify Hck as a drug target in the treatment of 
imatinib-resistant CML where Hck is over-expressed. 
3.3 RESULTS 
3.3.1 Design of an inhibitor analog-sensitive Hck allele  
Crystal structures of various non-receptor tyrosine kinases have shown that within the ATP-
binding site lies a small, naturally occurring hydrophobic pocket. The access to this pocket is 
controlled by a large “gatekeeper residue”, typically a Thr, Met, Leu or Phe, which sterically 
blocks the access of many small molecules to this pocket (349, 354). Based on this observation, 
numerous groups have successfully applied a kinase inhibitor-sensitization approach to a great 
number of protein kinase families (such as MAP kinase fus3p; CDK Cdc28; PAK Cla4; Abl; 
PI3K) by replacing the gatekeeper residue with a smaller residue such as Gly or Ala (295, 386, 
387). In particular, replacement of the “gatekeeper residue” in v-Src (I338) to either Gly or Ala 
rendered it susceptible to inhibition by NaPP1 (388), suggesting this approach would work with 
Hck.  
In this work, we applied this chemical genetic strategy to the development of an Hck 
kinase variant that is sensitive to inhibition by NaPP1. To do this, we replaced the gatekeeper 
residue [Thr338; numbering based on crystal structure of human c-Src (62)] by Ala. Figure 17A 
depicts the Hck crystal structure in complex with PP1 (PDB:1QCF) in which NaPP1 was 
overlaid onto the crystal coordinates of PP1. Analysis of this structure reveals potential steric 
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clash between the Thr338 and the naphthyl moiety of NaPP1.  Replacement of T338 with Ala 
generates more space in the catalytic domain, allowing NaPP1 access to the hydrophobic pocket 
(Figure 17B). Based on the successful generation of analog-sensitive alleles in other Src kinases, 
we hypothesized that this mutation will render the kinase sensitive to NaPP1 without disrupting 
normal kinase activity or signaling.  
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Figure 17: Generation of the NaPP1-sensitive Hck 
(A) Orientation of NaPP1 in the ATP-binding site of Hck [based on the PDB: 1QCF of the crystal structure of Hck 
in complex with PP1; model created using PyMOL (Delano Scientific, LLC)]. The overall structure of Hck is shown 
in the left panel, with the SH3 domain in red, SH2 domain in blue, and the kinase domain in grey. The gatekeeper 
residue (Thr338) is highlighted in magenta. The spatial coordinates of the pyrazolo-pyrimidine ring of PP1 (not 
shown) were used to manually model the position of NaPP1 (shown as green sticks) within the ATP-binding site. 
The right panel shows a closer view of the NaPP1 position relative to the gatekeeper residue. This view shows that 
the naphthyl ring of NaPP1 clashes with the side chain of the gatekeeper residue, which may account for the lack of 
NaPP1 sensitivity of the wild type kinase. (B) The left panel represents Hck-T338A mutant expected to be sensitive 
to NaPP1. The T338A mutation was modeled in the Hck structure, and the Ala residue is highlighted in red. The 
right panel shows a close-up of NaPP1 orientation relative to the gatekeeper mutation. Note that the T338A mutation 
creates a space adjacent to the naphthyl moiety of NaPP1, which accounts for the NaPP1 sensitivity. (C) Chemical 
structures of the general SFK inhibitor PP1 and the modified analog, NaPP1.  
3.3.2  Replacement of Thr338 with Ala renders Hck sensitive to NaPP1 
To test whether the T338A mutation induces sensitivity to the bulky PP1 analog, NaPP1, the 
wild-type and T338A forms of Hck were expressed as recombinant proteins in Sf9 insect cells 
and purified to homogeneity. To facilitate the purification of these proteins in the downregulated 
conformation, we modified the natural C-terminal tail sequence, Y(527)QQQP, to Y(527)EEIP 
(here referred to as Hck-YEEI mutant). The YEEI modification promotes autphosphorylation of 
the tail Tyr527 in the absence of Csk, and increases affinity for the SH2 domain (63, 389). Thus, 
the YEEI tail variant of Hck does not require Csk to adopt the downregulated conformation, 
enabling high-yield purification from Sf9 cells without the need for Csk co-expression (63, 82).  
The recombinant purified Hck-YEEI and Hck-T338A-YEEI protein kinases were then assayed in 
vitro with a peptide substrate in the presence or absence of NaPP1. As shown in Figure 18A, 
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NaPP1 potently inhibited the Hck-T338A-YEEI mutant with an IC50 of 26.6 nM +/- 1.26 nM. In 
contrast, the NaPP1 IC50 for Hck-YEEI was almost 50-fold higher (1.3 µM +/- 0.39 µM). 
Importantly, NaPP1 did not inhibit a recombinant purified form of the c-Abl tyrosine kinase core 
consisting of the N-terminal cap (Ncap) region, the SH3 domain, the SH2 domain, and the kinase 
domain (referred to hereafter as “Ncap-c-abl”). 
 One potential problem concerning the introduction of the gatekeeper mutation in the 
ATP-binding site of Hck is cross-sensitization to imatinib. To rule out this possibility, we also 
tested Hck-T338A sensitivity to imatinib in the in vitro kinase assay using the same set of 
purified recombinant kinases.  As shown in Figure 18A, imatinib did not inhibit the activity of 
wild-type Hck or the Hck-T338A mutant, further supporting the validity of this approach. In 
contrast, imatinib inhibited the Ncap-c-Abl with an IC50 of 350 nM +/- 53 nM, consistent with 
previous work (390). 
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Figure 18: Hck-T338A mutant is sensitive to NaPP1 but not to imatinib in an in-vitro kinase assay 
Recombinant wild type Hck-YEEI, Hck-T338A-YEEI, and Ncap-c-abl were purified to homogeneity from Sf9 
insect cells. Kinase activity in the presence of NaPP1 (A) or imatinib (B) was assessed in vitro using a FRET-based 
assay with a peptide substrate. Representative experiments are shown and the percent of inhibition is expressed as 
mean ± S.D. from the results of four assay wells per condition. To obtain IC50 values, data were best fit using non-
linear regression analysis.  The entire experiment was repeated twice and produced comparable results. 
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3.3.3  NaPP1 potently and selectively inhibits Hck-T338A in a fibroblast transformation 
assay 
To determine whether the Hck-T338A mutant is sensitive to NaPP1 in a cell-based assay, we 
tested the ability of NaPP1 to reverse transformation of fibroblasts by an active form of Hck-
T338A. For these experiments, we replaced the C-terminal Tyr-527 with a Phe residue (hereafter 
referred to as an YF mutation) in both the wild-type and the T338A mutant. This mutation was 
previously shown to prevent tail Tyr527 phosphorylation by Csk and SH2 domain engagement, 
resulting in a marked increase in the kinase activity and oncogenic transformation of fibroblasts 
(84-86). The resulting Hck-YF and Hck-T338A-YF mutants were expressed in Rat-2 fibroblasts 
and their transforming potential and sensitivity to NaPP1 was compared in a soft-agar colony 
formation assay. Fibroblasts expressing wild-type Hck, Hck-T338A, or the G418 selection 
marker were used as negative controls. As shown in Figure 19A, neither wild-type Hck nor the 
T338A mutant induced fibroblast transformation, demonstrating that Ala substitution at the 
gatekeeper position does not result in kinase activation. In contrast, both Hck-YF and Hck-
T338A-YF had robust and comparable transforming activity, demonstrating that the T338A 
mutation does not interfere with the biological functions of the kinase in this system. Hck 
activity in each of the Rat-2 cell lines was assessed by anti-pTyr immunoblotting of lysates, and 
the results are presented in Figure 19B. Both Hck-YF and Hck-T338A-YF showed strong 
constitutive activity in this assay, demonstrating both autophosphorylation and phosphorylation 
of endogenous substrates such as pp40 (390). In contrast, Hck or Hck-T338A showed very little 
kinase activity, consistent with their lack of transforming function (Figure 19B). 
We next assessed the specificity of NaPP1 for Hck-T338A-YF in this system.  As shown 
in Figure 19A, NaPP1 blocked the transforming activity of Hck-T338A-YF with an IC50 of ~ 0.1 
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μM. This effect correlated with inhibition of Hck-T338A-YF activity as assessed by anti-pTyr 
immunoblotting (Figure 19B). Conversely, neither colony formation nor kinase activity were 
affected by NaPP1 in cells transformed by Hck-YF, even at concentrations as high as 1 μM 
(Figures 19A and B). These results establish that the T338A mutation is functionally silent and 
confers NaPP1 sensitivity on Hck in a cell-based assay. 
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Figure 19: Hck-T338A is biological active in fibroblasts and selectively sensitive to NaPP1 
Rat-2 fibroblasts were infected with recombinant retroviruses carrying a neomycin selection marker (vector control), 
wild-type Hck, Hck-T338A, Hck-YF or Hck-T338A-YF and selected with G418. (A) The stable cell lines were 
plated in triplicate in soft-agar in the presence of the indicated concentrations of NaPP1.  The general SFK inhibitor 
and parent compound PP1 (3 µM) was used as a positive control. Transformed colonies were stained with MTT 
after 10 to 14 days. The soft-agar plates were scanned and the number of colonies was determined using the BioRad 
imaging densitometry system and QuantityOne colony-counting software. Results from a representative experiment 
are shown as the mean number of colonies of three plates ± S.D. The experiment was repeated two times with 
similar results. (B) Control or Rat-2 fibroblasts transformed by Hck-YF or Hck-T338A-YF were plated overnight 
with the indicated concentrations of NaPP1. Lysates were probed with a general anti-phosphotyrosine antibody to 
determine the phosphorylation status of pp40, an endogenous substrate of Hck. As a loading control, Hck expression 
levels were determined in replicate blots using an anti-Hck antibody. One representative experiment is shown. 
 
3.3.4  Over-expression of Hck and Hck-T338A protects K562 CML cells from imatinib-
induced apoptosis and inhibition of colony formation  
Previous studies have shown that blast crisis CML patients that develop resistance to imatinib 
display increased Hck and/or Lyn kinase expression levels or activities in the absence of 
mutation in Bcr-Abl (218, 219, 314). To determine whether Hck overexpression in CML cells is 
sufficient to induce imatinib resistance, Hck and Hck-T338A were expressed in K562 cells using 
recombinant retroviruses. Cells infected with a retrovirus carrying only the neomycin resistance 
marker served as a negative control. Following selection with G418, the K562-neo, K562-Hck 
and K562-Hck-T338A cell populations were treated with increasing concentrations of imatinib 
for 72 h. The percent of apoptotic cells were then determined by anti-phosphatidyl serine 
antibody staining and flow cytometry. As shown in Figure 20, imatinib induced apoptosis in a 
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dose-dependent manner in the K562-neo cell population, with apoptotic cells evident with as 
little as 0.3 µM imatinib.  Strikingly, over-expression of wild-type Hck or Hck-T338A in K562 
cells was sufficient to reverse the apoptotic effects of imatinib at both 0.3 and 1 µM (p ≤ 0.02).  
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Figure 20: Expression of wild-type Hck or Hck-T338A protects K562 cells from imatinib-induced apoptosis 
K562-neo, K562-Hck and K562-Hck-T338A cell populations were incubated for 72 h in the absence or presence of 
the indicated concentrations of imatinib. Apoptotic cells were stained with an anti-phosphatidylserine-Alexa Fluor 
488 conjugated antibody and the percentage of apoptotic cells was determined by flow cytometry. (A) Histograms 
from a representative flow cytometry experiment with the percentage of apoptotic cells shown above each plot. (B) 
Bar graph showing the average of three independent experiments ± S.D. The difference between K562-neo and 
K562-Hck or between K562-neo and K562-Hck-T338A was statistically significant as demonstrated by a two-tailed 
Student’s t-test at 0.3 µM and at 1 µM imatinib (p ≤ 0.02). No statistically significant difference was obtained 
between K562-Hck and K562-Hck-T338A at any of the imatinib concentrations tested. 
 
As a second measure of biological activity, we next investigated whether expression of 
Hck in K562 cells reverses imatinib-induced inhibition of colony formation. To address this 
issue, K562-Hck, K562-Hck-T338A, and K562-neo cells were plated in soft-agar in the presence 
of the DMSO vehicle control (0 µM) or increasing concentrations of imatinib. As shown in 
Figure 21, K562 cells expressing wild-type Hck or Hck-T338A yielded a comparable number of 
colonies as the vector control cells when plated in soft-agar in the absence of imatinib. This 
suggests that expression of Hck or Hck-T338A alone does not enhance the basal level of K562 
cell colony-forming activity. Imatinib induced a dose-dependent inhibition of colony formation 
in all three cell lines. However, cells expressing wild-type Hck or Hck-T338A displayed 
statistically significant resistance to imatinib-induced inhibition of colony formation when 
compared to control cells. More specifically, 0.03 µM imatinib reduced the number of K562-neo 
colonies by nearly 50%, while it did not have a statistically significant impact on cells expressing 
either form of Hck (p ≤ 0.01). Furthermore, K562-Hck and K562-Hck-T338A were three times 
more resistant to 0.1 µM imatinib than K562-neo cells in this assay (p ≤ 0.01). Taken together, 
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results from both the apoptosis and colony growth assays demonstrate that overexpression of 
Hck is sufficient to induce resistance to imatinib.  
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Figure 21: Expression of wild-type Hck or Hck-T338A protects K562 cells from imatinib-induced inhibition 
of soft-agar colony formation 
K562-neo, K562-Hck, and K562-Hck-T338A cells were plated in triplicate in soft-agar in the presence of the 
indicated concentrations of imatinib and incubated for 7-10 days to allow colony growth. At the end of the 
incubation period, the soft-agar plates were scanned. (A) Representative plates showing the soft-agar colony growth 
in the presence of imatinib. (B) Plates were imaged and colony counts were determined using the BioRad 
QuantityOne colony-counting software. The bargraph shows the mean of three independent experiments ± S.D. The 
difference between K562-neo and K562-Hck or between K562-neo and K562-Hck-T338A was statistically 
significant by two-tailed Student’s t-test at 0.03 µM, 0.1 µM and 0.3 µM imatinib (p ≤ 0.01). No statistically 
significant difference was obtained between K562-Hck and K562-Hck-T338A at any of the imatinib concentrations.  
3.3.5  Resistance to imatinib-induced apoptosis and inhibition of colony growth is 
dependent on Hck kinase activity 
To address the hypothesis that the resistance to imatinib requires Hck kinase activity, we tested 
whether specific inhibition of Hck-T338A with NaPP1 restored sensitivity to imatinib. For this 
experiment, K562-neo, K562-Hck and K562-Hck-T338A cells were incubated with imatinib 
over the same concentration range as in Figure 20 (0 to 1 µM) in the presence of escalating doses 
of NaPP1 (0 to 3 µM). After 72 h, cells were stained with an anti-phosphatidyl serine antibody 
and the percentage of apoptotic cells was determined by flow cytometry. The results presented in 
Figure 22 show the apoptotic response to imatinib plotted for each concentration of NaPP1. 
Similar to the results presented in Figure 20C, K562-Hck and K562-Hck-T338A cells displayed 
resistance to imatinib-induced apoptosis when compared to K562-neo control cells.  Addition of 
NaPP1 to K562-neo cells as well as cells expressing wild-type Hck did not affect the level of 
apoptosis induced by imatinib, demonstrating that NaPP1 alone is not cytotoxic and does not 
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affect wild-type Hck at these concentrations.  In contrast, addition of NaPP1 to K562-Hck-
T338A cells induced a dose-dependent reversal of resistance to imatinib to a level similar to 
K562-neo control cells, suggesting that resistance to imatinib-induced apoptosis requires the 
kinase activity of Hck.  
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Figure 22: Specific inhibition of Hck-T338A kinase activity using NaPP1 restores the apoptotic response to 
imatinib of K562-Hck-T338A cells 
K562-neo, K562-Hck, and K562-Hck-T338A were incubated with the indicated combinations of imatinib and 
NaPP1 for 72 h. The concentration range for NaPP1 was from 0 to 3 µM, and for imatinib from 0 to 1 µM. 
Apoptotic cells were stained with an anti-phosphatidylserine-Alexa Fluor 488 conjugated antibody and the 
percentage of apoptotic cells was determined by flow cytometry. The response to imatinib was plotted for each 
individual NaPP1 concentration. Each point represents the means generated from three independent experiments ± 
S.D.  
 
Next, we determined whether NaPP1 resensitizes K562-Hck-T338A cells to imatinib in 
the soft-agar colony assay. To address this issue, each K562 cell population was plated in soft 
agar with combinations of imatinib (0 to 0.3 µM) and NaPP1 (0 to 3 µM) and incubated for 7 
days to allow colony formation. Imatinib-induced inhibition of colony formation was determined 
for each NaPP1 concentration, and the results are plotted in Figure 23. In addition, colony 
formation IC50 values for imatinib were determined by sigmoidal-dose response curve fitting.  
Imatinib inhibited K562-neo colony formation with an IC50 of 35.9 nM ± 6.8 nM in the absence 
of NaPP1, and this value was unaffected by NaPP1 treatment. Overexpression of wild-type Hck 
or Hck-T338A in K562 cells increased the IC50 value for the inhibition of colony formation  by 
imatinib by a factor of four, to 135 nM ± 11 nM and 146 nM ± 17.7 nM, respectively. Similar to 
the K562-neo control cells, NaPP1 did not affect the inhibition of colony formation by imatinib 
in K562 cells expressing wild-type Hck, consistent with the lack of NaPP1 activity against the 
wild-type kinase. In contrast, addition of NaPP1 to K562-Hck-T338A cells induced a dose-
dependent reversal of the inhibition of colony formation IC50 for imatinib, from 146 nM ± 17.7 
nM to 32 nM ± 6.6 nM, a value close to that observed with the K562-neo control cell population. 
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These results demonstrate that selective inhibition of Hck-T338A kinase activity restores 
sensitivity to imatinib in terms of colony-forming activity as well.  
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Figure 23: Specific inhibition of Hck-T338A kinase activity using NaPP1 restores the sensitivity to imatinib of 
K562-Hck-T338A cells in soft-agar assay 
K562-neo, K562-Hck, and K562-Hck-T338A cells were plated in triplicate in soft-agar in the presence of the 
indicated combinations of imatinib and NaPP1. Colonies were stained 10-14 days later, and were counted using 
scanned images of the plates and the BioRad QuantityOne colony-counting software. The entire experiment was 
repeated twice from independently derived cell populations and yielded similar results. A representative experiment 
is shown. Each point represents the average of three plates ± S.D. The response to imatinib at each NaPP1 
concentration was determined by curve-fitting using non-linear regression analysis and IC50 determination. The IC50 
values are displayed to the right of each plot. 
 
To determine whether the reversal of imatinib sensitivity was associated with inhibition 
of Hck-T338A tyrosine kinase activity, Hck was immunoprecipitated from cells following 
exposure to the same imatinib concentrations used in the apoptosis and colony assays in 
combination with 3 µM NaPP1 (Figure 24). Immunoblot analysis using an antibody specific to 
phospho-Tyr416 in the activation loop of the active form of Hck was used to determine the 
activation status of Hck. The results show that 3 µM of NaPP1 completely inhibited the T338A 
mutant of Hck consistent with the complete reversal of imatinib sensitivity observed at this 
concentration. In contrast, NaPP1 did not inhibit the activity of wild-type Hck kinase. In 
addition, to confirm the specificity of NaPP1, we also immunoprecipitated Lyn and performed 
immunoblot analysis with anti-phospho-Tyr-416 antibody as a measure of Lyn activation. Figure 
24B shows that 3 µM NaPP1 did not affect Lyn activation loop phosphorylation at any of the 
imatinib concentrations.    
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 Figure 24: NaPP1 specifically inhibits Hck-T338A mutant in K562 cells 
K562-neo, K562-Hck, and K562-Hck-T338A cells were plated in 0.5% FBS overnight and treated with the 
indicated concentrations of imatinib and NaPP1 for 5 hours. Hck (A) or Lyn (B) were immunoprecipitated from 
clarified lysates and immunoblotted with an anti-Src phosphospecific pY416 antibody that recognizes the tyrosine-
phosphorylated activation loop of Hck and Lyn. Duplicate membranes were blotted for Hck and Lyn as a loading 
control.  This experiment was repeated twice from independent cell lines, and representative blots are shown.  
 
 117 
3.3.6  Hck or Hck-T338A overexpression in K562 cells is associated with increased 
phosphorylation of Bcr-Abl at multiple Tyr residues 
Previous work from our laboratory and others has shown that SFKs trans-phosphorylate c-Abl or 
Bcr-Abl at various residues. This may in turn induce an active conformation and thus directly 
decrease sensitivity to imatinib, and may also increase the activity of some Bcr-Abl-dependent 
signaling pathways. For example, c-Src and Hck were shown to phosphorylate c-Abl at Tyr-412, 
and to induce imatinib resistance (367). Moreover, Hck and other SFKs were shown to 
phosphorylate Bcr-Abl at Tyr-89 in the SH3 domain and at Tyr-245 in the SH2:kinase linker 
region in vitro (194). Phosphorylation at both these residues was predicted to induce activation 
due to disruption of intra-molecular negative regulatory interaction between the SH3 domain and 
the SH2: kinase linker. However, subsequent dynamics analysis using hydrogen-deuterium 
exchange mass spectrometry suggests that phosphorylation of Tyr-89 but not Tyr-245 disrupts 
this interaction (195). Furthermore, Hck also phosphorylates Bcr-Abl in the Bcr-portion of the 
protein at Tyr-177, a residue that links Bcr-Abl to Ras activation and is required for 
leukemogenesis (229-232). In addition, work presented in Chapter 2 using Hck-T338M, a mutant 
resistant to the global SFK-inhibitor A-419259, suggests that Hck along with other Src kinases 
contributes to trans-phosphorylation of Bcr-Abl at Tyr-89, 245, and 177, but it does not affect 
Tyr-412 in K562 cells.  
To test whether the resistance to imatinib observed in response to Hck overexpression 
correlates with phosphorylation of these Bcr-Abl Tyr residues, we performed immunoblotting 
with phosphospecific antibodies on K562-neo, K562-Hck, and K562-Hck-T338A cell lysates 
following treatment with a combination of imatinib and NaPP1. Figure 25 shows that in the 
absence of imatinib, the relative levels of phosphorylation at Tyr-89 and Tyr-245 increased in 
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response to the expression of either wild-type Hck or Hck-T338A. In addition, the blots from 
K562-neo control cells show phosphorylation at these residues is significantly inhibited at 0.1 
µM imatinib, while K562-Hck and K562-T338A cells display an increased phosphorylation at 
0.1 µM imatinib (in the case of pY245), and even at 0.3 µM imatinib in the case of pY89. 
Furthermore, addition of 3 µM NaPP1 inhibited the phosphorylation of these residues in cells 
expressing Hck-T338A when added with 0.1 µM imatinib (for pY245) or with 0.3 µM imatinib 
(for pY89). This suggests that the increase in phosphorylation at Tyr-89 and Tyr-245 is mediated 
by Hck and requires the Hck kinase activity. Although increased phosphorylation at Tyr-89 is 
expected to induce an increased activity of Bcr-Abl, this was not correlated with an increase in 
the phosphorylation of CrkL, a Bcr-Abl substrate. Therefore, the significance of Tyr-89 and Tyr-
245 phosphorylation by Hck in the context of imatinib resistance remains unclear.  
In addition to Tyr-89 and Tyr-245, we also determined how expression of Hck affects 
Tyr-177 phosphorylation in the Bcr-derived portion of the oncoprotein. As shown in Figure 25, 
Bcr-Abl from K562-Hck and K562-Hck-T338A cells demonstrate persistent phosphorylation at 
this residue even in the presence of 0.3 and 1 µM imatinib, while phosphorylation of Tyr-177 in 
control cells is completely inhibited at these imatinib concentrations. In addition, co-incubation 
with NaPP1 inhibits Bcr-Abl Tyr-177 phosphorylation in K562-Hck-T338A but not K562-Hck 
cells.  Since phosphorylation of Tyr-177 creates a binding site for Grb2 and induces increased 
Ras signaling (210, 218), it is possible that Hck expression may restore Ras-dependent anti-
apoptotic signaling that contributes to imatinib resistance.  
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 Figure 25: Wild-type Hck or Hck-T338A overexpression increases phosphorylation of Bcr-Abl at various Tyr 
residues in an Hck-kinase dependent manner. 
K562-neo, K562-Hck, and K562-Hck-T338A cells were plated in 0.5% FBS overnight and treated with the 
indicated concentrations of imatinib and NaPP1 for 5 hours. Cell lysates were resolved on SDS-PAGE gels and 
immunoblotted with phosphospecific antibodies for Abl pY245 and pY89, Bcr pY177, and for CrkL pY207. As 
loading controls, duplicate blots were also probed with anti-actin and anti-Abl (for Bcr-Abl expression levels). The 
experiment was repeated twice from independent cell lines. Representative blots are shown. 
 
3.4 DISCUSSION 
Resistance to imatinib, the primary line of treatment for CML patients, has typically been 
associated with persistence or reactivation of Bcr-Abl signaling or due to selection for drug-
resistant Bcr-Abl mutants. However, emerging evidence show that other mechanisms of imatinib 
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resistance in absence of Bcr-Abl mutations also have significant clinical importance. Consistent 
with a growing body of evidence implicating the Src family kinases in various phases of CML, 
recent evidence has linked Hck and Lyn overexpression or enhanced activation to imatinib 
resistance in the absence of Bcr-Abl mutations(218, 219, 314, 331). In this report, we 
investigated whether Hck overexpression is sufficient to induce resistance to imatinib and 
established a direct cause and effect relationship between Hck overexpression and resistance to 
imatinib in a CML cell line with wild-type Bcr-Abl.  
 To address this problem, we hypothesized that overexpression of Hck in CML cells 
would create resistance to imatinib. To be able to demonstrate that this imatinib resistance is due 
to the kinase activity of Hck, we employed a chemical genetic method to generate an Hck allele 
(Hck-T338A) that is uniquely targeted by NaPP1, a bulky analog of the global SFK inhibitor 
PP1. The advantage of this chemical genetic approach is that it allows for specific inhibition of 
Hck activity while leaving the Hck protein and its complexes intact. Thus data derived using this 
approach is more directly applicable to drug discovery than gene expression knockdown by 
siRNA or other approaches. Since the original description of this method by Shokat’s group 
(388), this approach has been successfully applied to both serine/threonine and tyrosine kinases 
from diverse families (386).  
As part of the Hck-T338A validation strategy, we first needed to establish that this 
inhibitor analog-sensitizing mutant did not result in a loss- or gain-of-function and that it was 
selectively sensitive to inhibition by NaPP1 but not affected by imatinib. To address these issues 
we used both in vitro and cell-based assays. We observed that the Hck-T338A mutant maintains 
its catalytic activity against an artificial substrate in an in-vitro kinase assay (Figure 18A).  When 
expressed in fibroblasts as the active form Hck-T338A-YF, it induces Rat-2 fibroblast oncogenic 
 121 
transformation. Moreover, as shown in Figure 19B, expression of Hck-T338A-YF induced 
phosphorylation of pp40, a transformation-related endogenous Hck substrate (95-97). Taken 
together, these results show that the T338A mutation is well tolerated and does not induce a loss 
of the catalytic activity of Hck.  
Replacement of the corresponding gatekeeper residue with Ala in other receptor or non-
receptor tyrosine kinases such as c-Abl, c-Src or PDGFRB were recently shown to have mild 
activating effects when expressed in the human embryonic kidney cell line 293T as shown by the 
increased tyrosine phosphorylation of total cellular protein (310). However, these mild activating 
effects were not sufficient to transform murine BaF3 myeloid cells to IL-3 independence (310). 
In the case of Hck, evidence presented in this report suggests that the replacement of the 
gatekeeper residue to Ala does not induce a gain-of-function in Hck. For example, expression of 
Hck-T338A in Rat-2 fibroblasts did not induce oncogenic transformation, while the active Hck-
T338A-YF induced Rat-2 transformation at levels similar to those observed with Hck-YF with a 
wild-type kinase domain (Figure 19A).  In addition, neither wild-type Hck nor Hck-T338A 
expression in Rat-2 fibroblasts induced tyrosine phosphorylation of total cellular lysates, as 
shown in Figure 19B.  Lastly, K562-Hck-T338A cells did not form a higher number of colonies 
in soft-agar when compared to K562-Hck cells (Figure 19A). Although these data indicate that 
Hck-T338A does not exhibit gain-of-function activity, our experiments do not rule out the 
possibility that the gatekeeper mutation induces a gain-of-function undetectable by our end-point 
assays such as a change of substrate specificity. 
We next evaluated the sensitivity of Hck-T338A to NaPP1, and found that this 
gatekeeper substitution made Hck almost 50 times more sensitive to NaPP1 than the wild-type 
kinase in vitro (Figure 18A). In addition, mutation of the gatekeeper residue to a less bulky 
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amino acid did not induce cross-sensitivity to imatinib (Figure 18B). Importantly, NaPP1 did not 
inhibit the recombinant Abl kinase core, consistent with the specificity of this compound for the 
Hck-T338A mutant (Figure 18A). Furthermore, NaPP1 inhibited Hck-T338A-YF-, but not Hck-
YF-induced transformation of Rat2 fibroblasts (Figure 19A). Consistent with the inhibition of 
colony formation, NaPP1 inhibited Hck-T338A-YF activity, but not Hck-YF (Figure 19B).  
Having validated the NaPP1-sensitive mutant, we next showed that Hck or Hck-T338A 
overexpression in CML cells is sufficient to cause increased survival and colony- forming 
activity in the presence of imatinib (Figures 20 and 21).  Colony growth in soft agar was strongly 
affected, with the IC50 value for inhibition of colony growth increased by 4-fold upon 
overexpression of either form of Hck in K562 CML cells (Figure 23). The resistance to imatinib 
induced by Hck-T338A overexpression was completely reversed by NaPP1 in a concentration-
dependent manner in cells expressing Hck-T338A, but not in cells expressing the wild-type Hck 
(Figure 22 and 23). The reversal of imatinib sensitivity in terms of survival and colony growth 
correlated with a complete inhibition of Hck-T338A activity by NaPP1 treatment, whereas wild-
type Hck activity was unaffected (Figure 24).  These results show that the imatinib resistance 
induced by Hck overexpression is specifically dependent upon Hck kinase activity. 
Hck-induced resistance to imatinib may occur through a feedback mechanism that 
induces an active conformation of Bcr-Abl tyrosine kinase domain and therefore imatinib 
resistance, or through Bcr-Abl-kinase independent mechanisms. Using phospho-specific 
antibodies, we present evidence that Hck expression induces a slight increase in phosphorylation 
of Tyr-89 and Tyr-245 in the Abl core, and that phosphorylation at these residues is reversible 
with NaPP1.  Recent work has shown that phosphorylation at Tyr-89, which localizes to the RT-
loop of the SH3 domain, disrupts its intra-molecular interaction with the SH2: kinase linker and 
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was predicted to promote an active conformation of the Abl core (195). Whether or not Hck-
mediated phosphorylation of SH3 Tyr-89 in the context of Bcr-Abl contributes to the imatinib 
resistance observed here is not clear.  The lack of increased phosphorylation of the Bcr-Abl 
substrate, CrkL, in the presence of Hck suggests that Tyr-89 phosphorylation does not markedly 
upregulate Bcr-Abl tyrosine kinase activity. In contrast to Tyr-89, our results also show an 
increase in Tyr-177 phosphorylation that is strongly reversed by NaPP1 in K562-Hck-T338A 
cells but not in cells expressing wild-type Hck.  Since phosphorylation of Tyr-177 facilitates Ras 
signaling (210, 218), enhanced phosphorylation of this site may stimulate mitogenic and anti-
apoptotic pathways downstream of Ras that contribute to increased growth and survival of Hck-
expressing K562 cells in the presence of imatinib.  
Although this study addressed the possible feedback effects of Hck on Bcr-Abl activity or 
signaling that may account for imatinib resistance, Bcr-Abl-independent mechanisms may play a 
role as well. For example, recent evidence shows that Bcr-Abl activates autocrine IGF-1 
signaling through Hck and Stat5b (222). Thus, overexpression of Hck may induce an increase in 
autocrine IGF-1 signaling. In other experimental systems, IGF-1 was shown to have 
antiapoptotic effects due to ß-catenin stabilization (391). Therefore, it is possible that the Hck-
induced imatinib resistance observed here may be due in part to an increase in IGF-1-induced 
anti-apoptotic effects.  In addition, several SFKs have been shown to phosphorylate the 
cytoplasmic domain of Muc-1, a transmembrane glycoprotein overexpressed in CML. 
Phosphorylation of this Muc-1 region promotes the binding, stabilization, and increased nuclear 
targeting of ß-catenin (223, 224). Determination of whether Hck-mediated stabilization of β-
catenin activation through either of these pathways leads to imatinib resistance will require 
further investigation.  
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Although significant, the degree of Hck-induced imatinib resistance reported in this study 
can be overcome by increasing the concentration of imatinib. In CML patients, therefore, 
therapeutically attainable concentrations imatinib (up to 5 µM) may override this resistance 
mechanism. However, if the Hck-induced imatinib resistance mechanism is independent of Bcr-
Abl, then simply increasing the concentration of imatinib would not eliminate the resistant cell 
population. On the contrary, imatinib exposure may exert a selective pressure that could lead to 
the expansion of cells in which this resistance mechanism is predominant. Furthermore, in a 
clinical setting, patients may progress via clonal evolution and thus more than one molecule may 
be involved in imatinib resistance. The recent observation that both Lyn and Hck are activated in 
patients resistant to imatinib in the absence of Bcr-Abl mutations supports this hypothesis.  
In addition, experiments in this study were performed in K562, a cell line derived from a 
CML patient in blast crisis. Since progression to blast crisis is accompanied by additional genetic 
abnormalities, it is possible that these cells are already equipped with the necessary changes in 
the signaling pathways that can support Hck-induced imatinib resistance.  Whether or not Hck 
overexpression would have a similar effect in cells derived from patients in chronic phase is not 
clear.  Future experiments will address this important possibility as well. 
Given the occurrence of imatinib resistance, various second-generation tyrosine kinase 
inhibitors, such as nilotinib, have been developed to override this phenomenon. In an attempt to 
study the potential mechanisms of nilotinib-resistance, a recent report describes the generation of 
a nilotinib-resistant K562 cell line by exposure to gradually increasing concentrations of the drug 
(392). In this cell line, nilotinib resistance was linked to Lyn upregulation. In addition, an 
increase in Lyn mRNA expression was found in 2 out of 7 patients that developed resistance to 
nilotinib (392). This report suggests that SFK upregulation may represent a common mechanism 
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of resistance to Bcr-Abl inhibitors in addition to selection of drug-resistant Bcr-Abl kinase-
domain mutants. This observation also suggests that patients developing imatinib resistance 
without Bcr-Abl mutations may also be cross-resistant to other Bcr-abl inhibitors.  In this 
context, it would be interesting to determine whether Hck overexpression also induces resistance 
to nilotinib.  
In sum, the results presented in this report demonstrate for the first time that 
overexpression of Hck is sufficient to confer imatinib resistance to CML cells derived from a 
blast crisis patient, and that this mode of resistance requires Hck kinase activity. In addition, 
using chemical genetic principles, we have created a cell-based model system that allows for 
specific and temporal inhibition of Hck kinase activity. Previously, such experiments were 
hindered by the lack of specific inhibitors for individual SFK members. Additional studies of the 
mechanisms by which Hck induces imatinib resistance will improve the understanding and 
therapy for advanced stage CML.  Along these lines, inhibitors selective for Hck may be of 
benefit in imatinib–resistant CML.  
3.5 MATERIALS AND METHODS 
3.5.1 Cell Culture 
Rat-2 fibroblasts were purchased from the ATCC and maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 5% FBS, 100 U/ml penicillin G, 100 μg/ml streptomycin 
sulfate, and 0.25 μg/ml amphotericin (Antibiotic-Antimycotic, Invitrogen). Sf9 insect cells were 
cultured in Grace’s medium (Gibco) supplemented with 10% FBS and 50 μg/ml gentamicin 
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(Gibco). The K562 myeloid leukemia cell line, derived from a CML patient in blast crisis (373), 
was obtained from the ATCC and maintained in RPMI 1640 supplemented with 10% fetal 
bovine serum (FBS) (Atlanta Biologicals), and Antibiotic-Antimycotic (Invitrogen).  
3.5.2 Protein purification 
Using site-directed mutagenesis, the Thr-338 to Ala (T338A) mutation was introduced into 
coding sequence of human p59 Hck-YEEI (QuikChange XL Site-directed Mutagenesis Kit, 
Stratagene) (86). The Hck-YEEI and Hck-T338A-YEEI constructs also contained N-terminal 
hexahistidine tags. The Ncap-c-Abl construct encompasses residues 1-531 of human c-Abl-1b 
with residues 15-56 deleted, and contains a C-terminal cleavage site for the tobacco etch virus 
(TEV) protease and a hexahistidine tag, both introduced by PCR. Hck-YEEI, Hck-T338A-YEEI 
and the Ncap-c-abl constructs were cloned into pVL1392 (BD Biosciences) and each plasmid 
was used to create high-titer recombinant baculovirus in Sf9 insect cells using Baculogold DNA 
and the manufacturer’s protocol (BD Biosciences). For protein production, Sf9 cells (1 L) were 
grown in suspension in Grace’s medium (Invitrogen) supplemented with 10% FBS and 50 μg/ml 
gentamycin. Sf9 cells were cultured to a density of 2 × 106 cells/ml and then infected with either 
Hck-YEEI or Hck-T338A-YEEI baculoviruses. For the Ncap-c-Abl construct, Sf9 cells were co-
infected with Abl and YopH phosphatase baculoviruses at a multiplicity of infection of 10. 
YopH is a protein-tyrosine phosphatase that promotes a downregulated conformation of Ncap-c-
Abl that permits high-yield purification from Sf9 cells (188). Sf9 cells were grown for 48 h, 
centrifuged, washed in PBS, and then the pellets were resuspended in buffer A [20 mM Tris-HCl 
(pH 8.3), 10% glycerol, and 5 mM ß - mercaptoethanol], lysed by sonication, and centrifuged at 
16,000 rpm for 30 min. The recombinant Hck or Ncap-c-Abl proteins were purified from the 
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supernatant using a combination of ion exchange and affinity chromatography as originally 
described by Schindler et al. for Hck (63). Upon purification, the proteins were dialyzed against 
20 mM Tris-HCl (pH 8.3) containing 100 mM NaCl and 3 mM DTT.  
3.5.3 In vitro kinase assay 
Kinase assays were performed using the FRET-based Z’-Lyte Src kinase assay kit and Tyr-2 
peptide substrate according to the manufacturer’s instructions (Invitrogen). All assays were 
performed in quadruplicate in low volume, non-binding 384-well plates (Corning). The assay 
was first optimized to determine the amount of each kinase and the incubation time necessary to 
phosphorylate 50-60% of the Tyr-2 peptide in the absence of inhibitor.  Final ATP and Tyr-2 
substrate concentrations were held constant at 50 μM and 2 μM, respectively.  For inhibition 
experiments the kinases were pre-incubated with NaPP1 or imatinib in kinase assay buffer for 30 
min, followed by incubation with ATP and Tyr-2 peptide for 1 h. Fluorescence was assessed on a 
Gemini XS microplate spectrofluorometer (Molecular Devices). IC50 values were calculated 
from the means of 4 wells and using a sigmoidal curve fit and Prism software (GraphPad 
Software, Inc).  
3.5.4  Rat-2 fibroblasts transformation assays 
Using site-directed mutagenesis, the T338A mutation was introduced in the active form of Hck 
(Hck-YF). The wild-type Hck, Hck-T338A, Hck-YF and Hck-T338A-YF constructs were 
subcloned into the retroviral vector pSRαMSVtkneo (375). The resulting constructs were used to 
generate high-titer retroviral stocks by co-transfection of 293T cells with an ecotropic packaging 
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vector. Control retroviruses were prepared using the parent pSRαMSVtkneo vector. Rat-2 
fibroblasts were infected as follows: 2.5 x 104 Rat-2 cells were plated per well in 6-well plates 
and incubated with viral stocks in a final volume of 5 ml in the presence of polybrene (4 µg/ml 
final concentration). To enhance infection efficiency, the plates were centrifuged at 3,000 rpm 
for 4 h at 18 °C. Following infection, the virus was replaced with fresh medium. To obtain stable 
cell lines, G418 (800 µg/ml) selection was started 48 h after infection and continued for 14 days. 
At the end of the selection period, the G418 concentration was decreased at 400 µg/ml.  
3.5.5  Retroviral transduction of K562 leukemia cells 
Wild-type Hck and the Hck-T338A mutant were subcloned into the retroviral expression vector 
pMSCV-IRES-neo (Clontech) between the MSCV promoter and IRES sequence. Retroviral 
stocks were produced from the resulting constructs in 293T cells using an amphotropic 
packaging vector as described abovefor Rat-2 cells. K562 cells were plated in 6 well plates at 1 x 
106 cells/ well in 5 ml of undiluted viral supernatant in the presence of 4 μg/ml polybrene, and 
centrifuged at 3000 rpm for 3 h at room temperature. After infection, cells were washed, returned 
to regular medium for 48 h and then placed under G418 selection (800 μg/ml) for 14 days. At the 
end of the selection period, cells were maintained in medium with 400 μg/ml G418.  
3.5.6 Soft-agar colony assays 
Soft-agar fibroblast transformation assays were performed in triplicate in 35 mm Petri dishes 
(Falcon) using Seaplaque Agarose (FMC Bioproducts). One ml of 0.5% bottom agarose in 
complete culture medium was poured in the presence of either vehicle (0.5% DMSO) or NaPP1 
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at twice the final desired concentration. After the hardening of the bottom layer, 1 x 104 Rat-2 
cells were mixed in culture medium containing 0.3% agarose and 1 ml was poured onto the 
bottom layer. Seven to ten days later, the colonies were stained with MTT and the soft-agar 
plates were scanned and quantitated using colony counting software (BioRad QuantityOne). 
K562 leukemia cells were plated in soft-agar as described above at a cell density of 2 x 
103 cells/plate and in the absence or presence of imatinib or of combinations of NaPP1 and 
imatinib. Staining of the colonies with MTT was performed after 7 days of incubation. Colony 
counting was performed as described above. 
3.5.7 Apoptosis assay 
Apoptosis was determined by measuring cell-surface phosphatidyl serine (PS) using an Alexa 
Fluor 488-conjugated anti-PS antibody (Upstate Biotechnology) and flow cytometry.  Cells (1 x 
105/ml) were treated with vehicle alone (0.5% DMSO), imatinib or combinations of NaPP1 and 
imatinib for 72 h at 37°C.  Following incubation, cells were centrifuged at 1000 rpm for 5 min, 
washed three times with ice-cold PBS and resuspended to 4 x 106 cells/ml in staining buffer (1% 
FBS in PBS).  Aliquots (50 μl) were transferred to 96-well round bottom tissue culture plates, 
mixed with the anti-PS antibody (0.21 μg/well), and incubated on ice for 1 h. Cells were washed 
three times in ice-cold PBS and analyzed using a FACSCalibur flow cytometer (Becton-
Dickinson) and CellQuest software. 
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3.5.8 Antibodies 
The following antibodies were used in this study: anti-actin (MAB1501; Chemicon), anti-Hck 
polyclonal (N-30; Santa Cruz Biotechnology), anti-Hck monoclonal (Transduction Laboratories), 
anti-Lyn (Santa Cruz Biotechnology), anti-c-Abl (Calbiochem), anti-Src phosphospecific (Src 
pY-416; Upstate Biotechnology), anti-Bcr phospho-Tyr-177 (Cell Signaling), anti-c-Abl 
phospho-Tyr-89 (Cell Signaling), anti-c-Abl phospho-Tyr-245 (Cell Signaling), anti-CrkL 
phospho-Tyr-207 (Cell Signaling), and anti-phosphotyrosine (PY-99; Santa Cruz). 
3.5.9 Immunoprecipitation and immunobloting 
Hck expression and activation in Rat-2 fibroblasts was analyzed by plating 5 x 105 cells in 100 
mm dishes in the presence of NaPP1 or vehicle control (0.5% DMSO). After incubation at 37 °C 
overnight, cells were lysed in ice-cold radioimmunoprecipitation assay (RIPA) lysis buffer (50 
mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM EDTA, 10 mM MgCl2, 1% Triton X-100, 1% 
sodium deoxycholate, and 0.1% SDS) supplemented with the protease inhibitors aprotinin (25 
μg/ml), leupeptin (25 μg/ml) and PMSF (1 mM) and the phosphatase inhibitors NaF (10 mM), 
and Na3VO4 (1 mM). Total protein concentration in clarified cell lysates was measured using the 
Bradford assay (Pierce). Aliquots of total protein were heated directly in SDS sample buffer and 
resolved by SDS-PAGE, transferred by PVDF membranes and blotted with either anti-Hck to 
detect Hck protein expression or anti-phosphotyrosine antibodies for the detection of 
phosphorylated pp40, an endogenous Hck substrate. To check the levels of Hck, Bcr-Abl or actin 
or to check the phospho-tyrosine content of Bcr-Abl using phospho-specific antibodies in K562 
cells, 5 x 106 cells were incubated overnight in 0.5% FBS, and then treated for 5 h with vehicle 
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control (DMSO, 0.5%) or with imatinib and/or NaPP1. At the end of the incubation period, the 
cells were collected by centrifugation, washed twice with PBS and lysed in ice-cold RIPA buffer 
and processed as above. For Hck or Lyn immunoprecipitation, protein concentrations were first 
normalized in lysis buffer, followed by addition of 1 μg of anti-Hck or anti-Lyn antibody and 25 
μl of protein G-Sepharose (50% slurry; GE Healthcare Life Sciences). Following incubation for 
2 h at 4 °C, immunoprecipitates were washed three times with 1.0 ml of RIPA buffer and heated 
in SDS sample buffer. Following SDS-PAGE, proteins were transferred to PVDF membranes for 
immunoblot analysis. Immunoreactive proteins were visualized with appropriate secondary 
antibody-alkaline phosphatase conjugates and NBT/BCIP colorimetric substrate (Sigma).  
3.5.10 Statistical analysis 
Data obtained from multiple independent experiments are given as mean ± S.D. values. 
Statistical comparisons between two cell lines at individual drug concentrations were performed 
using a two-tailed unpaired Student’s t-test (normal distribution and unequal variance). To 
protect against potential multiplicity problems, for all analyses a p value less than 0.02 was 
considered statistically significant.  Statistical analyses were done using Microsoft Excel.  
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4.0  OVERALL DISCUSSION 
4.1 SUMMARY OF FINDINGS AND SIGNIFICANCE 
Prior to this study, extensive work from our laboratory and others showed that SFKs play an 
unquestionable role in CML pathogenesis as downstream targets and mediators of Bcr-Abl 
signaling. Typically, due to a lack of small molecule inhibitors specific to individual SFK 
members, these studies were performed using general SFK inhibitors such as PP1, or A-419259; 
using SFK dominant negative mutants; or using siRNA technology to selectively decrease the 
expression of SFK members (211, 215, 221). Although remarkably informative, as a group, these 
methods were not able to clearly delineate the relative contribution of individual SFKs to Bcr-
Abl signaling, or to determine whether they have unique or overlapping functions. Therefore, in 
the first aim of my thesis, I set out to determine the individual contribution of Hck to Bcr-Abl 
signaling using chemical genetics.  
In addition, in cell-based models of imatinib resistance obtained by prolonged exposure 
of CML cells to increasing concentrations of imatinib, resistance was shown to be associated 
with Lyn overexpression while no Bcr-Abl mutations or amplification was detected (219). 
Furthermore, analysis of clinical samples from CML patients with imatinib resistance but wild-
type Bcr-Abl has shown that Lyn and/or Hck are highly activated, suggesting that both kinases 
may be involved in imatinib resistance (218, 219). Although Lyn’s role in imatinib resistance has 
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been addressed in previous reports, the role of Hck is less understood. Given this lack of 
information, in the second aim of my thesis I addressed the role of Hck in Bcr-Abl-mutation-
independent imatinib resistance. 
4.1.1 Hck individual contribution to Bcr-Abl signaling 
To directly define the individual contribution of Hck to Bcr-Abl signaling and pathogenesis, I 
used a chemical genetics method in which I introduced a point mutation at the gatekeeper 
position in the ATP-binding site of Hck to render it resistant to a general SFK inhibitor, A-
419259. This mutant was designed based on the observation that variation at this position is an 
important structural determinant of kinase sensitivity to small molecule inhibitors (300, 332, 
348-350). In addition, a close inspection of the crystal structure of Hck in complex with A-
420983, an A-419259 analog suggested that replacement of the gatekeeper residue with Met, a 
bulky amino acid would induce a steric clash with the inhibitor molecule (Chapter 2). Thus, 
replacement of the gatekeeper residue Thr338 of Hck with Met resulted in a mutant resistant by 
more than 30-fold to the broad-spectrum SFK inhibitor, A-419259. In addition, I showed that, 
with the exception of a subtle decrease in the Km for ATP, this mutation was silent in terms of 
kinase function and activity, a feature essential for the utility of this approach. Next, I showed 
that expression of the Hck-T338M mutant in CML cell lines has a moderate protective effect 
against the A-419259-induced inhibition of cell proliferation. This suggests that although Hck 
contributes to Bcr-Abl-induced cell growth, other Src kinases may play a role. Furthermore, I 
was able to show that Hck-T338M expression fully protects CML cells against the A-419259-
induced apoptosis, and this effect correlated with a sustained Stat5 and Erk activation in the 
presence of the compound. This suggests that Hck plays a non-redundant role in mediating the 
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anti-apoptotic effects of Bcr-Abl. In addition, using phospho-specific antibodies against pTyr-
177, pTyr-89, and pTyr-245 of Bcr-Abl, I showed that although Hck plays a role in 
phosphorylation of these residues, other Src kinases are likely to be involved as well. Finally, in 
an effort to show a role for SFKs in survival and proliferation of CML progenitor cells, I showed 
for the first time that A-419259 induces growth arrest and apoptosis in CD34+ cells isolated from 
three CML patients, with potency equal to imatinib.  
The significance of this study includes the following. (1) This is the first study to 
delineate the redundant and non-redundant functions of Hck in Bcr-Abl signaling. Based on this 
study, we can conclude that Hck has a non-redundant function in mediating the anti-apoptotic 
effects of Bcr-Abl, while it is likely to cooperate with other Src kinases in mediating the 
proliferative effects of Bcr-Abl, as well as phosphorylation of Bcr-Abl at residues important for 
oncogenic activity. (2) This study shows for the first time that inhibition of SFKs in primitive 
CD34+ progenitor cells from CML patients induces apoptosis to an extent similar to imatinib, as 
measured by caspase activation. On a cautionary note, I was not able to correlate the level of 
caspase activation with an actual percentage of apoptotic cells in my study due to the small size 
of each sample. On this note, other laboratories reported that the apoptotic effects of imatinib in 
CML CD34+ cells are limited to ~ 30 % (393). However, even a moderate apoptotic effect of 
SFK inhibitors on CML CD34+ cells argues that SFK inhibitors used in combination with other 
anti-CML therapies may be beneficial for the elimination of CML progenitors. The fact that 
dasatinib, a dual Src/Abl inhibitor targets more primitive progenitors than imatinib supports this 
idea (217). In summary, this work validates Hck as a specific target for the development of 
apoptotic drugs for the treatment of CML and brings more supporting evidence for the role of 
SFKs in CML pathogenesis.  
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4.1.2 The role of Hck in Bcr-Abl-mutation-independent imatinib resistance 
To establish whether Hck kinase activity is important in Bcr-Abl-mutation-independent 
resistance to imatinib, I adapted a second chemical genetic approach initially described by 
Shokat et al. for use with Hck [reviewed in (386)].  To do this, I introduced a space-creating 
mutation at the gatekeeper position (T338A) to render the kinase uniquely sensitive to NaPP1, a 
bulky analog of the global SFK inhibitor PP1. As expected, the T338A mutation induced 
sensitivity to NaPP1 while being silent in terms of Hck function and activity. Then, I expressed 
wild-type Hck and Hck-T338A mutant in CML cells and showed that it caused resistance to 
imatinib-induced apoptosis and inhibition of colony growth. Furthermore, sensitivity to imatinib 
was restored in cells expressing the Hck-T338A mutant upon the addition of NaPP1, 
demonstrating that imatinib resistance requires Hck kinase activity. In addition, data presented in 
this study suggests that Hck overexpression induced increased and sustained phosphorylation of 
Bcr-Abl at Tyr-89, Tyr-245 and Tyr-177, residues previously shown to be important for Bcr-Abl 
oncogenicity (194, 195). Phosphorylation at Tyr-89 in the SH3 domain of c-Abl was previously 
proposed to promote kinase activation due to the disengagement of the SH3 domain from the 
SH2:kinase linker (194, 195). However, I was not able to correlate sustained Tyr-89 and Tyr-245 
phosphorylation in the presence of imatinib with enhanced Bcr-Abl activity as determined by the 
phosphorylation of Bcr-Abl substrate, CrkL.  Sustained phosphorylation of Bcr-Abl Tyr-177 was 
also observed in the presence of imatinib following Hck overexpression, and this 
phosphorylation event was reversed by NaPP1 addition.  
 This study showed for the first time a direct cause and effect relationship between Hck 
overexpression and imatinib resistance in CML cells transformed by wild-type Bcr-Abl.  In 
addition, this Hck-induced imatinib resistance required the kinase activity of Hck as 
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demonstrated using Hck-T338A and NaPP1. However, I was not able to clearly outline the 
mechanism of Hck-induced resistance to imatinib. Previous studies in our laboratory and others 
showed that Hck and other Src kinases such as Lyn cross-phosphorylate Bcr-Abl on residues 
important in oncogenesis such as Tyr-89, Tyr-245, and Tyr-177 (194, 195). The finding that Hck 
induces increased and sustained phosphorylation of Bcr-Abl at Tyr-89, Tyr-245 and Tyr-177 is 
consistent with these studies. However the relevance of Bcr-Abl phosphorylation to the 
mechanism by which Hck induces resistance to imatinib remains elusive, especially since no 
sustained of Bcr-Abl activity in the presence of imatinib was observed as a consequence of Hck 
overexpression. A recent study published by Wu and co-workers shows that in imatinib-resistant 
cells, Lyn activation mediates a sustained phosphorylation of Bcr-Abl at Tyr-177 (218), and 
raised the possibility that Lyn prevents full inactivation of Bcr-Abl signaling by retaining critical 
adaptor protein (Grb2) binding sites on Bcr-Abl (218).  Our data shows a similar effect induced 
by Hck overexpression. Therefore, the observed imatinib resistance may be mediated by 
increased Bcr-Abl-dependent signaling in the absence of increased Bcr-Abl kinase activity.  
Examination of phospho-CrkL blots from various imatinib-resistant patient samples 
which display increased levels of Lyn and/or Hck activities show a mixed response to imatinib 
(218, 314). More specifically, some patient samples show sustained phospho-CrkL levels in the 
presence of imatinib, while in other samples imatinib induces complete CrkL 
dephosphorylation(218, 314). This suggests that although the resistance to imatinib in all these 
patients is associated with increased SFK activity, the mechanisms may differ on a case-by-case 
basis.  
The data presented in Chapter 2 show that Hck plays a non-redundant role in mediating 
the anti-apoptotic effects of Bcr-Abl. In addition, consistent with previous reports in our 
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laboratory (194, 195), these data suggest that although Hck phosphorylates Bcr-Abl at sites that 
might help to sustain an active conformation (Tyr-89, Tyr-245), other SFK also contribute to 
phosphorylation at these sites. Therefore, the moderate level of resistance observed upon Hck 
overexpression (Chapter 3) suggest that both Hck and Lyn activities are required to induce a 
level of resistance to imatinib observed in clinical samples. Furthermore, we can speculate that 
the mixed response to imatinib in terms of CrkL de-phosphorylation observed in clinical samples 
might be a consequence of the interplay between the relative protein or activity levels of Hck and 
Lyn.  
4.2 UTILITY OF CHEMICAL GENETICS FOR TARGET VALIDATION STUDIES 
Protein kinases are one of the largest groups of drug targets, considered to be the second most 
important after G-protein-coupled receptors (394). Traditionally, pharmacological target 
validation studies have been carried out using genetic approaches. However, these genetic 
approaches can be misleading and may fail to identify important targets due to some 
compensatory changes in related pathways.  In addition, kinase-independent functions of 
genetically deleted proteins might complicate the interpretation of the results (395). In theory, an 
ideal alternative approach to target validation is the use of small molecule inhibitors to dissect 
signaling pathways. However, this approach is also problematic since most inhibitors act on 
multiple kinase targets due to the high degree of homology of the ATP-binding sites of tyrosine 
kinases. The work presented in this dissertation constitutes an example of how one can avoid 
these pitfalls by combining two conceptually opposite chemical genetic methods to tease out the 
involvement of putative druggable targets in a pathological process.  
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Chemical genetics approaches involve the use of small molecules (hence “chemical”) in 
conjunction with mutations (hence “genetics”) at a conserved hydrophobic residue (termed the 
“gatekeeper”) located in the ATP-binding site of a kinase. Replacement of the gatekeeper residue 
of a kinase of interest with either a bulky or with a smaller amino acid serves as a selectivity 
filter with respect to the binding of ATP-analog inhibitors. For example, in the case of Hck, 
replacement of the gatekeeper residue (Thr-338) with Met precludes binding of the general SFK 
inhibitor A-419259. Conversely, replacement of Thr-338 with Ala induced unique sensitivity of 
Hck to NaPP1, a bulky analog of the SFK inhibitor PP1. Thus, on one hand, pairing the 
expression of Hck-T338M mutant with A-419259 in an appropriate cellular context allows the 
inhibition of all endogenously expressed wild-type SFKs without affecting the activity of Hck-
T338M. On the other hand, pairing the expression of Hck-T338A with NaPP1 in an appropriate 
cellular context (that lacks the wild-type Hck) allows the highly specific inhibition of Hck-
T338A activity while all the endogenously expressed wild-type SFKs are not affected.  Both of 
these methods have been previously validated individually for use with other tyrosine kinases. 
However, when applied in combination to the study of one particular kinase of interest as shown 
in this thesis, they have the power to provide an increased understanding of the role of a 
particular kinase in a pathological process.  This is why chemical genetics represents a highly 
valuable method for rational drug target validation studies, with applicability to many different 
tyrosine kinases and therefore, many different disease states. 
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4.3 FUTURE DIRECTIONS  
4.3.1 Investigate the role of Hck in Bcr-Abl signaling in Hematopoietic Stem Cells (HSC).  
The cellular origin of CML begins with formation of the Ph+ chromosome in the hematopoietic 
stem cell from where it is subsequently transmitted to all hematopoietic lineages. Multipotent 
hematopoietic progenitor cells are receptive to Bcr-Abl expression and generate an abnormal 
expansion of mature myeloid cells (396). Recent studies indicate that despite the impressive 
success of imatinib, CML patients have a rare but consistently detectable population of Bcr-Abl+, 
CD34+ HSC that are not efficiently killed by this drug (346). Dasatinib, a dual Abl/Src inhibitor 
was shown to inhibit Bcr-Abl in CD34+ CML stem cells more effectively than imatinib, although 
not completely (217). However, the dasatinib activity spectrum comprises not only Bcr-Abl and 
Hck but also other SFKs including Fgr, Fyn, Lck, Lyn, and Yes (363) as well as the Kit, PDGFR, 
and Ephrin receptor tyrosine kinases (364). Many of these kinases have no demonstrated role in 
CML pathogenesis and therefore, their inhibition might be deleterious to the outcome of the 
disease or might contribute to side effects associated with long-term drug treatment. In addition, 
Owen Witte and co-workers showed that Bcr-Abl expression during in-vitro hematopoietic 
development of embryonic stem cells causes expansion of multipotent and myeloid progenitors 
(397). To study the involvement of Hck in early Bcr-Abl-induced HSC signaling, one could 
construct a Hck-T338A homozygous ES cell line and then perform an in vitro differentiation 
assay that allows Bcr-Abl expression (397). To test whether Hck plays a role in this Bcr-Abl-
dependent abnormal expansion of hematopoietic progenitor cells, a two-step in vitro 
differentiation of ES-Hck-T338A cells in methylcellulose could be performed in the presence or 
absence of NaPP1. This procedure involves primary differentiation of ES cells into embryoid 
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bodies (EBs) followed by secondary plating in methylcellulose containing a cocktail of 
hematopoietic cytokines to form hematopoietic colonies. Bcr-Abl will be transfected in the EB –
derived hematopoietic progenitors, and selection started at the time of methylcellulose plating. 
Hematopoietic progenitors present in the EBs will grow out into discrete hematopoietic colonies 
that are easily identified in the methylcellulose cultures. Quantitation of these colonies will allow 
a direct estimation of the number and type of hematopoietic progenitors that result upon Bcr-Abl 
expression and Hck-T338A inhibition by NaPP1. If Hck is required for the Bcr-Abl-induced 
abnormal expansion of multipotent and myeloid progenitors (395), then NaPP1 is expected to 
abolish these Bcr-Abl-dependent effects and induce normal hematopoietic differentiation in ES-
Hck-T338A cells.  
4.3.2  Further explore the relevance of SFK overexpression/activation in imatinib 
resistance 
Data presented in this dissertation shows that Hck overexpression is sufficient to induce imatinib 
resistance. However, to further clarify the significance of SFKs in imatinib resistance, additional 
studies need to be undertaken.  
First, although I showed that Hck overexpression is sufficient to induce imatinib 
resistance in cellular CML models, it is not clear whether Hck can sustain imatinib resistance in 
vivo. In a previous report, Wu and co-workers used an imatinib resistant K562 cell line 
overexpressing Lyn to generate a mouse xenograft CML model (314).  Mice harboring tumors 
induced by these cells underwent an initial response to imatinib, however after continual therapy 
(8 days) tumors in imatinib-treated mice could not be distinguished from tumors in control mice 
(314). To develop evidence that Hck overexpression is sufficient to create imatinib resistance in 
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vivo, K562 cells expressing vector alone, wild-type Hck or the Hck-T338A mutant could be 
subcutaneously administrated in nude mice to generate solid tumors. Based on the results in 
Chapter 3 of this thesis, mice bearing tumors from K562-Hck or K562-Hck-T338A would be 
expected to show an initial response to imatinib, followed by a relapse. Furthermore, since in our 
cell-based experiments resistance to imatinib requires the kinase activity of Hck, administration 
of NaPP1 along with imatinib is anticipated to decrease the burden of the tumors originated from 
K562-Hck-T338A cells, due to a reversal of imatinib sensitivity. 
 Second, the mechanism of Hck-induced imatinib resistance should also be determined.  
Experiments performed in Chapter 3 suggest that Hck may induce resistance to imatinib by 
prompting a sustained activation of signaling pathways downstream of Tyr-177 of Bcr-Abl. To 
test this hypothesis, one could determine whether Hck expression induces a sustained Bcr-
Abl/Gab2 association. In addition, the activation of signaling pathways downstream of phospho-
Y177, such as the Ras/Erk and PI3K/Akt pathways should also be assessed.  
Third, a recent study showed that resistance to nilotinib, a second-generation Bcr-Abl 
inhibitor is associated with an increased Lyn mRNA levels in CML patients(392). This suggests 
that in a clinical setting, various Bcr-Abl inhibitors may induce resistance through similar 
mechanisms and that patients may also display cross-resistance to various Bcr-Abl inhibitors. To 
determine whether Hck overexpression may induce cross-resistance to nilotinib, the same cell-
based system described in Chapter 3 could be used. Thus, to test this hypothesis, one could 
compare the apoptosis or inhibition of colony growth in response to nilotinib in K562-neo 
control cells vs. K562-Hck and K562-Hck-T338 cells, and look for kinase-dependence of these 
effects using NaPP1 as I have successfully demonstrated with imatinib. 
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4.4 CLOSING REMARKS 
Imatinib, the current first-line CML therapy, has demonstrated significant activity in all phases 
of the disease, due not only to its ability to inhibit Bcr-Abl, but also due to its promiscuous 
character (314). More specifically, the therapeutic effects of Bcr-Abl are in part associated with 
its ability to inhibit c-Kit along with Bcr-Abl (295). However, despite the high level of 
hematologic and cytogenetic responses in clinical trials, patients with advanced-stage CML often 
develop resistance. These growing levels of resistance to imatinib point to a need for new 
therapeutic targets. In addition, a recent survey conducted by The Chronic Myelogenous 
Leukemia Society of Canada (http://www.news-medical.net/?id=43908), showed that imatinib 
although generally deemed as well tolerated, induced persistent side effects such as nausea, 
fatigue, headaches, vomiting, edema, and myelosuppression. Moreover, imatinib has been 
recently shown to be cardiotoxic (http://www.fda.gov/medwatch/safety/2006/safety06. 
htm#Gleevec). Therefore, new therapies with an increased control on specificity are required 
since the incidence of side-effects may be associated with the promiscuous character of a drug.  
To design such dugs, it is important to have a better understanding of which signaling molecules 
are highly important in a disease process or in imatinib resistance. In this context, the work 
presented in this dissertation was aimed to refine the importance and role of Hck in Bcr-Abl 
signaling and imatinib resistance. It is my hope that similar work will be undertaken to evaluate 
the role of other individual signaling molecules in CML pathogenesis and resistance. This in turn 
will provide the necessary information for the development of new therapies not only effective in 
treating imatinib-resistant patients but also with minimal side effects. Recent advances in 
structure-based drug design methods are promising with regard to their ability to exploit 
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particularities of protein structures to target away the kinases not important in a pathological 
process (398). 
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